Index to Volume 63—1995

AUTHOR INDEX

Original articles are indicated by (O), editorial (E), correspondence (C), news and notes (N), abstracts (A), book reviews (B), obituaries (Ob).

Abalos, R. M., (A) 647, (O) 8
Abbot, N. C., (A) 318, 476
Abdulmumini, T., (A) 498
Abe, C., (A) 163
Abebe, F., (A) 477, 482
Abel, L., (A) 485
Abou-Zeid, C., (A) 477
Actor, P., (A) 638
Adal, K. A., (A) 169
Adams, E., (A) 145
Adams, J. L., (A) 169
Adams, L. B., (A) 488, 644
Adhikari, N., (A) 623
Afghani, B., (A) 345
Agarwal, U., (C) 105
Agius, P. V., (A) 353
Aguet, M., (A) 600
Aguilar, C. R., (A) 313
Ahsan, C. R., (A) 652
Ahsan, N., (A) 471
Ahuja, R. K., (O) 518
Akarasewi, P., (A) 638
Al-Qubati, Y., (C) 574
Al-Samie, A. R., (C) 574
Alangaden, G. J., (A) 624
Alava, P. J. J., (A) 595
Alchorne, M. M. A., (A) 620
Alexander, R., (C) 115
Ali, A., (A) 475
Alito, A., (A) 188
Allaudeen, H. S., (A) 589
Allen P., (A) 156
Allen, N. B., (A) 172
Allworth, A. M., (A) 356
Almedia, S. N., (A) 623
Altagracia, M., (A) 135
Altamirano, M., (A) 170
Alvarado Calvillo, R., (A) 135
Alvarenga, A. E., (A) 324
Alves, V. A. F., (A) 146
Alzari, P. M., (A) 351
Amar, D., (A) 133
Amicosante, G., (A) 365
Amicosante, M., (A) 488
Anand, P., (A) 145
Anandan, D., (A) 143
Anandaraj, H., (A) 621
Andersen, A. B., (A) 366, 633
Andersen, P., (A) 490
Anderson, A., (A) 478
Anderson, G. A., (A) 319
Anderson, P., (A) 345
Anderson, R., (A) 188
Andrade, A. L. S. S., (A) 329, 619, (C) 95
Andrade, H. F., Jr., (O) 381
Andres, P. W., (A) 355
Andrews, J. M., (A) 491
Andrien, M., (A) 151
Angeli, A., (A) 475
Angelo, H. R., (A) 316
Anglim, A. M., (A) 169
Antia, N. H., (A) 155, 488, (C) 573
Aoki, K., (A) 636
Appelberg, R., (A) 145, 170, 599, 599, 624
Arala Chaves, M., (A) 345, 364
Aranda, C. M., (C) 103
Araujo, M. G., (A) 136, 313, 593, 594
Arbeit, R. D., (A) 500
Arbiser, J. L., (A) 468
Arni, S., (A) 610
Arnoldi, J., (A) 324
Arolkar, S. K., (A) 488
Arora, P. N., (A) 320, 485
Arora, V. K., (C) 454
Arunthathi, S., (A) 140
Arya, A., (A) 605
Arzet, H., (A) 168
Asano, S., (A) 187
Aschhoff, M., (A) 319, (E) 448
Atkinson, S., (A) 487
Audit, C. O., (A) 346
Averill, L., (A) 351

Averill, L. E., (A) 363
Avery, D. T., (A) 330
Awofeso, N., (A) 617, (E) 453
Ayoub, A., (A) 631

Babst, A., (A) 639
Bacerdo, M., (A) 349
Bachelet, M., (A) 148
Bacon, P. A., (A) 601
Bacosi, D., (A) 363
Baelden, M. C., (A) 157
Bagre, S., (A) 312
Baguley, B. C., (A) 627
Bai, G. H., (A) 497
Baik, S.-H., (A) 492
Bainson, K. A., (A) 310
Bajaksouzian, S., (A) 180
Baker, A. M., (A) 489
Baker, A. S., (A) 472
Bakos, L., (A) 599
Balagon, M. V. F., (A) 647
Balaji, K. N., (A) 346, 363
Balin, L. M., (A) 476
Banerjee, A., (A) 158, 176, (O) 518
Banerjee, P. P., (A) 607
Bannerjee, A., (A) 352
Baptista, P. L., (A) 599
Barbara-Burnham, L., (A) 178
Barbosa, A. D., (A) 146
Barcelo, A., (A) 188
Barker, H., (A) 183
Barnes, P. F., (A) 153
Barnes, P. F. T., (A) 333
Barr, P. J., (A) 336, (O) 381
Barrow, W. W., (A) 160
Bartok, A. E., (A) 178
Bartoloni, A., (A) 363
Barton, C. H., (A) 489
Basak, P., (A) 607
Baskin, G. B., (A) 616
Bassey, E., (A) 609
Basten, A., (A) 145
Basu, J., (A) 334
Basu, M. K., (A) 590
Bathurst, I. A., (O) 381
Baulard, A., (A) 607
Baumgartner, W. A., (A) 364
Becaro, E., (A) 620
Beck, J. S., (A) 318, 476, 490
Beck, L.-A., (A) 186
Beckman, E. M., (A) 322
Beggs, M., (A) 628
Behar, S. M., (A) 322
Beiguelman, B., (A) 617
Belisle, J. T., (A) 181, 355, 629
Benditt, E. P., (A) 494
Benz, R., (A) 162
Berche, P., (A) 607
Berhanu, F., (A) 312
Berhanu, T., (A) 312
Bermudez, L. E., (A) 170, 178, 322, 346
Bernillon, M.-H., (A) 180
Berning, S. E., (A) 625
Bertho, A. L., (A) 154
Bertrand, G., (A) 500
Berzofsky, J. A., (A) 633
Besson, M., (A) 171
Betti, F., (A) 363
Bhaduri, T., (A) 157
Bharadwaj, V. P., (A) 146, (O) 202
Bharti, R., (A) 311
Bhat, D. A., (A) 608
Bhat, L., (A) 140
Bhatia, A. S., (A) 595, (O) 202
Bhatia, V., (A) 332
Bhatia, V. A., (A) 158
Bhatia, V. N., (A) 332, 334
Bhattacharya, B. C., (O) 518
Biehle, J. R., (A) 626
Bigbie, M. R., Jr., (A)]636
Bila, V., (A) 171
Billman Jacobe, H., (A) 330, 358
Birdi, T. J., (C) 573
Birke, J. A., (A) 167
Bisetti, A., (A) 488
Bitter, M., (A) 493
Bjorkman, S., (A) 469
Black, W. A., (A) 170
Blackwell, J., (A) 487
Blackwell, J. M., (A) 353, 360, 489
Blanc, L., (A) 317, 620
Blanchard, J. L., (A) 616
Blanchard, J. S., (A) 494
Bloch, A. B., (A) 625
Bloom, B. R., (A) 148, 153, 158, 483, 491, 601, 628, 629, 656
Bluethmann, H., (A) 600
Boccuzzi, A., (A) 475
Bodkin, M., (A) 366
Bodmer, T., (A) 468
Boelens, J. J., (C) 456
Boerrigter, G., (O) 1
Boesen, H., (A) 490
Bohm, R. P., (A) 616
Bollet, C., (A) 173
Bolstrom, A., (A) 176
Bonaccorsi, P., (A) 626
Bong Mastek, M., (A) 614
Bonifacio, K., (A) 154
Bonilha, V. F., (A) 617
Bonk, S., (A) 349
Bono, L., (A) 363
Boocock, P. A., (O) 265
Boom, W. H., (A) 346, 363
Borecki, I., (A) 617
Borish, L. C., (A) 137
Borretta, G., (A) 475
Bothamley, G. H., (A) 490
Bottasso, O., (A) 322, 628
Bottger, E. C., (A) 347, 363, 494

Bouckaert, A. E., (A) 157
Boughton, B. J., (A) 490
Bouquet, S., (A) 473
Bourget, T., (A) 314
Bownds, S. E., (A) 498
Brand, M. E., (E) 450
Brand, P. W., (A) 272
Brasil Filho, A. A., (A) 597
Breen, G. A., (A) 140
Brennan, P. J., (A) 148, 160, 164, 181, 285, 339, 482, 493, 607, 610, 611, 615, 629, 645, 647, 652, 656
Brenner, M. B., (A) 322, 656
Brett, S. J., (A) 174
Brettle, R. P., (A) 632
Bretzel, G., (C) 100
Brewer, T. F., (A) 491
Brickell, P. M., (A) 327
Britschgi, T. B., (A) 607
Brittain, D., (A) 186
Britton, W., (A) 145, 154, 330, 332, 358, 468, 591, 615
Brocavich, J. M., (A) 140
Broers, B., (A) 494
Broser, M., (A) 366
Brown, A. M., (A) 483
Brown, B. A., (A) 190, 362, 470
Brown, D. H., (A) 146, 625
Brown, E. J., (A) 614
Brown, I. N., (A) 183, 353
Brown, M., (A) 142
Brucker, A. J., (A) 142
Bryskier, A., (A) 499
Bucana, C. D., (A) 599
Budinsky, R., (A) 588, 590
Bujdoso, R., (A) 348
Bulla, G. J., (O) 369
Bulto, R., (A) 141
Burrini, C., (A) 363
Burroughs, A. K., (A) 181
Burroughs, M., (A) 638
Burwen, D. R., (A) 625
Buston, D., (A) 360
Butany, J. W., (A) 469
Butler, M., (A) 490
Butlin, C. R., (A) 332
Butlin, S. R., (A) 476
Bwire, R., (A) 135
Byass, P., (A) 312, 312, 319
Bygbjerg, I. C., (A) 316

Cabrera, A., (A) 141
Callahan, J. E., (A) 493
Callister, S. M., (A) 498
Calvieri, S., (A) 626
Camarena, A., (A) 155
Camargo Marciano, L. H. S., (A) 623
Cambau, E., (A) 161, 171, 610
Campa, M., (A) 488
Caneshi, J. R. T., (A) 605
Cangelosi, G. A., (A) 607
Canosa, B., (A) 628
Carbon, C., (A) 317
Cardi, B. A., (O) 381
Carlesimo, M., (A) 626
Carmichael, J., (A) 355
Carneiro, J., (A) 364
Carrazana Hernandez, G. B., (A) 486, 618, 618
Carroll, D., (A) 491
Cartel, J.-L., (A) 151, 151, 329, 589
Carus, N. H., (A) 472
Casal, M., (A) 499
Cassis, I., (A) 494
Castano Hernandez, S., (A) 618
Castellazzi, Z., (A) 166
Castells Rodellas, A., (A) 147
Castes, M., (A) 360
Castro, A. G., (A) 145, 170, 599, 599, 624
Cattermole, J., (A) 478
Cauthen, C. M., (A) 171
Cavalieri, S. J., (A) 626
Cawthon, V. L., (A) 639
Celik, O., (A) 320, (O) 23
Cellona, R. V., (A) 647
Centeno, M., (A) 480
Cesario, F., (A) 475
Cestari, T. F., (A) 599
Chacko, S., (C) 115
Chakrabarti, P., (A) 334
Chakrabarty, A. K., (C) 105
Chalise, Y., (A) 332
Champsi, J. H., (A) 322
Chan, C. H., (A) 627
Chan, C. H. S., (A) 491
Chan, C. Y., (A) 190
Chan, J., (A) 491, 629
Chan, K. W., (A) 492
Chang, K., (A) 180
Chang, Y., (A) 149
Chanteau, S., (A) 637
Chapuis, F., (A) 473, 473
Chapuis, L., (A) 347
Chatterjee, D., (A) 156, 482, 611, 656
Chatterji, D., (A) 358
Chattopadhya, D., (C) 105, (O) 249
Chaturvedi, V., (A) 479, 481
Chaurasia, A. K., (O) 422
Chehl, S. K., (O) 259
Chen, Q., *et al.*, (A) 342
Cheng, A. F. B., (A) 190
Chensue, S. W., (A) 323
Chervenak, K. A., (A) 346
Chiang, T., (A) 487
Chiang, T. J., (A) 325, 325, 326, (O) 222
Child, J., (A) 491
Childerstone, A., (A) 496
Chin, D. P., (A) 172, 177, 639
Chin-A-Lien, R. A. M., (A) 472, 474
Ching, L. M., (A) 627
Chiplunkar, S. V., (A) 327
Chirgwin, K. D., (A) 360

Cho, P. W., (A) 364
Cho, S.-N., (A) 492, 647, (C) 101
Cho, W., (C) 101
Choi, H.-Y., (C) 101
Chojnacki, T., (A) 339
Chong, Y., (A) 492
Choudhri, S. H., (A) 469
Choudhuri, K., (E) 430
Chow, C. C., (A) 627
Christopher, A., (A) 133
Chu, P., (A) 316
Chui, D. H., (A) 147
Churchward, G., (A) 179
Ciesielski, C. A., (A) 625
Cigel, F., (A) 603
Cirillo, J. D., (A) 158, 483
Clark-Curtiss, J. E., (A) 477, 614
Clarridge, J. E., (A) 352
Clemens, D. L., (A) 175, 323
Cleto, M., (A) 185
Cocito, C., (A) 492
Cocram, C. S., (A) 627
Coene, M., (A) 157
Coghill, G., (A) 476
Cohen, H., (A) 366
Cohen, S., (A) 329
Cohen, Y., (A) 500
Colditz, G. A., (A) 491
Cole, C. H., (A) 492
Cole, S. T., (A) 160, 176, 334, 351, 352, 352, 609
Collins, D. M., (A) 500, 628
Collins, F., (A) 609
Colston, A., (A) 348
Colston, M. J., (A) 158, 159, 327, 331(O) 35
Commez, L. E. A., (A) 595
Comstock, G. W., (A) 348
Condos, R., (A) 185
Conradt, P., (A) 600
Content, J., (A) 173
Converse, P. J., (A) 476
Convit, J., (A) 360, 480, (C) 576
Cooksey, R. C., (A) 628
Cooper, A., (A) 156
Cooper, A. M., (A) 493
Corey, G. R., (A) 172
Corkill, M., (A) 493
Corrigan, O. I., (A) 137
Corson, L., (A) 183
Costa, H. C., (A) 312, 314
Couet, W., (A) 473
Courtois, P. H., (A) 473
Courtright, P., (A) 140
Cox, D. C., (A) 139
Cox, R. A., (A) 159
Coyner, B. J., (A) 169
Cozzi, J., (A) 189
Craig, L. E., (A) 476
Crawford, J. T., (A) 163, 187, 628
Cree, I. A., (A) 476
Croft, R. P., (A) 619
Cros, P., (A) 180
Cross, H., (A) 621
Crouzat, M., (A) 619
Cunha, P. R., (A) 329
Curbelo Santana, L., (A) 474
Curcic, R., (A) 172
Currie, H., (O) 62
Curtis, J., (A) 164
Cynamon, M. H., (A) 179, 180, 592, (C) 295
Czuprynski, C. J., (A) 169

D'Souza, S., (A) 353
Dabbs, E. R., (A) 482
Daffe, M., (A) 633
Dale, J. W., (A) 183, 608
Dalpino, D., (A) 617
Daniel, A. E., (A) 140
Daniel, E., (C) 115, (E) 450, (O) 529
Danis, F., (A) 141
Dannenberg, A. M., (A) 348
Darling, T. N., (A) 172
Das, G., (A) 359
Das, N., (A) 590
Das, R. K., (A) 317
Daugelat, S., (A) 600, 602, 603
Daumerie, D., (A) 587
Dautrey, S., (A) 317
Davenport, M. P., (A) 154
Davies, E. G., (A) 353
Davies, J. K., (A) 349
De Blaquiere, G. E., (A) 164
de Carvalho, M. L. R., (A) 593, 594
De Geiking, I., (A) 475, 598
de Haas, P. E. W., (A) 188, 366
de Hernandez, O., (A) 472
De Hoffmann, E., (A) 339
De Wit, T. F. R., (A) 477
Deanta, M. T. J., (A) 189
Deepak, S., (A) 167
Deggerdal, A., (A) 328
Degrave, W. M., (A) 613
Degroot, A. S., (A) 633
Dehaas, P. E. W., (A) 631
Deighton, J., (A) 327
Delabarrera, S., (A) 476
dela Cruz, E. C., (O) 8
Deleuran, B. W., (A) 603
Deleuran, M., (A) 603
Deleys, R., (A) 151
de lisle, G. W., (A) 500, 628
Dell, A., (A) 482, 611
Dellagostin, O. A., (A) 608
Delon, A., (A) 473
Demicco, P., (A) 173, 630
Demissee, A., (A) 602
Deneeling, H., (A) 631
Deng, L. Y., (A) 493
Denis, M., (A) 147, 173
Deo, M. G., (A) 327
de Oliveira, P. R. D., (A) 314
Deresinski, S. C., (A) 178
Deretic, V., (A) 172

Desar N., (A) 623
Deshpande, R. G., (A) 608
Desikan, K. V., (A) 587, (O) 417
Desikan, P., (A) 148, (O) 417
Deso, G., (A) 363
de Soldenhoff, (A) 141, 142
Dessen, A., (A) 494
Desvareene, S., (A) 180
de Vries, R. R.P., (A) 477, 490, (O) 369
de Wit, M. Y. L., (A) 477
de Wit, T. R. R., (A) 477
Dey, A., (A) 621
Dey, M. S., (A) 164
Dhaka, R. S., (A) 320
Dhaliwal, U., (C) 454
Dhandayuthapani, S., (A) 172
Dhar, S., (C) 111, (E) 92
Dhople, A. A., (A) 312
Dhople, A. M., (A) 312, 587, 608
Diallo, A. S., (A) 317
Diaz, F. M., (A) 153
Dickson, L., (A) 478
Didier, P., (A) 495
Dierckx, P., (A) 151
Dietrich, A., (A) 632
Dietrich, M., (A) 136
Dillon, B. J., (A) 496
Dixon, J. A., (A) 168
Dlugovitzky, D., (A) 628
Dobos, K. M., (A) 629
Dockrell, H. M., (A) 325, 326, 332, 487(O) 222
Dominguez-Gil Hurle, A., (A) 184
Donahue, S. A., (A) 355, 645
Donnabella, V., (A) 349
Donoghue, H. D., (O) 42
Dooley, S. W., (A) 187
Doran, T., (A) 358
Doran, T. J., (A) 349
dos Santos, S. N. M. B., (A) 136, 313
Doucet-Populaire, F., (A) 587
Douvas, G. S., (A) 349
Down, J. A., (A) 164
Drateln, C. R., (A) 594
Dreyhaupt, T., (A) 137
Drijfhout, J. W., (A) 477
Drowart, A., (A) 151, 151, 324, 329
Dube, M., (A) 178
Dubourdieu, D., (A) 619
Duchrow, M., (A) 324, 336, 336
Dumarey, C. H., (A) 148
Dupont, M.-A., (A) 633
Duppre, N. C., (A) 605, 613
Dupree, W. G., (A) 615
Duval, P., (A) 619
Dworkin, B., (A) 190
Dyachina, M. N., (C) 457

Eales, L. J., (A) 608
Ebrahimzadeh, A., (A) 637
Edinborough, N. B., (A) 167
Edward, V. K., (C) 289
Eger, T., (A) 188
Eiglmeier, K., (A) 615
Eisenach, K., (A) 163
Elkin, E. P., (A) 177
Ellard, G. A., (C) 117
Ellner, J. J., (A) 180, 351, 363, 500
Elsaatari, F. A. K., (A) 173
Elston, R. C., (A) 185
Emler, S., (A) 494
Endo, N., (A) 187
Engstrand, L., (A) 173
Epstine, O., (A) 181
Eriksen, N., (A) 494
Eriksen, T., (A) 469
Escuyer, V., (A) 607
Espitia, C., (A) 605
Esposito, G., (A) 608
Esquenazi, D., (A) 154
Estrada-Parra, S., (O) 56, 546
Etzel, J. V., (A) 140
Ewan, P. W., (A) 327
Ewing, D. R., (A) 614
Ewing, M., (A) 612

Faber, W., (Ob) 298
Faber, W. R., (A) 472
Failbus, S., (A) 332
Fairchok, M., (A) 497
Fajardo, T. T., Jr., (A) 647, (O) 8
Fakouhi, T. D., (A) 314
Falcone, V., (A) 609
Falkow, S., (A) 165
Faraawi, R., (A) 175
Farinoti, R., (A) 317
Farolan, M., (A) 185
Farr, B. M., (A) 169
Fattorini, L., (A) 365
Favreliere, S., (A) 473
Fazal, N., (A) 495
Feenstra, P., (A) 310, (Ob) 298
Feitosa, M. F., (A) 617
Felies, A., (A) 175
Felmlee, T. A., (A) 177, 366, 609
Ferguson, R. B., (A)]636
Ferra Torres, T. M., (A) 486, 618
Feval, F., (A) 318
Fiallo, P., (A) 594
Fifis, T., (A) 330
Fijii, K., (A) 596
Filhi, J. T. G., (A) 613
Filla, J., (A) 603
Filley, E., (A) 477, (O) 369
Fine, P. E. M., (A) 282, 324, 487, 620
Finiasz, M., (A) 476
Fink, S., (A) 476
Fiss, E. H., (A) 334
Fitzgerald, M., (A) 170
Flad, H. D., (A) 324, 336, 336
Flesch, I. E. A., (A) 148, 600
Fleury, R. N., (A) 597, 617, (C) 103
Flynn, J., (A) 491

Flynn, J. L., (A) 601, 629
Fomukong, N. G., (A) 183
Fonseca, L., (A) 596
Ford, J. G., (A) 497
Forlenza, S., (A) 140
Foto, J. G., (A) 167
Fournet, B., (A) 182
Franceschini, N., (A) 365
Frank, I., (A) 142
Franzblau, S. G., (A) 284, (O) 8
Fraser, V., (A) 363
Fredrickson, M., (A) 355
Frei, R., (A) 356
Frieden, T. R., (A) 637
Friedmann, P., (A) 316
Frommel, D., (A) 141, 161, 588, 602, 631, (O) 369
Frothingham, R., (A) 649
Fsihi, H., (A) 609
Fujiki, H., (A) 636
Fujita, M., (A) 150
Fukuchi, K., (A) 494
Fukumoto, M., (A) 179
Fukutomi, Y., (A) 648, 652
Furihata, K., (A) 482
Furlong, S. T., (A) 322
Furney, S. K., (A) 356
Furukawa, F., (A) 596
Fyge, A., (A) 469

Gabre, S., (A) 312
Galle, J., (A) 336
Gallo, M. E. N., (A) 613
Gan, H. X., (A) 629
Ganapati, R., (A) 279
Ganesan, J., (C) 109
Ganesapillai, T., (C) 109
Gangadharam, P. R. J., (A) 496
Gangal, S. G., (A) 327
Ganguly, N. K., (A) 359
Garbino, J. A., (A) 617, 622
Garcia, C. C., (C) 570
Garcia-Patos Briones, V., (A) 147
Gardner-Medwin, J. M. M., (A) 350
Gaston, J. S. H., (A) 495, 601
Gaudin, P. B., (A) 364
Gaus, W., (A) 136
Gautam, S., (A) 344
Gee, B., (A) 639
Gelber, R. H., (A) 148, 164, 313, (C) 113, 295, (O) 259
Geluk, A., (A) 329
Georghiou, P. R., (A) 356
Gerdes, J., (A) 324, 336, 336
Gerra-Infante, R., (O) 546
Gesser, B., (A) 603
Gevaudan, M. J., (A) 173, 630
Gheorghiu, M., (A) 149
Ghidella, C., (A) 597
Ghossein, R. A., (A) 174
Gibbs, J. H., (A) 490
Gibson, B. W., (A) 630
Gibson, J. L., (A) 362
Gicquel, B., (A) 149, 354, 637
Gidoh, M., (A) 484
Gil, R., (A) 472
Gillespie, S. H., (A) 179
Gillis, T. P., (A) 163, 286, 615, 644, 649
Giphart, M. J., (O) 241
Giralt, E., (A) 188
Girard, W., (A) 470
Girard, W. M., (A) 190
Girdhar, A., (A) 168
Girdhar, B. K., (A) 168, 479
Giurintano, D. J., (A) 275
Glaser, J. B., (A) 141
Gobin, J., (A) 630
Godthelp, B. C., (A) 351
Goh, K. S., (A) 160, 499
Gokhale, S. D., (A) 343
Goldman, S., (A) 142
Goldstein, M. M., (A) 601, 629
Golkar, L., (A) 481
Gomes, S., (A) 624
Gomez-Flores, R., (A) 630
Goncalves, A., (A) 617
Goncalves, R. P., (A) 617
Gones, A., (A) 189
Gong, J.-H., (A) 333
Goni, P., (A) 188
Gonzalez, A. B., (A) 478
Gonzalez, B., (A) 185
Gonzalez, K., (A) 141
Gonzalez, P., (A) 177
Gonzalez, P. C., (A) 639
Gonzalez-Abreu, E., (A) 478
Gonzalez-Abreu Castels, E., (A) 474
Gonzalez-Montaner, L. J., (A) 631
Gonzalez Segredo, A., (A) 474
Good, N. L., (A) 355
Good, R. C., (A) 337
Goodall, J. C., (A) 601
Gordon, S. M., (A) 177
Gorminski, B. M., (A) 359
Gormus, B. J., (A) 616
Gosselin, D., (A) 484
Goswami, S., (A) 334
Goto, M., (A) 594, 650
Gounon, P., (A) 633
Graham, D. Y., (A) 173
Grange, J. M., (A) 490
Gratz, R., (A) 632
Grauwin, M.-Y., (A) 589
Graybill, J. R., (A) 187
Greenburg, S. S., (A) 495
Gregoire, D., (A) 157
Greifinger, R. B., (A) 187
Gretzy, D. M., (A) 493
Griffin, D., (A) 625
Griffith, D. E., (A) 190, 470
Griggs, D. J., (A) 159
Grimaud, J., (A) 473, 473
Grimont, P., (A) 637

Grisso, C. L., (A) 153
Groenen, G., (A) 595
Grosset, J., (A) 171, 176, 178, 347, 354, 500, 587, 631
Grosset, J.-H., (A) 176, 347
Grossi, M. A., (A) 180
Grossi, M. A. F., (C) 95
Grossmann, S., (A) 588
Grover, S., (A) 485
Groves, M. J., (A) 335, 496
Gruber, T., (A) 141
Guardiola, G., (A) 180
Guarnaccia, J. R., (A) 182
Guebre Xabier, H., (A) 631
Guebre Xabier, M., (A) 161, 588
Guedes, A. C. M., (A) 593, 594
Guerra-Infante, F., (O) 56
Guillemin, I., (A) 610
Guilloud Bataille, M., (A) 485
Guistini, S., (A) 626
Gummer, B. H., (A) 627
Guo, Q., *et al.,* (A) 313
Guo, Z.-P., (A) 356
Gupta, M. D., (A) 320
Gupta, R., (A) 181
Gupta, S., (A) 630
Gupta, U. D., (O) 202
Gupte, M. D., (A) 165

Haagsma, J., (A) 188
Hachem, C. Y., (A) 173
Haddad, N., (A) 607
Hadley, W. K., (A) 172, 177, 639
Haftel, H. M., (A) 149, 481
Haghighat, D., (A) 178
Hagio, S., (A) 594
Hah, Y.-M., (C) 101
Hahn, M., (A) 324, 336, 336
Haile-Mariam, H. S., (A) 161
Haines, V. L., (A) 476
Hale, K. A., (A) 490
Hall, M. C., (A) 159
Hamblin, A. S., (A) 157
Hamid, M. A., (A) 595
Hamilton, B. D., (A) 363
Hamrick, M. R., (A) 352
Hanano, R., (A) 495
Hanash, S. M., (A) 149, 481
Handley, C. J., (A) 479
Hanna, B., (A) 349
Harada, A., (A) 603
Harboe, M., (A) 364, 482
Hargrave, J. C., (A) 468
Hari, L., (O) 391
Harkiss, G. D., (A) 478
Harmsen, D., (C) 100
Harris, D. P., (A) 174
Harris, L., (A) 469
Harth, G., (A) 175, 496
Harth, M., (A) 175
Hartskeerl, R. A., (A) 613
Hasan, A., (A) 496
Hashiguchi, Y., (A) 595
Hastings, R. C., (A) 330, (B) 299
Hatta, M., (A) 650
Havlik, J. A., (A) 177
Havlir, D., (A) 178, 350
Hawes, G. E., (A) 351
He, D., (N) 461
He, R., *et al.,* (A) 340
Heersma, H., (A) 631
Heesemann, J., (C) 100
Hefta, S. A., (A) 160
Heger, W., (A) 175
Heiba, I. M., (A) 185
Heifets, L., (A) 353, 633
Helge, H., (A) 152, 355
Hellyer, T., (A) 183
Hengel, H., (A) 606
Henriques, B., (A) 175
Henwood, J., (A) 601
Herbert, D., (A) 136
Hermans, C. J., (A) 613
Hermans, J., (O) 369
Hermans, P. W. M., (A) 188, 482, 631
Hermon Taylor, J., (A) 497
Hernandez, E., (A) 189
Hertle, R. W., (A) 142
Hess, J. H., (A) 148, 600, 603
Hetherington, S. V., (A) 631
Hetland, G., (A) 150, 150
Heym, B., (A) 176, 351
Hickman, D., (A) 469
Hidaka, T., (A) 484
Hill, A. R., (A) 176
Hinderer, R., (A) 149
Hiran, S., (A) 141
Hiromatsu, K., (A) 355
Hirsch, C. S., (A) 351
Hirschel, B., (A) 494
Hirschtick, R., (A) 138
Ho, A. S. S., (A) 491
Hodgson, A. L. M., (A) 349
Hoessli, D. C., (A) 610
Hoette, M., (A) 186
Hoffner, S. E., (A) 175, 176, 352
Hofler, G., (A) 184
Hogeweg, M., (A) 141, 142
Hoglund, P., (A) 469
Holmgren, A., (A) 615
Holoshitz, J., (A) 149, 481
Hong, B.-Y., *et al.,* (A) 588
Honore, N., (A) 176, 334, 351, 352
Hopewell, P. C., (A) 172, 177, 639
Horohov, D. W., (A) 638
Horowitz, H., (A) 190
Horsburgh, C. R., (A) 172, 177, 177, 639
Horwitz, M. A., (A) 175, 323, 496, 612
Hosie, A. H. F., (A) 335
Hosokawa, A., (A) 595
Howe, R. C., (A) 330, 602, (O) 369
Hruban, R. H., (A) 364
Hu, L. F., (A) 140

Huang, S., (A) 600
Huang, W.-J., *et al.*, (A) 313
Huang, Y.-X., *et al.*, (A) 340
Hudak, A., (A) 176
Huerre, M., (A) 619
Hughes, M. S., (A) 186
Hunt, D. W. C., (A) 183
Hunt, J. M., (A) 177, 366
Hunter, R. L., (A) 589
Hunter, S. A., (A) 355
Hunter, S. W., (A) 164, 615
Husain, S., (A) 168, 343
Hussain, R., (A) 325, 325, 326, 487, (O) 222
Huygen, K., (A) 151, 151, 324, 329

Ibanez, M. A., (A) 312, 587, 608
Iida, N., (A) 636
Iivanainen, E., (A) 610
Ilangumaran, S., (A) 150, 610
Imai, T., (A) 335
Imamura, S., (A) 596
Imboden, P., (A) 468
IMMYC Steering Committee (WHO) , (O) 48
Inan, E., (O) 23
Inderlied, B., (A) 591
Inderlied, C. B., (A) 170, 178, 346
Inderparkash, (A) 166
Ingledew, N., (A) 322
Inglis, N. F., (A) 335
Inoue, T., (A) 650
International Federation of Anti-Leprosy Organizations, (A) 468
Irgens, L. M., (C) 97
Isa Isa, R. A., (A) 166
Iseman, M. D., (A) 625
Ishaque, M., (C) 100
Ivanyi, J., (A) 174, 478, 490, 605
Iwasaki, S., (A) 482
Iyer, D. V., (A) 333
Izumi, S., (A) 147, 596, 650

Jacob, M. S., (A) 133
Jacobs, M. R., (A) 180
Jacobs, N. J., (A) 500
Jacobs, W. R., Jr., (A) 158, 176, 181, 334, 352, 483, 494, 609, 628
Jacobson, R. R., (A) 272, 589
Jadhav, V. H., (A) 142
Jaffre, Y., (A) 486
Jagannath, C., (A) 496, 589
Jain, A., (O) 249
Jakeman, N. R. P., (A) 486
Jakeman, P., (A) 313, 486
Jalal, H., (A) 159
Jamet, P., (O) 195
Jamil, S., (O) 222
Jamison, D. T., (A) 134
Jann, E., (A) 324
Janson, A. A. M., (A) 477, (O) 369
Jarings, G. H., (A) 613
Jarlier, V., (A) 161, 171, 587, 610
Jayakumar, J., (A) 319, (E) 448
Jayalakshmi, P., (C) 109, 291
Jayasheela, M., (A) 143, 319
Jeansson, S., (A) 364
Jenner, P. J., (A) 331
Jensen, B. N., (A) 490
Jesudasan, K., (O) 18
Ji, B.-H., (A) 178, 347, 354, 631, (O) 195
Ji, Y., (A) 159
Jimenez de Anta, T., (A) 188
Jimenez Zamudio, L., (A) 155
Jin, S.-H., (A) 365
Jin, Y. F., (A) 159
Jing, Z., *et al.*, (A) 319
Job, C. K., (A) 274, 319, 589, (E) 448
Jogaikar, D. G., (A) 142
John, S., (A) 319
Johnson, B., (A) 638
Jollow, D., (A) 588
Jollow, D. J., (A) 590
Jones, B. E., (A) 333
Joone, G. K., (A) 188
Joseph, W. R., (A) 627
Juhlin, I., (A) 175
Jurado, S. H. M., (A) 595

Kailasam, S., (A) 496
Kalabalikis, P., (A) 353
Kaleab, B., (A) 478
Kalla, G., (A) 598
Kallenius, G., (A) 175
Kalyanina, O. V., (C) 457
Kamino, H., (A) 172
Kampirapap, K., (A) 338
Kanoh, H., (A) 335
Kaplan, G., (A) 280, 326, 605, 638, 651, 653
Kapur, V., (A) 352, 637
Kar, P. K., (A) 320
Kardjito, T., (A) 490
Karlix, M. A., (A) 636
Karnjan, S., (A) 338
Karopoulos, C., (A) 479
Kashyup, A., (C) 105
Kataoka, K., (A) 187
Kathet, B., (A) 332
Kato, L., (A) 611
Katoch, K., (A) 595, 604, (O) 202
Katoch, V. M., (A) 337, 611, (O) 202
Katsukawa, C., (A) 657
Katz, D. R., (A) 327
Kaufmann, S. H. E., (A) 148, 154, 326, 495, 600, 600, 600, 602, 603, 606
Kaukab, F., (A) 487
Kaur, H., (A) 310
Kaur, I., (C) 111, (E) 92
Kawakami, R. P., (A) 628
Kawamura, I., (A) 150
Kawatsu, K., (A) 650, 652
Kawuma, H. J. S., (A) 135
Kazanjian, P. H., (A) 182
Kazda, J., (C) 97

Kazen, R., (A) 588
Kebret, Z., (A) 588
Kelly, P., (A) 360
Kemp, R. J., (A) 356
Kemper, C. A., (A) 178
Kempsell, K. E., (A) 159
Keni, M., (A) 322
Kennedy, N., (A) 179
Kenney, T. J., (A) 179
Kern, P., (A) 136
Keystone, J. S., (A) 133, 469
Khaliq, S., (A) 487
Khan, M. B., (A) 608
Khanolkar Young, S., (A) 327
Khawas, I. B., (A) 144, 144, 321
Khoo, K. H., (A) 482, 611, 629
Khuller, G. K., (A) 361
Khulumani, P., (A) 341
Kiehn, T. E., (A) 353
Kifayet, A., (A) 325, (O) 222
Kifle, A., (O) 369
Kigawa, H., (A) 335
Kikuchi, K., (A) 179
Kim, J.-D., (A) 492, 647
Kim, S.-K., (A) 492
Kimura, T., (A) 594
King, A., (A) 185
King, C. H., (A) 337, 657
King, W., (A) 360
Kinney, D., (A) 349
Kinzig, M., (A) 137
Kisyombe, G., (A) 179
Kitajima, S.-I., (A) 594, 650
Kitaura, H., (A) 658
Klatser, P. R., (A) 158, 162, 479, 492, 612, 613, (Ob) 298
Klausner, J. D., (A) 638
Klegerman, M. E., (A) 335, 496
Klein, N., (A) 353
Klemens, S. P., (A) 179, 180
Klewer, M., (A) 632
Klinger, J. D., (A) 360
Klintz, L., (A) 176
Klopman, G., (A) 180
Klug, S., (A) 175
Kochi, A., (A) 357
Kode, J. A., (A) 327
Koizumi, F., (A) 620
Kolenda, H., (A) 137
Kolk, A. H. J., (A) 477, 482, 492
Kolls, J., (A) 495
Kolls, J. K., (A) 488
Kolonoski, P., (A) 170, 346
Komatsu, A., (A) 650
Kondo, K. L., (A) 591
Kong, D. Q., (A) 483
Kopparty, S. N. M., (A) 621
Kostman, J. R., (A) 632
Kovacovich, J., (A) 187
Koya, G., (A) 147
Koyuncu, M., (A) 320, (O) 23
Krahenbuhl, J. L., (A) 282, 488, 638, 644
Kramnik, I., (A) 613
Kravzov, J., (A) 135
Kreiswirth, B. N., (A) 352, 637
Kremer, L., (A) 607
Kren, V., (A) 171
Krieger, H., (A) 617
Kripke, M. L., (A) 599
Krishnamurthy, P., (A) 166
Kroes, R., (C) 456
Kroger, H., (A) 632
Kronenberg, M., (A) 656
Kuipers, M., (A) 167
Kulkarni, V. N., (A) 621
Kumar, B., (C) 111, (E) 92
Kumar, P., (A) 364
Kumar, S. B., (A) 494
Kumararatne, D. S., (A) 495
Kumaresan, J. A., (A) 341, 586
Kundu, M., (A) 334
Kunimoto, D. Y., (A) 483
Kunkel, S. L., (A) 323
Kuo, M. C., (A) 323
Kurup, A. M., (A) 621
Kurzynski, T. A., (A) 498
Kuschke, R. H., (A) 156
Kuteyi, V. I. O., (A) 482

Labrousse, V., (A) 148, 499
Lacchini, C., (A) 363
Lackmann, P. J., (A) 327
Ladel, C. H., (A) 326, 600, 602, 603
Ladiwala, U., (A) 145
Lagranderie, M. R. R., (A) 149
Lagrange, P. H., (A) 485
Lai, C. K. W., (A) 491
Lai, Z., *et al.*, (A) 341
Laing, R., (A) 632
Lakhdarghazal, F., (A) 160
Lam, E., (A) 349
Lammas, D. A., (A) 495
Lammers, H., (E) 453
Lancaster, M. V., (A) 639
Landwehr, D., (O) 535
Lane, S. J., (A) 612
Laneelle, G., (A) 160
Langermans, J. A. M., (A) 153, 604
Laochumroonvorapong, P., (A) 651
Lap, V. D., (A) 485
Larkin, C., (A) 360
Larsen, C. G., (A) 603
Launois, P., (A) 151, 151, 324, 329
Law, A. S., (A) 277, (N) 461
Law, K., (A) 366
LeClerc, C. D., (A) 149
Leboeuf, M. A. A., (C) 95
Lee, B. W. E., (A) 496
Lee, B.-Y., (A) 612
Lee, R. K., (A) 591
Leedom, J. M., (A) 178
Leeming, J. P., (A) 159

Leen, C. L. S., (A) 632
Lehman, L. F., (O) 507
Lehmann, B., (A) 593
Lehner, T., (A) 496
Leiker, D. L., (A) 329
Leitch, A. G., (A) 632
Lemange, M. M., (A) 316
Lemassu, A., (A) 633
Lemieux, S., (A) 484
Lenicker, H. M., (A) 353
Lenti, E., (A) 594
Lerner, S. A., (A) 624
Leung, J. C. K., (A) 491
Levee, G., (A) 637
Lever, P., (C) 456, (O) 507
Levin, M., (A) 353
Levis, W. R., (A) 141
Lewallen, S., (A) 140
Lewis, M., (A) 167
Lewis, M. E., (O) 77
Lewis, S., (A) 185
Li, H. Y., (A) 140
Li, H.-Y., (O) 213
Li, J.-Y., (A) 180
Li, L. I., (A) 352
Li, M. S., (A) 190
Li, Q. L., (A) 614
Li, T., (O) 213
Li, T., *et al.*, (A) 612
Li, W.-Z., *et al.*, (A) 341
Li, X., *et al.*, (A) 618
Lian, T. K., (C) 291
Liao, J., *et al.*, (A) 320
Licourt, N., (A) 606
Lieberman, J. M., (A) 345
Lienhardt, C., (O) 62
Likassa, R., (A) 478
Lim, E. M., (A) 354, 615
Lin, C. K., (A) 591
Lin, M. S., (A) 481
Lincoln, P., (A) 323
Lindner, B., (A) 338
Lins-Lainson, Z., (A) 487
Linton, C. J., (A) 159
Lisowska, K., (A) 359
Liu, C., *et al.*, (A) 618
Liu, F.-W., (O) 213
Liu, J., (A) 360
Liu, Q., (A) 609
Locht, C., (A) 607
Lockwood, C. M., (A) 327
Lockwood, D. N. J., (A) 327
Lombardi, C., (A) 329, (C) 95
Londei, M., (A) 605
Long, P., *et al.*, (A) 622
Lopez, A. D., (A) 133, 134, 134
Lopez Marin, L. M., (A) 160
Lopez Sifontes, M. E., (A) 618
Lora Robles, M., (A) 141
Lounis, N., (A) 178, 354, 500, 631
Lowe, N. J., (A) 314
Lowenstein, C. J., (A) 629
Lowrie, D. B., (A) 331, 355
Lu, W., *et al.*, (A) 343
Lubbers, W. J., (A) 141, 142
Lucas, S. B., (A) 144, 487, 620, (O) 222
Luchesi, S., (A) 628
Luengu, M., (A) 596
Luesse, H. G., (C) 97
Lugon, J. R., (A) 186
Lugon, N. V., (A) 186
Lundin, K. E. A., (A) 328, 329
Lyon, D., (A) 190

Mabilat, C., (A) 180
Machabert, N., (A) 180
Mack, P. A., (A) 616
Madeira, S., (A) 312
Madej, J. J., (A) 639
Madhusudan, K., (A) 335
Madsen, L., (A) 625
Maekawa, S., (A) 650
Maganu, E. T., (A) 341, 586
Magro, G., (A) 475
Maguire, A. M., (A) 142
Mahadevan, P. R., (A) 590
Mahajan, P. M., (A) 142
Mahato, S. B., (A) 590
Maiti, T. K., (O) 518
Majumder, S., (A) 181
Mak, T. W., (A) 627, 629
Makino, M., (A) 657
Makonkawkeyoon, S., (A) 638
Malaviya, G. N., (A) 168, 343, 622
Malkovska, V., (A) 603
Malta, A. M., (A) 653
Manavathu, E. K., (A) 624
Manchester, K., (O) 77, 265
Manders, S. M., (A) 632
Mane, I., (A) 329, 589
Manimozhi, N.. (O) 18
Manivannan, K. A., (A) 622
Manjarrez Marmolejo, J., (A) 135
Mansukhani, K., (A) 143, (O) 409
Mantella, A., (A) 363
Mao, Z.-M., (O) 213
Marchal, G., (A) 352
Marchoux Chemotherapy Study Group, (O) 195
Marciano, L. H. S. C., (A) 622
Marco, F., (A) 188
Mariano, M., (A) 605
Marks, S. C., (A) 143
Marostenmaki, J., (A) 170
Marques, F., (A) 617
Marques, F. B., (A) 312
Marques, M. A. M., (A) 652
Marshall, P. S., (A) 612
Martelli, A. C. C., (A) 312
Martelli, C. M. T., (A) 329, 619, (C) 95
Martin, C., (A) 637
Martin, G. M., (A) 494
Martin, J., (A) 483

Martin, L. N., (A) 616
Martinez Cabarga, M., (A) 184
Martiniuk, F., (A) 349
Martins, C. F., (A) 596
Mascarenhas, M. F., (A) 139
Maslov, A. K., (C) 457
Maslow, J. N., (A) 500
Mason, C., (A) 495
Mason, C. M., (A) 488
Masso, F., (A) 182
Mateo, F., (A) 176
Mathers, D. M., (A) 183
Mathurin, S., (A) 189
Matsuki, G., (A) 484
Matsumoto, S., (A) 658
Matsumura, Y., (A) 596
Matsuo, E., (A) 650
Matsuo, T., (A) 658
Matsuoka, M., (A) 648, 650, 651, 652, 658
Matsushima, K., (A) 603
Matsuzaki, G., (A) 355
Matz, J., (A) 137
Maw, W. W., (O) 539
Maxwell, J. D., (A) 362
May, M. H., (A) 349
Mayr, N., (A) 143, (O) 409
Mazurek, G. H., (A) 190
Mazzaccaro, R. J., (A) 656
McAdam, K. P. W. J., (A) 156, (O) 222
McAdam, R. A., (A) 483
McClure, H. M., (A) 616
McConnell, I., (A) 348
McCormick, A. Q., (A) 183
McCormick, J., (A) 160
McCormick, P. A., (A) 181
McCourt, D. W., (A) 614
McCray, E., (A) 497
McCutchan, J. A., (A) 178
McEvoy, P. L., (A) 357
McFadden, J., (A) 608
McGowan, J. R., (A) 177
McHugh, S. M., (A) 327
McIntyre, N., (A) 181
McKenna, M. T., (A) 497
McLean, K., (A) 330, (O) 369
McMillan, D. C., (A) 590
McNeil, M. R., (A) 181, 339, 493
McNerney, R., (A) 179
Medda, S., (A) 590
Medina, Y., (A) 606
Mehdi, S. Q., (A) 487
Mehra, N. K., (O) 241, 518
Mehra, V., (A) 148
Mehta, J. M., (A) 142
Mehta, R. T., (A) 630
Meister, G. E., (A) 633
Meleon, R. H., (A) 329
Meloen, R. M., (A) 328
Mendez, L., (A) 632
Mendez Sampeiro, P., (A) 155
Menne, T., (A) 603
Menz, B., (A) 326
Menzies, R., (A) 623
Merker, H. J., (A) 175
Messadi, F., (A) 631
Metchock, B., (A) 177
Meyers, W. M., (A) 136, 476, 596, 616
Mezo, N., (A) 353, 633
Miesel, R., (A) 632
Mikami, Y., (A) 482
Mikusova, K., (A) 493
Miles, B. A., (A) 625
Millan, J., (A) 473, 473
Millar, D. S., (A) 497
Millar, M. R., (A) 159
Millard, F. J. C., (A) 362
Miller, L., (A) 349
Millesi, H., (A) 143, (O) 409
Mills, J. A., (A) 181
Minagawa, F., (A) 648
Minnucci, F., (A) 476
Minoprio, P., (A) 145, 170
Mishra, G. C., (A) 359
Misra, N., (O) 35
Misra, R. S., (O) 35
Mitra, D. K., (O) 241, 518
Mitsuyama, M., (A) 150
Mittal, A., (C) 293
Miyaji, M., (A) 482
Miyazaki, R., (A) 658
Mizuno, A., (A) 161
Mizuno, K., (A) 596
Mizushima, Y., (A) 496
Mkandwire, P. K., (A) 620
Mobayen, M. H., (A) 318
Mock, B. A., (A) 489
Modlin, R. L., (A) 152, 153, 328, 331, 333, 656
Molloy, A., (A) 638
Mombaerts, P., (A) 603
Monchy, D., (A) 619
Monroni, C., (A) 356
Monroy Noyola, A., (A) 135
Montano, L. F., (A) 182
Moore, C. H., (A) 630
Moore, T. D., (A) 638
Mor, N., (A) 353, 633
Moraes Neto, O. L., (A) 619
Moran, C. A., (A) 596
Morein, B., (A) 606
Moreira, A. L., (A) 154, 605, 651
Moreno, C., (A) 174
Moreno, F., (A) 187
Morgan, A., (A) 145
Morgan, A. R., (A) 332
Mori, H., (A) 187
Morini, J., (A) 322
Morita, C. T., (A) 322
Morita, T., (A) 187
Morlock, G. P., (A) 628
Morris, H. R., (A) 482, 611
Morris, P., (A) 335, 496
Morris, S., (A) 497

Morrison, N. E., (E) 86
Morwitz, M. A., (A) 630
Moschella, S. L., (A) 468
Mostafa, H. M., (C) 97
Moumouni, A., (A) 486
Mukasa, A., (A) 355
Mukherjee, A., (A) 332, 332, (O) 249
Muller, D., (A) 603
Murphy, D. T., (A) 190
Murray, A., (A) 354
Murray, C. J. L., (A) 133, 133, 134, 134
Murray, J. C., (A) 172
Murray, L. P., (A) 148, 164, (O) 259
Musser, J. M., (A) 352, 637
Mustafa, A. S., (A) 328, 329
Muthukkaruppan, V. R., (A) 150, 480
Myer, M. S., (A) 188
Myers, N., (A) 164

Naafs, B., (A) 472, 474, 590, (Ob) 298
Nabeshima, S., (A) 355
Nadeau, J. G., (A) 163
Nagai, S., (A) 477
Nagaraja, V., (A) 157, 335
Nagarajan, M., (O) 391
Nagaraju, B., (A) 320
Nah, S. H., (A) 143
Naik, S. S., (A) 314
Nakamura, M., (O) 28
Nakamura, S., (A) 484
Nakanaga, K., (A) 651, 652
Nakandakari, S., (A) 617
Nakata, K., (A) 640
Narang, P., (A) 148
Narayan, N. P. S., (A) 150, 331
Narayanakumar, T. S., (A) 622
Naser, S. A., (A) 173
Nasiruddin, (A) 610
Nassos, P. S., (A) 177, 639
Natal, S., (A) 631
Nath, I., (A) 281, 331, (O) 35
Natrajan, M., (A) 595, (O) 202
Nau, H., (A) 175
Nau, R., (A) 137
Navalkar, R. G., (A) 608
Nayak, R., (A) 346
Ndiaye, M. N., (A) 151, 329
Nedunchezian, D., (A) 184
Negesse, Y., (A) 141
Neill, S. D., (A) 186
Nelson, A. M., (A) 596
Nelson, S., (A) 488
Nery, J. A. C., (A) 605, 613, (C) 570
Nettleman, M. D., (A) 355
Neubert, D., (A) 152, 175, 355
Neubert, R., (A) 152, 355
Neupane, K., (A) 591
Newman, G. W., (A) 182, 629
Newport, M. J., (A) 353
Ngowi, F. I., (A) 179
Niang, M. N., (A) 151
Nibbering, P. H., (A) 182
Nicholls, R. D., (A) 613
Nichols, C., (A) 142
Niemczyk, S., (A) 500
Nietupski, R., (A) 360
Nikaido, H., (A) 607
Nishiwaki, S., (A) 636
Nishiyama, T., (A) 658
Nogueira, A. C., (A) 152
Nolan, C. M., (A) 163
Nomaguchi, H., (A) 651, 652, 658
Nomoto, K., (A) 150, 355
Nonaka, S., (A) 595
Noordeen, S. K., (A) 486, (E) 559
Norden, M. A., (A) 498
Norisaki, N., (A) 482
North, R., (A) 651
Nowak, J., (A) 603
Nunzi, E., (A) 594
Nurilygn, A., (O) 369
Nutman, T. B., (A) 328
Nyabenda, J., (A) 324
Nyasulul, S., (A) 620
Nycz, C. M., (A) 163

Obara, A., (A) 596
Oberti, J., (A) 485
O'Brien, D., (A) 490
O'Brien, L., (A) 355
O'Brien, R. J., (A) 347
Obura, M., (A) 487
Ockenfels, H., (A) 632
O'Driscoll, C. M., (A) 137
Offringa, R., (A) 615
Oftung, F., (A) 328, 329
Ogata, J., (A) 147
Ohara, N., (A) 161, 658
Ohmen, J. D., (A) 153
Ohta, K., (A) 335
Okabe, S., (A) 636
Okamoto, H., (A) 596
Okelo, C., (A) 487
Okuku, P., (A) 487
Olive, D. M., (A) 360
Oliver, J. L., (A) 638
Olliaro, P., (A) 631
Olsson-Liljequist, B., (A) 176
Oner, F., (A) 335, 496
Onorato, I., (A) 171, 497, 625
Onyebujoh, P. C., (A) 498
Onyi, G. O., (A) 190
Opromolla, D. V. A., (A) 312, 314, 596, 597, 597, 597, 617
Ordway, D. J., (A) 355
Orefici, G., (A) 365
Orege, P. A., (A) 487
O'Reilly, J. R., (A) 137
Orme, I. M., (A) 156, 170, 355, 356, 493
Orsi, P. G., (A) 363
Ortalo-Magne, A., (A) 633
Ortega, V. V., (A) 153

Oskam, L., (A) 613
Osoriorico, L., (A) 135
Ostroff, C. R., (A) 639
Ostroff, S. M., (A) 172, 177
O'Sullivan, J. F., (A) 188, 496
Oswald, I. P., (A) 148
Ottenhoff, T. H. M., (A) 329, 615
Owen, B. M., (A) 474
Ozturk, A., (A) 320, (O) 23

Pacheco, G. O., (A) 153
Paez, A., (A) 182
Pakpreo, P., (A) 603
Palamanda, J. R., (A) 469
Paletta, C., (A) 189
Palmer, B. D., (A) 627
Palmer, B. F., (A) 471
Palou, M., (A) 173
Palumbo, C. L., (A) 169
Palumbo, L., (A) 637
Pan, H.-Y., *et al.*, (A) 341
Pande, T. K., (A) 141
Pandya, S., (A) 145
Pani, S., (A) 141
Pannikar, V., (A) 587
Panteix, G., (A) 180
Panunto-Castelo, A., (O) 231
Paone, G., (A) 488
Paramasivan, C. N., (A) 136
Pares, A., (A) 189
Park, B. K., (A) 316
Park, H. S., (A) 481
Park, S., (A) 492
Parkash, O., (A) 148, 479, (C) 572
Parry, J. V., (A) 620
Pascopella, L., (A) 628
Pasvol, G., (A) 174
Patel, B. N., (A) 146
Paterson, D. L., (A) 356
Patil, M. A., (O) 202
Patil, S. A., (A) 604
Patki, A. H., (A) 142
Patrick, C. C., (A) 631
Patrus, O. A., (A) 136, 313, 593, 594
Pattyn, S. R., (A) 285, 595
Pavithran, K., (A) 142
Peake, P. W., (A) 154, 358
Pearson, A. J., (A) 180
Pearson, J. R., (A) 349
Pedersen, B. K., (A) 357
Pederson, K., (A) 603
Pedrosa, J., (A) 145, 170, 624
Peerapakorn, S., (A) 338
Peetermans, W. E., (A) 153, 604
Peloquin, C. A., (A) 625
Penati, V., (A) 363
Pereira, G. M. B., (A) 605
Perez, I., (A) 606
Perez, M. H., (A) 183
Perrin, L., (A) 494
Perronne, C., (A) 500
Persing, D. H., (A) 177, 366, 609
Pertel, P., (A) 138
Pervin, K., (A) 496
Pesce, C., (A) 594
Pessolani, M. C. V., (A) 160, 615, 652
Peterhans, E., (A) 478
Peters, J., (A) 591
Petrini, B., (A) 175
Petrofsky, M., (A) 346
Petty, R. E., (A) 183
Pfeffer, K., (A) 629
Philippi-Schulz, S., (A) 191
Phillips, G., (A) 492
Piddock, L. J., (A) 159, 190
Piersimoni, C., (A) 363
Pietro, R. C. L., (A) 331
Pietrzak, J., (A) 356
Pinho, J. R. R., (A) 336, (O) 381
Pinto, J., (A) 345
Pita, M., (A) 606
Pithie, A. D., (A) 495
Pividori, J. F., (A) 322
Plikaytis, B. B., (A) 352
Pocidalo, J.-J., (A) 500
Poenca, N. G., (A) 315
Poiesz, B. J., (A) 141
Poincelet, M., (A) 610
Polak, J. M., (A) 164
Ponnighaus, J. M., (A) 324, 591, 620, (O) 1, 535
Popper, H. H., (A) 184
Porcelli, S. A., (A) 322, 656
Portaels, F., (A) 163, 483, 631
Portillo Gomez, L., (A) 497
Portnoi, D., (A) 354
Posadas-Lopez, A., (O) 546
Poupard, J. A., (A) 638
Powell, K. J., (A) 362
Powell, R. J., (A) 350
Prabhakar, M. C., (A) 336
Prabhakar, R., (A) 136, (O) 391
Prange, H. W., (A) 137
Prasad, H. K., (A) 331
Prigozy, T. I., (A) 656
Pritchard, S., (A) 492
Puzo, G., (A) 614

Qiao, J., et al., (A) 591
Qiu, W.-P., (A) 320, 321
Quemard, A., (A) 494
Quesada, D., (A) 160
Quesada-Pascual, F., (O) 56, 546
Quezada, R., (A) 155
Quinn, F. S., (A) 337

Raats, C. J. I., (A) 153, 604
Rabson, A. R., (A) 174
Radford, A. J., (A) 349
Radzioch, D., (A) 613
Rafi, A., (O) 42
Raghavan, A., (A) 358
Rahelu, M., (A) 495

Raizman, M. B., (A) 472
Rajagopalan, M., (A) 362
Rajalingam, R., (O) 241, 518
Ralph, E. D., (A) 175
Ramachandran, A., (A) 138
Ramakrishnan, A. G., (O) 395
Ramakrishnan, L., (A) 165
Ramasastry, C. V., (A) 320
Ramesh, V., (A) 310, 335, (C) 293, (O) 35
Ramon, J., (A) 317
Ramos, E., (A) 155
Ramos, F., (A) 487
Ramu, G., (A) 150, 315, 331, 480, 591, 604
Ran, S.-P., (O) 213
Ran, Y. P., (A) 356
Rao, B. B., (A) 318
Rao, D. C., (A) 617
Rao, P. S., (A) 138, 166, 315
Rao, P. S. A., (O) 529
Rao, P. S. S., (A) 140
Rashid, M. A., (A) 595
Rastogi, N., (A) 148, 160, 499, 499
Raszaka, W. V., (A) 357
Ratledge, C., (A) 612, 614
Ratliff, T. L., (A) 614
Rattan, A., (A) 162
Ratterree, M. S., (A) 616
Rauzier, J., (A) 354
Ravi, S., (A) 138
Raviglione, M. C., (A) 347, 357
Ravn, P., (A) 357
Rayment, N., (A) 327
Raynes, J., (O) 222
Raynes, J. G., (A) 156
Reddy, M. V., (A) 496
Reddy, P. S., (A) 358
Reddy, S. G., (A) 156
Reepmeyer, J. C., (A) 139
Rees, R. J. W., (A) 324
Reeve, J. R., (A) 630
Rege, V. L., (A) 139
Reibman, J., (A) 366
Reimondo, G., (A) 475
Reingold, A. L., (A) 172, 177, 639
Remold, H. G., (A) 182, 629
Repiso Montero, T., (A) 147
Revel, V., (A) 161
Rhoades, E. R., (A) 493
Rhodes, L. E., (A) 316
Rhodes, M. O., (A) 139
Ribeiro, A., (A) 345, 364
Richard, V., (O) 259
Richards, S. B., (A) 187
Richardus, J. H., (A) 619
Richeldi, L., (A) 488
Richter, E., (A) 324, 336, 336
Rifabutin Study Group, (A) 631
Rifkin, I. R., (A) 327
Rinke de Wit, T. F., (O) 369
Rios, C., (A) 135
Ritacco, V., (A) 188
Riviere, M., (A) 614
Rivoire, B., (A) 160, 615, 645
Roach, T. I. A., (A) 489
Robb, M. L., (A) 357
Roberts, A. D., (A) 356, 493
Roberts, C. A., (O) 77, 265
Roberts, C. G. P., (A) 633
Roberts, G. D., (A) 177, 366
Robinson, S., (A) 498
Robuck, K. S., (A) 493
Roche, P. W., (A) 154, 330, 344, 358
Rodes, J., (A) 189
Rodrigues, S., (A) 620
Rodriguez, N., (A) 606
Rodriguez, V., (A) 480
Rodriguez Barreras, M., (A) 474
Roger, P. C. J., (A) 492
Rojas, V., (A) 472
Rom, W., (A) 349, 638
Rom, W. N., (A) 185, 366, 640
Romkes Sparks, M., (A) 469
Romzek, N. C., (A) 481
Roniker, B., (A) 314
Ronn, A. M., (A) 316
Rook, G. A. W., (A) 322, 477, 498
Roos, B. R., (O) 422, 552
Roque-Barreira, M.-C., (O) 231
Rosenwasser, L. J., (A) 137
Ross, D. G., (A) 174
Rossi, A., (A) 626
Roth, C., (A) 469
Rothe, J., (A) 600
Roul, R. K., (A) 319
Rouse, D., (A) 497
Routes, J. M., (A) 137
Rowley, M. J., (A) 479
Roxo, E., (A) 605
Rubenstein, E., (A) 317
Rubiales, F. C., (A) 153
Rubilar, M., (A) 632
Ruchal, S. P., (A) 344
Ruiz, J., (A) 188
Ruiz, P., (A) 499
Ruiz Silva, J., (A) 628
Rusch-Gerdes, S., (A) 336
Russell, D. G., (A) 156
Russin, V. L., (A) 632
Ruth, J., (A) 323
Ruzany, F., (A) 186

Saab, N., (A) 318
Sacchettini, J. C., (A) 494
Sada, E., (A) 155
Saha, B., (A) 359
Saha, K., (C) 105, (O) 249
Saha, N. G., (A) 595
Sahu, K., (A) 317
Saito, H., (A) 653, (O) 539
Salafia, A., (A) 475, 598
Salfinger, M., (A) 163
Salgado, J. L., (A) 154

Salodkar, A. D., (A) 598
Salomon, R. N., (A) 174
Saltini, C., (A) 488
Samaha, D., (A) 136
Sampaio, E. P., (A) 605, 653, (C) 570
Samson, P. D., (A) 327, 476
Sanchez, L., (A) 182
Sanchez Navarro, A., (A) 184
Sanders, C. A., (A) 639
Sanders, W. E., (A) 626
Sandoval, F., (A) 654
Sandoval, S., (A) 182
Sane, S., (A) 621
Sansarricq, H., (A) 166
Santamaria, L., (A) 164
Santos, A. R., (A) 613
Santos, D. O., (A) 154
Santos, M. I. R., (A) 146
Santos-Argumedo, L., (O) 56, 546
Saporta, L., (A) 598
Sarai, A., (A) 184
Saran, B. R., (A) 142
Sarkar, S., (A) 334
Sarmento, A., (A) 599
Sarno, E. N., (A) 154, 605, 653, (C) 570
Sarthou, J. L., (A) 151, 151, 329
Saruni, A. O. S., (A) 179
Sasiain, M. C., (A) 476
Sathe, S. S., (A) 184
Sato, E., (A) 594, 650
Sato, K., (A) 653, (O) 539
Saunders, M., (A) 320
Saunderson, P. R., (A) 475
Saxena, U., (C) 293
Sayal, S. K., (A) 320
Schaefer, P., (A) 140
Schell, R. F., (A) 498
Schenberg, A. C., (A) 336, (O) 381
Schepers, P., (A) 162
Scherman, M., (A) 493
Scheuer, P. J., (A) 181
Schipper, A., (A) 141, 142
Schluger, N. W., (A) 185
Schluter, C., (A) 324, 336, 336
Schmahl, H. J., (A) 175
Schoel, B., (A) 154, 606
Schoolnik, G., (A) 360
Schorey, J. S., (A) 614
Schram, J. L., (A) 163
Schreiber, R., (A) 629
Schreuder, B. M. T., (A) 490
Schreuders, T., (A) 167
Schukkink, R. A. F., (A) 162
Schurr, E., (A) 485
Schurra, C., (A) 176
Scollard, D. M., (A) 488, (B) 578, (C) 295
Scott, D. K., (A) 645
Scott, F., (A) 181
Scuderi, J. D., (A) 483
Searle, S., (A) 489
Sedlaczek, L., (A) 359
Sekar, B., (A) 138, 143, 319
Sekosan, J., (A) 185
Sekosan, M., (A) 185
Sengupta, U., (A) 479, 592, 604
Senn, H. P., (A) 356
Senseng, C., (A) 185
Seo, Y.-H., (C) 101
Sepulveda, R. L., (A) 185
Sequiera, E. B., (A) 314
Sergeantson, S., (A) 145
Seydel, U., (A) 338
Shafer, R. W., (A) 360
Shah, J. S., (A) 360
Shah, V., (A) 140
Shank, D. D., (A) 163
Shankar Narayan, N. P., (A) 480, (O) 35
Shannon, E. J., (A) 161, 330, 588, 654, (O) 369
Sharma, R. N., (A) 143, 319
Sharma, V. D., (O) 202
Sharma, V. K., (C) 111, (E) 92
Sharman, G. J., (A) 614
Sharp, J. M., (A) 335
Sharples, C. E., (A) 360
Shaw, J., (A) 487
Shaw, M. A., (A) 360, 487, 489
Sheehan, T. M. T., (A) 490
Sheela, R., (A) 480
Shen, J.-P., *et al.*, (A) 330, 340
Shetty, V. P., (A) 155, (C) 104, 573
Shinnick, T. M., (A) 328, 337, 337, 352, 496, 657
Shiratsuchi, H., (A) 363
Shirley, A., (A) 276
Shivannavar, C. T., (O) 202
Shukla, P., (A) 139
Shuntawuttisettee, S., (A) 338
Shute, J., (A) 168
Sidhumalik, N., (A) 172
Sieling, P. A., (A) 331, 656
Sierra, M. F., (A) 360
Silva, C. L., (A) 331
Silva, I. M., (A) 619
Silva, M. F., (A) 331
Silva, M. T., (A) 624
Silva, R. A., (A) 170, 599
Silva, S. A., (A) 619
Silva, S. R. B., (A) 186
Silva, T. C., (A) 146
Silveira, F., (A) 487
Silver, R. F., (A) 500
Silverton, J. V., (A) 139
Sim, E., (A) 469
Simon, B., (A) 633
Simon, E. M., (A) 172, 177
Simonetti, M. T., (A) 363
Simpson, A., (A) 490
Simson, J. V., (A) 590
Singay, J., (A) 486
Singh, A. P., (A) 361
Singh, N., (C) 454
Singh, N. B., (A) 481
Singh, S., (A) 331

Singh, S. P., (A) 360
Singhal, B., (A) 145
Sinha, S., (A) 481
Sinhorini, I. L., (A) 605
Sinicropi, D. V., (A) 145
Sison, J.P., (A) 178
Siu, P., (A) 148, 164, (O) 259
Sivaram, M., (A) 621
Skamene, E., (A) 613
Skillman, L. P., (A) 357
Skinner, M. A., (A) 191
Skinner, P. S., (A) 356
Skinsnes, O. K., (A) 650
Skodt, V., (A) 603
Skuce, R. A., (A) 186
Small, P. M., (A) 360
Smith, A. W., (A) 484
Smith, D. R., (A) 160, 652
Smith, J. A., (A) 170
Smith, N. J., (A) 350
Smith, W. C. S., (A) 313, (O) 507
Smithwick, R. W., (A)]636
Snider, D. E., (A) 171, 357
Snider, T. G., (A) 638
Soares, D., (A) 332, 344, 591, 622, 623
Solis, R. L., (A) 606
Sommer, S. S., (A) 609
Sommerfeld, P., (A) 311
Son, K., (A) 335, 496
Soni, N. K., (A) 143
Sonnenberg, M. G., (A) 355
Sorensen, R. U., (A) 185
Sorgel, F., (A) 137
Soriano, T., (A) 656
Sornprasit, C., (A) 338
Sottil, J. P., (A) 619
Sougakoff, W., (A) 161, 171
Southwood, T. R., (A) 183
Souza, J. M. P., (A) 329
Sow, S., (A) 317
Spears, P. A., (A) 163
Speert, D. P., (A) 636
Speirs, R. J., (A) 592
Spies, H. S. C., (A) 186
Sprenger, S., (A) 154
Sramek, H. A., (A) 163
Sreevatsa, (A) 337, (O) 202
Srinivasan, H., (C) 291
Srinivasan, T. M., (O) 395
St. Julien, L., (A) 317
Stanford, J. L., (A) 318, 322, 498, (O) 42
Steenkamp, D. J., (A) 186
Steingrube, V. A., (A) 190, 362
Stephens, J., (A) 493
Stern, H. A., (A) 625
Stern, R. S., (A) 314
Sterne, J. A. C., (A) 324, 591, 620
Stevenson, K., (A) 335
Sticht-Groh, V., (A) 163, (C) 100
Stockman, L., (A) 177, 366
Stokes, R. W., (A) 636
Stone, B., (A) 360
Stone, E. N., (A) 172
Strachan, D. P., (A) 362
Stracke, R., (A) 365
Stratford, C. J., (A) 474
Strugnell, R. A., (A) 479
Struillou, L., (A) 500
Struyk, L., (A) 351
Stuart, R. S., (A) 364
Sturgill Koszycki, S., (A) 156
Subedi, A. M. C., (A) 476
Subramaniam, K., (A) 143
Subramanian, A., (A) 622
Subramanian, G., (A) 315
Subramanian, M., (A) 138, 166, 315
Sudik, H., (A) 650
Sueoka, E., (A) 636
Suffys, P. N., (A) 154, 6497, 13
Suganuma, M., (A) 636
Suite, M., (A) 167
Sullivan, E. A., (A) 637
Sultan, F., (A) 363
Sumiishi, A., (A) 650
Sussman, G., (A) 156
Suwa, Y., (A) 187
Suzuki, Y., (A) 657
Svenson, C. K., (A) 318
Svensson, C. K., (A) 139
Swabb, E., (A) 314
Swaminathan, G., (A) 136
Swiderek, K., (A) 629
Sylla, P. M., (A) 317, 586, 620
Sypek, J., (A) 601

Tabiro, T., (A) 147
Takada, H., (A) 355
Takaesu, Y., (A) 150
Takahashi, H., (A) 179
Takano, M., (A) 161, 658
Talhari, S., (A) 134, 278
Tambwekar, S., (A) 143, (O) 409
Tamez-Guerra, R., (A) 630
Tan, P. L. J., (A) 191
Tan, W. P., (A) 321, 344
Tanaka, K., (A) 470, 491
Taneja, V., (O) 241, 518
Taniguchi, T., (A) 335
Tank, B., (A) 474
Taylor, H. W., (A) 638
Tebas, P., (A) 363
Tekle Haimanot, R., (A) 141
Telenti, A., (A) 352, 468
Teran, L., (A) 155
Terencio de las Aguas, J., (A) 147, 168, 475
Terenghi, G., (A) 164
Terzolo, M., (A) 475
Thaker, A., (A) 362
Thappa, D. M., (A) 344
Thawani, G., (A) 332, 332
Theler, J. M., (A) 610
Thestrup Pederson, K., (A) 603

Theuvenet, W. J., (A) 344
Thole, J. E. R., (A) 329, 477, 477, 482, 615, 647(O) 369
Thomas, A., (O) 391
Thompson, K., (E) 567
Thompson, S. E., (A) 177
Thomsen, H. K., (A) 603
Thomsen, M. K., (A) 603
Thomsen, P. D., (A) 603
Thomssen, H., (A) 605
Thrasher, A., (A) 353
Thyagarajan, S. P., (A) 319
Tiendrebeogo, A., (A) 620
Tilles, J. G., (A) 178
Timm, J., (A) 354
Tingle, M. D., (A) 316
Titus, M. G., (A) 169
Tizard, M. L., (A) 497
Tobari, J., (A) 335
Tocanne, J. F., (A) 160
Toida, I., (A) 640
Tokunaga, H., (A) 594
Tollefson, J., (A) 167
Tomioka, H., (A) 653, (O) 539
Tomiyama, T., (A) 187
Tonegawa S., (A) 603
Tonelo, C., (A) 617
Toossi, Z., (A) 351, 363
Torrea, G., (A) 354, 637
Torrella, A., (A) 606
Torres, M., (A) 155
Torres Morales, A., (A) 628
Tortoli, E., (A) 363
Tramontana, J. M., (A) 638
Trenti, G., (A) 488
Trias, J., (A) 162
Triccas, J. A., (A) 330, 615
Triebold, K. J., (A) 601, 629
Truffot-Pernot, C., (A) 171, 176, 178, 347, 354, 587, 631
Truman, R. W., (A) 282
Tsang, M., (A) 148, 164, (O) 259
Tsenova-Berkova, L., (A) 651
Tsigler, D., (A) 184
Tsuchida, N., (A) 349
Tsukaguchi, K., (A) 346, 363
Tsutsumi, S., (A) 484
Tu, X., (A) 586
Turcotte, R., (A) 484
Turk, J. L., (A) 135, 164
Turkof, E., (A) 143, (O) 409
Turner, A. C., (A) 620
Tuur, S. M., (A) 596
Tyagi, J. S., (A) 162

Ueda, K., (A) 594
Ulrich, M., (A) 480
Ulstrup, J. C., (A) 364
Unadkat, J. D., (A) 469
Uplekar, M. W., (A) 155
Upton, R. J., (A) 612
Uqaili, Z., (O) 222
Ura, S., (A) 312, 597, 617
Ura, T., (A) 640
Utaipat, U., (A) 638
Uthoff, K., (A) 364
Utrup, L. J., (A) 638
Uyemura, K., (A) 481

Vadher, A., (C) 120
Vage, C., (A) 139, 318
Vakulenko, S. B., (A) 624
Valdez, R., (A) 476
Valentini, E., (A) 628
Valero, G., (A) 187
Valway, S. E., (A) 187
Van Agterveld, M., (A) 477
van Beers, S., (C) 456
van Brakel, W. H., (A) 144, 144, 168, 321, (O) 422, 552
Van Cua, V., (A) 485
van Embden, J. D. A., (A) 176, 188, 366, 631
van Furth, R., (A) 153, 182, 604
van Gemen, B., (A) 162
Van Heyningen, T., (A) 156
van Joost, T., (A) 474
van Linden, F., (A) 492
van Rensberg, C. E. J., (A) 188
Van Reyn, C. F., (A) 500
van Soolingen, D., (A) 188, 366, 615, 631
Van Thus, N., (A) 485
van Vooren, J. P., (A) 151, 151
Van den Barselaar, M. T., (A) 182
van der Vliet, G. M. E., (A) 162, 492
Vance, E. A., (A) 182
Vandenelsen, P. J., (A) 351
Vandepoele, M., (A) 157
Vanderkolk, J., (A) 353
Vanderzee, R., (A) 496
Vanuitert, B., (A) 142
Vargaftig, B. B., (A) 148
Vartak, R. R., (A) 314
Vasanthi, B., (A) 143
Vaughan, R., (A) 496
Vazquez, L., (A) 182
Veasey, R. S., (A) 638
Venisse, A., (A) 614
Verbov, J. L., (A) 316
Vercauteren, J., (A) 614
Verchot, B., (A) 473
Verdier, M., (A) 141
Verma, A., (A) 162
Verma, K. K., (A) 344
Verschuuren, M., (E) 453
Viana, P. C. F., (A) 186
Vicente, E. J., (A) 336, (O) 381
Vieira, L. M. M., (A) 605
Vijayakumaran, P., (O) 18
Vila, J., (A) 188, 189
Vila, L. M., (A) 481
Vilagut, L., (A) 189
Vilanova, M., (A) 345, 364

Vilde, J.-L., (A) 500
Villahermosa, L. G., (A) 647, (O) 8
Villar, I., (A) 189
Vinas, O., (A) 189
Vinayakumar, S., (A) 327
Virmond, M., (A) 623
Vishwanathan, K. A., (A) 141
Vittinghoff, E., (A) 172
Vogelsang, G., (A) 364
Vogt, H., (A) 478
Vohra, H., (A) 359
von Balestrem, W. C., (A) 324
Vordermeier, H.-M., (A) 174

Waddell, K. M., (A) 475
Wadee, A. A., (A) 156
Wagner, B., (A) 365
Wagner, M., (A) 365
Waguespack, C., (A) 163
Wahlen, P., (A) 175
Wakamatsu, A., (A) 146
Walker, G. T., (A) 163
Walker, L. L., (A) 657
Wallace, R. J., (A) 190, 362, 363, 365, 470
Wallis, C. K., (A)]636
Wallis, R. S., (A) 500
Walsh, G. P., (A) 616, 645, 647, (O) 8
Walter, C. S., (A) 135
Wang, J., (A) 651
Wang, S., (A) 180
Wang, X. H., (A) 481
Wang, X., *et al.*, (A) 623
Ward, A., (A) 469
Warmington, K., (A) 323
Warndorff, D. K., (A) 620
Watanabe, N., (A) 640
Waters, M. F. R., (A) 470, 477
Watson, A. S., (A) 631
Watson, J., (A) 167
Watson, J. M., (O) 507
Watt, B., (A) 632
Watt, N., (A) 478
Wayne, L. G., (A) 163, 337
Weiden, M., (A) 640
Weir, R. E., (A) 332
Weisbrod, T. R., (A) 158, 483
Weiss, F., (A) 318
Welch, J. T., (A) 592
Weng, X.-M., (O) 213
Were, M., (A) 487
Wheeler, J. G., (O) 62
Wheeler, P. R., (A) 156
Whelen, A. C., (A) 366, 609
White, J. K., (A) 489
White, M., (A) 353
Whitehead, S. H., (A) 489
WHO Leprosy Unit, (A) 592
Wichitwechkarn, J., (A) 338
Wieles, B., (A) 615
Wiese, M., (A) 338
Wiker, H. G., (A) 150, 364
Wilcke, T., (A) 490
Willcocks, L., (A) 632
Williams Chestnut, R. E., (A) 145
Williams, D., (A) 609
Williams, D. H., (A) 614
Williams, D. L., (A) 163, 366, 472, 615, 649
Williams, H., (A) 489
Wilson, A. B., (A) 327
Wilson, R. W., (A) 362
Wilson, S., (A) 179
Wilson, T. M., (A) 500
Winter, E., (A) 184
Winter, N., (A) 615
Wise, R., (A) 491
Withey, S. J., (A) 497
Woldehawariat, N., (A) 478
Wolf, S., (A) 601
Wolucka, B. A., (A) 339
Wondimu, A., (A) 476, 478, 602
Wong, A., (A) 170
Wong, D. K., (A) 630
Wood, J., (A) 490
Wormser, G. P., (A) 190
Woster, P. M., (A) 318
Wozel, G., (A) 593
Wright, E. L., (A) 160
Wu, J. Y., (A) 182
Wu, M., (A) 178
Wu, Q.-X., *et al.*, (A) 339, 342
Wu, X.-Q., *et al.*, (A) 339

Xia, L.-P., *et al.*, (A) 332
Xie, J. M., (A) 495
Xie, Y.-L., *et al.*, (A) 333
Xu, K., (A) 616
Xu, S. M., (A) 156
Xu, S., *et al.*, (A) 623
Xu, Z. F., (A) 627

Yadav, V. S., (A) 595
Yagco, B., (A) 178
Yajko, D. M., (A) 172, 177, 639, 639
Yakrus, M. A., (A) 639
Yamada, T., (A) 161, 658
Yamada, Y., (O) 539
Yamamoto, S., (A) 606, 640
Yan, L.-B., *et al.*, (A) 344]
Yang, J., et al., (A) 620
Yang, J. F., (A) 150
Yang, Z. H., (A) 366
Yang, Z.-L., *et al.*, (A) 342
Yang, Z.-M., *et al.*, (A) 342
Yano, I., (A) 636
Yao, Y. Z., (A) 178
Yassin, R. J., (A) 157
Yazawa, K., (A) 482
Yew, W. W., (A) 190
Yin, Y., *et al.*, (A) 344
Ying, Y.-P., (A) 657
Yogi, Y., (A) 652
Yoneda, T., (A) 351

Yongchaiyud, P., (A) 631
Yoshida, S., (A) 355
Yoshida, S. I., (A) 182
Young, D., (A) 191
Young, L. S., (A) 170, 178, 322, 346
Young, T. G., (A) 363
Yu, B., *et al.*, (A) 623
Yu, S. W., (A) 334
Yuan, S. N., (A) 191
Yuen, K. Y., (A) 352
Yukitake, H., (A) 658
Yuksel, A., (A) 598

Zehr, K. J., (A) 364
Zenteno, E., (A) 182
Zhang, G., (O) 507
Zhang, M., (A) 333
Zhang, Y., (A) 191
Zhang, Y. H., (A) 640
Zhang, Y. S., (A) 362
Zhao, T., et al., (A) 620
Zheng, D.-Y., (O) 213
Zheng, D.-Y., *et al.*, (A) 342
Zheng, T., (O) 507
Zhong, Y.-H., (A) 366
Zhou, G.-P., (A) 356
Zhou, H.-M., *et al.*, (A) 340
Zhou, X., (A) 593
Zhou, X.-T., *et al.*, (A) 333
Zicker, F., (A) 329, 619, (C) 95
Zolg, J. W., (A) 191
Zribi, M., (A) 631
Zugel, U., (A) 606
Zurcher, G., (A) 468
Zvonok, N. M., (A) 624
Zwadyk, P., Jr., (A) 164
Zwilling, B. S., (A) 146, 625

SUBJECT INDEX

This Subject Index is compiled from key words in the title of each entry. Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), abstracts (A), book reviews (B), reprinted article (R), and special section (SS).

Acid, fatty,
The effect of mixed micellar systems, bile salt/fatty acids, on the solubility and intestinal absorption of clofazimine (B663) in the anaesthetised rat. O'Reilly, J. R., *et al.* .....(A) 137

Acid-fast bacilli,
Acid-fast bacilli from former leprosy regions in coastal Norway showing PCR positivity for *M. leprae*. Mostafa, H. M., *et al.* .....(C) 97
In vitro experiments with *Centella asiatica*: investigation to elucidate the effect of an indigenously prepared powder of this plant on the acid-fastness and variability of *M. tuberculosis*. Herbert, D., *et al.* .....(A) 136

Acquired immunodeficiency syndrome (AIDS),
AIDS and tuberculosis/leprosy in Nigeria: the urbanisation factor. Awofeso, N. .....(A) 617
Acquired resistance in *M. avium* complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. Doucet-Populaire, F., *et al.* .....(A) 587
Growth-deficient mycobacteria in patients with AIDS: diagnosis by analysis of DNA amplified from blood or tissue. Emler, S., *et al.* .....(A) 494
Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic *M. avium* complex infection with rifabutin. Saran, B. R., *et al.* .....(A) 142
Isolation of the newly described species *M. celatum* from AIDS patients. Tortoli, E., *et al.* .....(A) 363
Low-dose desamethasone as adjunctive therapy for disseminated *M. avium* complex infections in AIDS patients. Wormser, G. P., *et al.* .....(A) 190
National trends in the concurrence of tuberculosis and acquired immunodeficiency syndrome. Burwen, D. R., *et al.* .....(A) 625
Pentoxifylline aggravates impairment in tumor necrosis factor alpha secretion and increases mycobacterial load in macrophages from AIDS patients with disseminated *M. avium intracellulare* complex infection. Sathe, S. S., *et al.* .....(A) 184
Polyclonal *M. avium* infections in patients with AIDS: variations in antimicrobial susceptibilities of different strains of *M. avium* isolated from the same patient. Van Reyn, C. F., *et al.* .....(A) 500
Predictors of survival in patients with AIDS and disseminated *M. avium* complex disease. Horsburgh, C. R., *et al.* .....(A) 177
The impact of *M. avium* complex bacteremia and its treatment on survival of AIDS patients–a prospective study. Chin, D. P., *et al.* .....(A) 172
The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol and rifampin, on *M. avium* complex bacteremia in patients with AIDS. Kemper, C. A., *et al.* .....(A) 178
Transient exacerbation of tuberculous lymphadenitis during chemotherapy in patients with AIDS. Hill, A. R., *et al.* .....(A) 176

Adenosine triphosphate (ATP),
The *M. leprae* genome: systematic sequence analysis identifies key catabolic enzymes, ATP-dependent transport systems and a novel po1A locus asociated with genomic variability. Fsihi, H. and Cole, S. T. .....(A) 609

Africa,
Immunotherapy with *M. vaccae* as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Onyebujoh, P. C., *et al.* .....(A) 498

Amoxicillin,
Susceptibilities of nontuberculosis mycobacterial species to amoxicillin-clavulanic acid alone and in combination with antimycobacterial agents. Utrup, L. J., *et al.* .....(A) 638

Anemia,

Dapsone-induced hemolytic anemia: effect of dapsone hydroxylamine on sulhydryl status, membrane skeletal proteins and morphology of human and rat erythrocytes. McMillan, D. C., *et al.* ..... (A) 590

Dapsone-induced hemolytic anemia: role of glucose-6-phosphate dehydrogenase in the hemolytic response of rat erythrocytes to N-hydroxydapsone. Grossmann, S., *et al.* ..... (A) 588

Antibody(ies),

Antibody reactivity to mycobacterial 65 kDa heat shock protein: relevance to autoimmunity. Karopoulos, C., *et al.* ..... (A) 479

Anticardiolipin antibodies in leprosy. Thawani, G., *et al.* ..... (A) 332

Association of antibodies to *M. leprae* and nerve antigens with lepra reactions in leprosy patients. Cho, S.-N., *et al.* ..... (A) 647

Autoantibodies to cerebroside sulphate (sulphatide) in leprosy. Wheeler, P. R., *et al.* ..... (A) 156

Circulating immune complexes in patients with advanced tuberculosis and their association with autoantibodies and reduced CD4+ lymphocytes. Dlugovitzky, D., *et al.* ..... (A) 628

Cross-reactivity of anti-*M. gordonae* antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. Vilagut, L., *et al.* ..... (A) 189

Detection of antibodies against phenolic glycolipid-I (PGL-I), 35-kDa and 30-40-kDa components of *M. leprae* on the cerebrospinal fluid of leprosy patients. Patil, S. A., *et al.* ..... (A) 604

Differing antibody IgG isotypes in the polar forms of leprosy and cutaneous leishmaniasis characterized by antigen-specific T cell anergy. Ulrich, M., *et al.* ..... (A) 480

Enhanced response of serum IgG class of anti-PGL-I antibodies in leprosy patients during onset and following clinical remission of type 1 and type 2 reactions. Saha, K., *et al.* ..... (C) 105

Identification of an antigenic domain on *M. leprae* protein antigen 85B, which is specifically recognized by antibodies from patients with leprosy. Filley, E., *et al.* ..... (A) 477

IgG subclass antibodies to mycobacterial sonicate and recombinant antigens in leprosy. Sheela, R., *et al.* ..... (A) 480

IgG subclass antibody to *M. leprae* 18,000 MW antigen is restricted to IgG1 and IgG3 in leprosy. Hussain, R., *et al.* ..... (A) 325

Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes; antibody responses to mycobacterial and leishmanial antigens. Sharples, C. E., *et al.* ..... (A) 360

Immunoglobulin G1 (IgG1) and IgG3 antibodies are markers for progressive disease in leprosy. Hussain, R., *et al.* ..... (A) 325

Infection of *M. bovis* bacillus Calmette-Guerin in antibody mediated gamma delta T-cell-depleted mice. Nabeshima, S., *et al.* ..... (A) 355

M. bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen. Gheorghiu, M., *et al.* ..... (A) 149

On the serum antibody against beta-glucuronidase binding protein (BGBP) among normal individuals and leprosy patients. Matsuo, E., *et al.* ..... (A) 650

T-cell determinants and antibody binding sites on the major mycobacterial secretory protein MPB59 of *M. bovis*. Roche, P. W., *et al.* ..... (A) 358

Testing for antibody to human immunodeficiency virus type 1 in a population in which mycobacterial diseases are endemic. Sterne, J. A. C., *et al.* ..... (A) 620

The role of IgM antiphenolic glycolipid-I antibodies in assessing household contacts of leprosy patients in a low endemic area. Soares, D. J., *et al.* ..... (A) 332

The role of antiperipheral nerve antibodies in nerve damage in leprosy. Desikan, P., *et al.* ..... (A) 148

[Ultramicro-ELISA (UMELISA) for the detection of IgM antibodies to *M. leprae* using eluates of dried blood spots.] Torrella, A., *et al.* ..... (A) 606

Antibodies, monoclonal,

The delayed-type hypersensitivity reaction is dependent on IL-8; inhibition of a tuberculin skin reaction by an anti-IL-8 monoclonal antibody. Larsen, C. G., *et al.* ..... (A) 603

Antigen(s),

A plan for preparation and application to humans of new leprosy skin-test antigens. Brennan, P. J., *et al.* ..... (A) 645

[A seroepidemiological study of leprosy in the household contacts with ELISA using ND-O-BSA and PGL as antigens.] Li, W.-Z., *et al.* ..... (A) 341
An HLA-DRw53-restricted T-cell epitope from a novel *M. leprae* protein antigen important to the human memory T-cell repertoire against *M. leprae*. Mustafa, A. S., *et al.* ..... (A) 328
Analysis of T-cell and B-cell responses to recombinant *M. leprae* antigens in leprosy patients and in healthy contacts: significant T-cell responses to antigens in *M. leprae* nonresponders. Thole, J. E. R., *et al.* ..... (O) 369
Antigen 85C on *M. bovis*, BCG and *M. tuberculosis* promotes monocyte-CR3-mediated uptake of microbeads coated with mycobacterial products. Hetland, G. and Wiker, H. G. ..... (A) 150
Antigen provoking gamma interferon production in response to *M. bovis* BCG and functional difference in T-cell responses to this antigen between viable and killed BCG-immunized mice. Kawamura, I., *et al.* ..... (A) 150
Antigenic properties and immunoelectron microproperties and immunoelectron microscopic localization of *M. fortuitum* beta lactamase. Wagner, B., *et al.* ..... (A) 365
Association of antibodies to *M. leprae* and nerve antigens with lepra reactions in leprosy patients. Cho, S.-N., *et al.* ..... (A) 647
Cellular and humoral immune responses to recombinant 65-kDa antigen of *M. leprae* in leprosy patients and healthy controls. Ilangumaran, S., *et al.* ..... (A) 150
Cellular immune response to common mycobacterial antigens in subjects seropositive for *Trypanosoma cruzi*. Bottasso, O. A., *et al.* ..... (A) 322
Characterization of a 10- to 14-kilodalton protease-sensitive *M. tuberculosis* H37Ra antigen that stimulates human gamma delta T cells. Boom, W. H., *et al.* ..... (A) 346
Cloning, sequencing and expression in *Escherichia coli* of the gene for alpha antigen from *M. scrofulaceum*. Takano, M., *et al.* ..... (A) 161
Comparison of the immune response against *M. tuberculosis* antigens between a group of patients with active pulmonary tuberculosis and healthy household contacts. Torres, M., *et al.* ..... (A) 155
Comparison of thermostable macromolecular antigens from leprosy-associated bacteria. Baelden, M. C., *et al.* ..... (A) 157
Cross-reactivity of anti-*M. gordonae* antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. Vilagut, L., *et al.* ..... (A) 189
Culture of nocardioform bacilli from leprosy patients and clinical evaluation of nocardioform bacilli-derived antigen. Basak, P. and Banerjee, P. P. ..... (A) 607
Demonstration of mycobacterial antigens in skin biopsies from suspected leprosy cases in the absence of bacilli. Barbosa, A. D., *et al.* ..... (A) 146
Differing antibody IgG isotypes in the polar forms of leprosy and cutaneous leishmaniasis characerized by antigen-specific T cell anergy. Ulrich, M., *et al.* ..... (A) 480
Epitope specificity and isoforms of the mycobacterial 19 kilodalton antigen. Harris, D. P., *et al.* ..... (A) 174
[Establishment of a PCR method by using the terminal repeated sequence of the gene encoded for 65 kDa antigen of *M. leprae*]Li, T., *et al.* ..... (A) 612
Evaluation of chemiluminescence, procoagulant activity and antigen presentation by monocytes from lepromatous leprosy patients with or without reactional episodes. Santos, D. O., *et al.* ..... (A) 154
Evidence of a superantigen in human tuberculosis. Ohmen, J. D., *et al.* ..... (A) 153
Fibronectin-binding antigen 85 and the 10-kDa groES-related heat shock protein are the predominant Th-1 response inducers in leprosy contacts. Launois, P., *et al.* ..... (A) 329
Human T-cell responses to secreted antigen fractions of *M. tuberculosis*. Boesen, H., *et al.* ..... (A) 490
Identification of an antigenic domain on *M. leprae* protein antigen 85B, which is specifically recognized by antibodies from patients with leprosy. Filley, E., *et al.* ..... (A) 477
IgG humoral response against the antigen 85 complex homologues in leprosy. Drowart, A., *et al.* ..... (A) 324
IgG subclass antibodies to mycobacterial sonicate and recombinant antigens in leprosy. Sheela, R., *et al.* ..... (A) 480
IgG subclass antibody to *M. leprae* 18,000 MW antigen is restricted to IgG1 and IgG3 in leprosy. Hussain, R., *et al.* ..... (A) 325

Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes; antibody responses to mycobacterial and leishmanial antigens. Sharples, C. E., *et al.* ..... (A) 360
Immunoaffinity chromatographic isolation of a high molecular weight seroreactive protein from *M. leprae* cell sonicate. Deshpande, R. G., *et al.* ..... (A) 608
Immunogenic properties of the *M. leprae* recombinant 18-kDa antigen purified from *Saccharomyces cerevisiae*; enhancement of delayed-type hypersensitivity after gamma-irradiation. Pinho, J. R. R., *et al.* ..... (O) 381
Immunohistological localization of mycobacterial antigens with the peripheral nerves of treated leprosy patients and their significance to nerve damage in leprosy. Shetty, V. P., *et al.* ..... (A) 155
Immunoprecipitation of mycobacterial antigens with sera from patients with leprosy. Kode, J. A., *et al.* ..... (A) 327
Immunoreactive antigens of a candidate leprosy vaccine: *M. habana*. Chaturvedi, V., *et al.* ..... (A) 481
Impact of antigen-presenting cells of cytokine profiles of human Th clones established after stimulation of *M. tuberculosis* antigens. Conradt, P. and Kaufmann, S. H. E. ..(A) 600
Induction of the autoantigen proliferating cell nuclear antigen in T lymphocytes by a mycobacterial antigen. Haftel, H. M., *et al.* ..... (A) 149
Infection of SCID mice with *M. leprae* and control with antigen activated "immune" human peripheral blood mononuclear cells. Converse, P. J., *et al.* ..... (A) 476
Interleukin-12 enhances antigen-specific proliferation of peripheral blood mononuclear cells from HIV-positive and negative donors in response to *M. avium*. Newman, G. W., *et al.* ..... (A) 182
Isolation of a fibronectin-binding tryptic peptide from the antigen 85A protein of *M. bovis* BCG. Klegerman, M. E., *et al.* ..... (A) 496
M. bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen. Gheorghiu, M., *et al.* ..... (A) 149
Mapping of T cell epitopes of the 30-kDa ex-antigen of *M. bovis* strain bacillus Calmette-Guerin in purified protein derivative (PPD)-positive individuals. Silver, R. F., *et al.* ....(A) 500
Molecular and immunological characterization of the highly conserved antigen 84 from *M. tuberculosis* and *M. leprae*. Hermans, P. W. M., *et al.* ..... (A) 482
Non-major histocompatibility complex-restricted cytotoxic activity of blood mononuclear cells stimulated with secreted mycobacterial proteins and other mycobacterial antigens. Ravn, P. and Pedersen, B. K. ..... (A) 357
Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. Beckman, E. M., *et al.* ..... (A) 322
Recognition of a unique peptide epitope of the mycobacterial and human heat shock protein 65-60 antigen by T cells of patients with recurrent oral ulcers. Hasan, A., *et al.* ..... (A) 496
Sustained T-cell activity to *M. tuberculosis* specific antigens in "split-anergic" leprosy. Kaleab, B., *et al.* ..... (A) 478
T-cell activity against antigen-85 but not against the 18-kDa and 65-kDa heat shock proteins in the early stages of acquired immunity against *M. leprae*. Launois, P., *et al.* ..... (A) 151
T-cell-epitope mapping of the major secreted mycobacterial antigen AG85A in tuberculosis and leprosy. Launois, P., *et al.* ..... (A) 151
The T cell response to secreted antigens of *M. tuberculosis*. Anderson, P. ..... (A) 345
The effect of prostglandin E(2) and indomethacin on the cytotoxic response to mycobacterial antigens. Yuan, S. N., *et al.* ..... (A) 191
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. McHugh, S. M., *et al.* ..... (A) 327

Arabinomannan,
CD1-restricted T-cell recognition of *M. leprae* lipoarabinomannan. Sieling, P. A., *et al.* ....(A) 656
Inositol phosphate capping of the nonreducing termini of lipoarabinomannan from rapidly growing strains of *Mycobacterium*. Khoo, K. H., *et al.* ..... (A) 611
Integration of mycobacterial lipoarabinomannans into glycosylphosphatidylinositol-rich domains of lymphomonocytic cell plasma membranes. Ilangumaran, S., *et al.* .....(A) 610

Lipoarabinomannan inhibits nonopsonic binding of *M. tuberculosis* to murine macrophages. Stokes, R. W. and Speert, D. P. ..... (A) 636
Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria. Wolucka, B. A., *et al.* ..... (A) 339
Structural analysis of the mannan region of lipoarabinomannan from *M. bovis* BCG. Venisse, A., *et al.* ..... (A) 614
Structural definition of acylated phosphatidylinositol mannosides from *M. tuberculosis*: definition of a common anchor for lipomannan and lipoarabinomannan. Khoo, K. H., *et al.* ..... (A) 482

Armadillo(s),
Analysis of vaccines prepared from armadillo-derived *M. leprae*; results of an interlaboratory study coordinated by the World Health Organization. IMMYC Steering Committee. ..... (O) 48
[Armadillos and leprosy.] Rodrigues, S., *et al.* ..... (A) 620
[Histologic study of the eyes of armadillos experimentally infected with *M. leprae* before and after chemotherapy.] Zhou, H.-M., *et al.* ..... (A) 340
Identification and purification of armadillo (*Dasypus novemcinctus*) immunoglobulins: preparation of specific antisera to evaluate the immune response in these animals. Santos-Argumedo, L., *et al.* ..... (O) 56
Immune response of armadillos (*Dasypus novemcinctus*). I. Use of lectins to identify lymphocyte subpopulations and to evaluate cell proliferation. Santos-Argumedo, L., *et al.* ..... (O) 546

Armed Forces,
Changing trends of leprosy in armed forces. Arora, P. N. and Grover, S. ..... (A) 485

Arthritis,
Experimental arthritis and uveitis in rats associated with *M. butyricum*. Petty, R. E., *et al.* ..... (A) 183
Septic arthritis due to *M. marinum*. Harth, M., *et al.* ..... (A) 175

Asia,
Boosting of tuberculin sensitivity among Southeast Asian refugees. Cauthen, C. M., *et al.* ..... (A) 171
Variants of HLA-DR2/DR51 group haplotypes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis in Asian Indians. Mehra, N. K., *et al.* ..... (O) 241
Vegetarian diet as a risk factor for tuberculosis in immigrant south London Asians. Strachan, D. P., *et al.* ..... (A) 362

Assay(s) (see also **ELISA**),
A study on performance of two serological assays for diagnosis of leprosy patients. Parkash, O., *et al.* ..... (A) 479
Colorimetric microwell plate hybridization assay for detection of amplified *M. tuberculosis* DNA from sputum samples. Cho, S.-N., *et al.* ..... (A) 492
Detection of *M. tuberculosis* directly from spiked human sputum by Q-beta replicase-amplified assay. Shah, J. S., *et al.* ..... (A) 360
Development of a whole blood assay to measure T cell responses to leprosy: a new tool for immuno-epidemiological field studies of leprosy immunity. Weir, R. E., *et al.* ..... (A) 332
High-performance liquid chromatographic assay of plasma thalidomide: stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease. Boughton, B. J., *et al.* ..... (A) 490

Australia,
Leprosy in the tropics and Australia. Britton, W. J. and Hargrave, J. C. ..... (A) 468

B663 (see also **Clofazimine**),
The effect of mixed micellar systems, bile salt/fatty acids, on the solubility and intestinal absorption of clofazimine (B663) in the anaesthetised rat. O'Reilly, J. R., *et al.* ..... (A) 137

Bacilli,
Culture of nocardioform bacilli from leprosy patients and clinical evaluation of nocardioform bacilli-derived antigen. Basak, P. and Banerjee, P. P. ..... (A) 607

Demonstration of mycobacterial antigens in skin biopsies from suspected leprosy cases in the absence of bacilli. Barbosa, A. D., *et al.* ....(A) 146

Bacteremia,

The impact of *M. avium* complex bacteremia and its treatment on survival of AIDS patients–a prospective study. Chin, D. P., *et al.* ....(A) 172

The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol and rifampin, on *M. avium* complex bacteremia in patients with AIDS. Kemper, C. A., *et al.* ....(A) 178

Bangladesh,

Classsification of leprosy cases under field conditions in Bangladesh. I. Usefulness of skin-smear examinations. Groenen, G., *et al.* ....(A) 595

Estimating the size of the leprosy problem: the Bangladesh experience. Richardus, J. H. and Croft, R. P. ....(A) 619

BCG (bacille Calmette-Guerin),

Activation of the hypothalamic-pituitary-adrenal axis differentially affects the antimycobacterial activity of macrophages from BCG-resistant and-susceptible mice. Brown, D. H. and Zwilling, B. S. ....(A) 146

Antigen 85C on *M. bovis*, BCG and *M. tuberculosis* promotes monocyte-CR3-mediated uptake of microbeads coated with mycobacterial products. Hetland, G. and Wiker, H. G. ....(A) 150

Antigen provoking gamma interferon production in response to *M. bovis* BCG and functional difference in T-cell responses to this antigen between viable and killed BCG-immunized mice. Kawamura, I., *et al.* ....(A) 150

Bacteriostatic activity of BCG/PPD-activated macrophages against *M. fortuitum* does not involve reactive nitrogen or oxygen intermediates. Nibbering, P. H., *et al.* ....(A) 182

Biochemical and immunological characterization of ribosomal fraction and culture filtrate from BCG. Yamada, T., *et al.* ....(A) 658

Composition and immunoreactivity of the A60 complex and other cell fractions from *M. bovis* BCG. Cocito, C. and van Linden, F. ....(A) 492

Contribution of alpha/beta and gamma/delta T lymphocytes to immunity against *M. bovis* bacillus Calmette Guerin: studies with T cell receptor-deficient mutant mice. Ladel, C. H., *et al.* ....(A) 603

Differential T cell responses to mycobacteria-secreted proteins distinguish vaccination with bacille Calmette Guerin from infection with *M. tuberculosis*. Roche, P. W., *et al.* ....(A) 330

Evaluation of tuberculin reactivity in BCG-immunized siblings. Sepulveda, R. L., *et al.* ....(A) 185

[Evolution of lesions induced by mycobacteria, BCG and H37Rv in hampsters.] Roxo, E., *et al.* ....(A) 605

Growth of *M. tuberculosis* in BCG-resistant and-susceptible mice: establishment of latency and reactivation. Brown, D. H., *et al.* ....(A) 625

Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes; antibody responses to mycobacterial and leishmanial antigens. Sharples, C. E., *et al.* ....(A) 360

Immune response to *M. bovis* bacille Calmette Guerin infection in major histocompatibility complex class I-and II deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Ladel, C. H., *et al.* ....(A) 602

In vivo growth characteristics of leucine and methionine auxotrophic mutants of *M. bovis* BCG generated by transposon mutagenesis. McAdam, R. A., *et al.* ....(A) 483

Increased gamma-delta T-lymphocyte response to *M. bovis* BCG in major histocompatibility complex class I-deficient mice. Muller, D., *et al.* ....(A) 603

Infection of *M. bovis* bacillus Calmette-Guerin in antibody mediated gamma delta T-cell-depleted mice. Nabeshima, S., *et al.* ....(A) 355

Influence of mouse strain and vaccine viability on T-cell responses induced by *M. bovis* bacillus Calmette-Guerin. Daugelat, S., *et al.* ....(A) 600

Isolation of a fibronectin-binding tryptic peptide from the antigen 85A protein of *M. bovis* BCG. Klegerman, M. E., *et al.* ....(A) 496

Lysis of human macrophages by cytolytic CD4+ T cells fails to affect survival of intracellular *M. bovis* bacille Calmette Guerin (BCG). Fazal, N., *et al.* ....(A) 495

M. bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen. Gheorghiu, M., *et al.* .....(A) 149
Mapping of T cell epitopes of the 30-kDa ex-antigen of *M. bovis* strain bacillus Calmette-Guerin in purified protein derivative (PPD)-positive individuals. Silver, R. F., *et al.* ....(A) 500
Nitric oxide production and mycobacterial growth inhibition by murine alveolar macrophages: the sequence of rIFN-gamma stimulation and *M. bovis* BCG infection determines macrophage activation. Hanano, R. and Kaufmann, S. H. E. .....(A) 495
Nucleotide sequence of the 85B-protein gene of *M. bovis* BCG and *M. tuberculosis*. de Wit, M. Y. L., *et al.* .....(A) 173
Protective effect of BCG against leprosy in South Sulawesi, Indonesia. Boelens, J. J., *et al.* .....(C) 456
Relationship between bacille Calmette-Guerin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Brewer, T. F. and Colditz, G. A. .....(A) 491
Relationship of secretion pattern of MPB70 homology with osteoblast-specific factor 2 to osteitis following *M. bovis* BCG vaccination. Ulstrup, J. C., *et al.* .....(A) 364
Secretion of human interleukin 2 by recombinant *M. bovis* BCG. Kong, D. Q. and Kunimoto, D. Y. .....(A) 483
Structural analysis of the mannan region of lipoarabinomannan from *M. bovis* BCG. Venisse, A., *et al.* .....(A) 614

Behcet's syndrome,
Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysical studies to detect thalidomide neuropathy. Gardner-Medwin, J. M. M., *et al.* .....(A) 350

Beta-glucuronidase,
On the serum antibody against beta-glucuronidase binding protein (BGBP) among normal individuals and leprosy patients. Matsuo, E., *et al.* .....(A) 650

Biopsy,
Biopsy of Skin Lesions in Leprosy; Stains, Pathogenesis and Classification by Kyoshi Harada. Scollard, D. M. .....(B) 578
Demonstration of mycobacterial antigens in skin biopsies from suspected leprosy cases in the absence of bacilli. Barbosa, A. D., *et al.* .....(A) 146
Detection of AFB in tuberculoid biopsies. Fleury, R. N. and Aranda, C. M. .....(C) 103
Morphology of cystic structures seen in leprosy biopsy suspensions kept at cooler temperatures. Bhatia, V. N. .....(A) 334

Blood,
Altered expression of CD11/CD18 on the peripheral blood phagocytes of patients with tuberculosis. Yassin, R. J. and Hamblin, A. S. .....(A) 157
Amplification of DNA of *M. tuberculosis* from peripheral blood of patients with pulmonary tuberculosis. Schluger, N. W., *et al.* .....(A) 185
Dapsone-induced hematologic toxicity; comparison of the methemoglobin-forming ability of hydroxylamine metabolites of dapsone in rat and human blood. Vage, C., *et al.* .....(A) 318
Development of a whole blood assay to measure T cell responses to leprosy: a new tool for immuno-epidemiological field studies of leprosy immunity. Weir, R. E., *et al.* ...(A) 332
Functional heterogeneity among CD4+ T-cell clones from blood and skin lesions of leprosy patients, identification of T cell clones distinct from Th0, Th1 and Th2. Howe, R. C., *et al.* .....(A) 602
Growth-deficient mycobacteria in patients with AIDS: diagnosis by analysis of DNA amplified from blood or tissue. Emler, S., *et al.* .....(A) 494
High-performance liquid chromatography determination of dapsone, monoacetyldapsone, and pyrimethamine in filter paper blood spots. Ronn, A. M., *et al.* .....(A) 316
Infection of SCID mice with *M. leprae* and control with antigen activated "immune" human peripheral blood mononuclear cells. Converse, P. J., *et al.* .....(A) 476
Interleukin-12 enhances antigen-specific proliferation of peripheral blood mononuclear cells from HIV-positive and negative donors in response to *M. avium*. Newman, G. W., *et al.* .....(A) 182
Non-major histocompatibility complex-restricted cytotoxic activity of blood mononuclear cells stimulated with secreted mycobacterial proteins and other mycobacterial antigens. Ravn, P. and Pedersen, B. K. .....(A) 357

Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Nogueira, A. C., *et al.* .....(A) 152
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. McHugh, S. M., *et al.* .....(A) 327
[Ultramicro-ELISA (UMELISA) for the detection of IgM antibodies to *M. leprae* using eluates of dried blood spots.] Torrella, A., *et al.* .....(A) 606

Bone,
A longitudinal study of alveolar bone loss around maxillary central incisors in patients with leprosy in Malaysia. Subramaniam, K., *et al.* .....(A) 143
Inflammatory bone changes in leprous skeletons from the medieval hospital of St. James and St. Mary Magdalene, Chichester, England. Lewis, M. E., *et al.* .....(O) 77
Reduction of clastogenic effect of clofazimine, an antileprosy drug, by vitamin A and vitamin C in bone marrow cells of mice. Sahu, K. and Das, R. K. .....(A) 317

Book reviews,
Biopsy of Skin Lesions in Leprosy; Stains, Pathogenesis and Classification by Kyoshi Harada. Scollard, D. M. .....(B) 578
Global Comparative Assessments in the Health Sector; Disease Burden, Expenditures and Intervention Packages, C. J. L. Murray and A. D. Lopez, eds. .....(B) 122
IADVL (Indian Association of Dermatologists, Venereologists and Leprologists) Textbook and Atlas of Dermatology, Volumes I and II. Hastings, R. C. .....(B) 299
Tuberculosis; Pathogenesis, Protection and Control, Barry R. Bloom, ed. .....(B) 122

Borderline leprosy,
[Dimorphous leprosy with a lesion of the radial nerve; a case report.] Lora Robles, M. and Gonzalez, K. .....(A) 142
[Evolution of borderline tuberculoid hanseniasis during multidrug therapy.] de Carvalho, M. L. R., *et al.* .....(A) 593
Neuropathy as the only sign of borderline lepromatous leprosy for 13 years. Mizuno, K., *et al.* .....(A) 596
Pathogenesis of generalized nodular type I reaction in a borderline leprosy patient. Jayakumar, J., *et al.* .....(A) 319
Treatment of bacilliferous BL/LL cases with combined chemotherapy and immunotherapy. Katoch, K., *et al.* .....(O) 202
[Type 1 reactions in borderline tuberculoid hanseniasis during multidrug therapy: time of appearance of nerve involvement.] de Carvalho, M. L. R., *et al.* .....(A) 594

Brazil,
Agreement between histopathological results in clinically diagnosed cases of indeterminate leprosy in Sao Paulo, Brazil. Lombardi, C., *et al.* .....(A) 329
Epidemiology Congresses to be held in April. .....(N) 123
[Experimental project for the control of hanseniasis in the city of Bauru, Sao Paulo, Brazil; evaluation after the first year of implementation.] Bonilha, V. F., *et al.* .....(A) 617
Hansen's disease in Brazil: treating difficult-to-reach patients. Talhari, S. .....(A) 278
IDEA formed. Law, A. S. .....(N) 461
[Prevalence of sulfone resistance in patients with hanseniasis in the city of Bauru, state of Sao Paulo.] Costa, H. C., *et al.* .....(A) 312
Spatial patterns of leprosy in an urban area of central Brazil. Martelli, C. M. T., *et al.* .....(A) 619
The genetic epidemiology of leprosy in a Brazilian population. Feitosa, M. F., *et al.* .....(A) 617

Cambodia,
Prevalence rates of leprosy in Cambodia; results of a sample survey. Landwehr, D. and Ponnighaus, J. M. .....(O) 535

Cameroon,
VIII Congres International des Leprologues de Langue Francaise. .....(N) 303
VIII Congres International des Leprologues de Langue Francaise. .....(N) 579

Cancer,
Cancer associated with leprosy. John, S., *et al.* .....(A) 319
The riminophenazine agents clofazimine and B669 reverse acquired multidrug resistance in human lung cancer cell line. van Rensburg, C. E. J., *et al.* .....(A) 188

Case holding,
Field evaluation of WHO-MDT of fixed duration at ALERT, Ethiopia: the AMFES project–I. MDT course completion, case holding and another score for disability grading. de Rijk, A. J., *et al.* ..... (A) 312

Catalase,
Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance to *M. tuberculosis*. Heym, B., *et al.* ..... (A) 351
Mutations in the catalase-peroxidase gene from isoniazid resistant *M. tuberculosis* isolates. Altamirano, M., *et al.* ..... (A) 170

Cell(s),
Activity of mycobacterial promoters during intracellular and extracellular growth. Dellagostin, O. A., *et al.* ..... (A) 608
Animal and cell-culture models for the study of mycobacterial infections and treatment. Orme, I. M., *et al.* ..... (A) 356
Cellular target of *in vitro*-induced suppressor cells derived from the spleen of *M. lepraemurium* infected mice and role of IFN-gamma in their development. Gosselin, D., *et al.* ..... (A) 484
Chemotherapeutic activity of clofazimine and its analogues againt *M. tuberculosis*: *in vitro*, intracellular and *in vivo* studies. Jagannath, C., *et al.* ..... (A) 496
Composition and immunoreactivity of the A60 complex and other cell fractions from *M. bovis* BCG. Cocito, C. and van Linden, F. ..... (A) 492
Continuous cultivation of *M. leprae* in primary cell cultures. Walker, L. L., *et al.* ..... (A) 657
Effect of inhibitors of cell envelope synthesis on beta sitosterol side chain degradation by *Mycobacterium* sp. NRRL MB 3683. Sedlaczek, L., *et al.* ..... (A) 359
Effect of interleukin-1 alpha on the growth of *M. microti* within J774A.1 cells. Majumder, S. and Gupta, R. ..... (A) 181
Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of *M. avium*. Mor, N., *et al.* ..... (A) 353
Enhancement of intracellular growth of *M. tuberculosis* in human monocytes by transforming growth factor-beta. Hirsch, C. S., *et al.* ..... (A) 351
Extra and intracellular activities of dirithromycin against *M. avium*. Gevaudan, M. J. and Demicco, P. ..... (A) 630
Fine needle aspiration cytology of mycobacterial spindle cell pseudotumor. Corkill, M., *et al.* ..... (A) 493
Glutamine synthetase of *M. tuberculosis*: extracellular release and characterization of its enzymatic activity. Harth, G., *et al.* ..... (A) 175
Impact of antigen-presenting cells of cytokine profiles of human Th clones established after stimulation of *M. tuberculosis* antigens. Conradt, P. and Kaufmann, S. H. E. ..... (A) 600
Integration of mycobacterial lipoarabinomannans into glycosylphosphatidylinositol-rich domains of lymphomonocytic cell plasma membranes. Ilangumaran, S., *et al.* ..... (A) 610
Intracellular activities of roxithromycin used alone and in association with other drugs against *M. avium* complex in human macrophages. Rastogi, N., *et al.* ..... (A) 499
Intracellular trafficking in *M. tuberculosis* and *M. avium* infected macrophages. Xu, S. M., *et al.* ..... (A) 156
M. marinum persists in cultured mammalian cells in a temperature-restricted fashion. Ramakrishnan, L. and Falkow, S. ..... (A) 165
Mast cells in lepromatous leprosy. Jayalakshmi, P. and Lian, T. K. ..... (C) 291
Mouse cell lines expressing *M. leprae* heat-shock protein 65 kDa gene: lymphoproliferative responses to the cell lines. Nakanaga, K., *et al.* ..... (A) 651
Mycobacterial cell wall components induce the production of TNF-alpha, IL-1 and IL-6 by bovine monocytes and the murine macrophage cell line RAW 264.7. Adams, J. L. and Czuprynski, C. J. ..... (A) 169
Permeability of the cell wall of *M. smegmatis*. Trias, J. and Benz, R. ..... (A) 162
Plasminogen activator inhibitor type 2 prevents programmed cell death of human macrophages infected with *M. avium*, serovar 4. Gan, H. X., *et al.* ..... (A) 629
Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelope. Deng, L. Y., *et al.* ..... (A) 493
Reduction of clastogenic effect of clofazimine, an antileprosy drug, by vitamin A and vitamin C in bone marrow cells of mice. Sahu, K. and Das, R. K. ..... (A) 317

Tat protein from HIV-1 binds to *M. avium* via a bacterial integrin–effects on extracellular and intracellular growth. Denis, M. ..... (A) 173
Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Nogueira, A. C., *et al.* ..... (A) 152
Thalidomide does not perturb CD2, CD4, CD5, CD8, HLA-DR, or HLA-A, B, C molecules *in vitro* on the membranes of cells with immune potential. Shannon, E. J., *et al.* ..... (A) 330

Cells, B,
Analysis of T-cell and B-cell responses to recombinant *M. leprae* antigens in leprosy patients and in healthy contacts: significant T-cell responses to antigens in *M. leprae* nonresponders. Thole, J. E. R., *et al.* ..... (O) 369
T and B cell responses to mycobacterial 65-kDa heat-shock protein in sheep infected with maedi visna virus. Harkiss, G. D., *et al.* ..... (A) 478

Cells, epithelial,
A *M. leprae* gene encosing a fibronectin binding protein is used for efficient invasion of epithelial cells and Schwann cells. Schorey, J. S., *et al.* ..... (A) 614

Cells, mononuclear,
Infection of SCID mice with *M. leprae* and control with antigen activated "immune" human peripheral blood mononuclear cells. Converse, P. J., *et al.* ..... (A) 476
Interleukin-12 enhances antigen-specific proliferation of peripheral blood mononuclear cells from HIV-positive and negative donors in response to *M. avium*. Newman, G. W., *et al.* ..... (A) 182
Non-major histocompatibility complex-restricted cytotoxic activity of blood mononuclear cells stimulated with secreted mycobacterial proteins and other mycobacterial antigens. Ravn, P. and Pedersen, B. K. ..... (A) 357
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. McHugh, S. M., *et al.* ..... (A) 327

Cells, natural killer (NK),
Interleukin-12 (IL-12) augments cytolytic activity of natural killer cell toward *M. tuberculosis*-infected human monocytes. Denis, M. ..... (A) 147

Cells, Schwann,
A *M. leprae* gene encosing a fibronectin binding protein is used for efficient invasion of epithelial cells and Schwann cells. Schorey, J. S., *et al.* ..... (A) 614

Cells, T,
An HLA-DRw53-restricted T-cell epitope from a novel *M. leprae* protein antigen important to the human memory T-cell repertoire against *M. leprae*. Mustafa, A. S., *et al.* ..... (A) 328
Analysis of T-cell and B-cell responses to recombinant *M. leprae* antigens in leprosy patients and in healthy contacts: significant T-cell responses to antigens in *M. leprae* nonresponders. Thole, J. E. R., *et al.* ..... (O) 369
Antigen provoking gamma interferon production in response to *M. bovis* BCG and functional difference in T-cell responses to this antigen between viable and killed BCG-immunized mice. Kawamura, I., *et al.* ..... (A) 150
CD1-restricted T-cell recognition of *M. leprae* lipoarabinomannan. Sieling, P. A., *et al.* ..... (A) 656
CD4+ T-cell responses to recombinant hsp65 and hsp18 of *M. leprae* and their trypsin-digested fragments in leprosy: diversity in HLA-DR restriction. Mitra, D. K., *et al.* ..... (O) 518
CD4+ alpha beta T cell and gamma delta T cell responses to *M. tuberculosis*–similarities and differences in Ag recognition, cytotoxic effector function, and cytokine production. Tsukaguchi, K., *et al.* ..... (A) 363
Characterization of a 10- to 14-kilodalton protease-sensitive *M. tuberculosis* H37Ra antigen that stimulates human gamma delta T cells. Boom, W. H., *et al.* ..... (A) 346
Contribution of alpha/beta and gamma/delta T lymphocytes to immunity against *M. bovis* bacillus Calmette Guerin: studies with T cell receptor-deficient mutant mice. Ladel, C. H., *et al.* ..... (A) 603
Crossrecognition of CD7 T cell receptor alpha beta cytotoxic T lymphocytes of peptides

in the self and the mycobacterial hsp60 with shared intermediate sequence homology. Zugel, U., *et al.* ..... (A) 606
Development of a whole blood assay to measure T cell responses to leprosy: a new tool for immuno-epidemiological field studies of leprosy immunity. Weir, R. E., *et al.* ... (A) 332
Differential T cell responses to mycobacteria-secreted proteins distinguish vaccination with bacille Calmette Guerin from infection with *M. tuberculosis.* Roche, P. W., *et al.* ..... (A) 330
Differing antibody IgG isotypes in the polar forms of leprosy and cutaneous leishmaniasis characerized by antigen-specific T cell anergy. Ulrich, M., *et al.* ..... (A) 480
Endogenously produced IL-12 is required for the induction of protective T cells during *M. avium* infections in mice. Castro, A. G., *et al.* ..... (A) 599
Expansion of mycobacterium-reactive gamma delta T cells by a subset of memory helper T cells. Vila, L. M., *et al.* ..... (A) 481
Functional heterogeneity among CD4+ T-cell clones from blood and skin lesions of leprosy patients, identification of T cell clones distinct from Th0, Th1 and Th2. Howe, R. C., *et al.* ..... (A) 602
Human CD4-, CD8-, alpha beta+ T-cell receptor T cells recognize different mycobacteria strains in the context of CD1b. Thomssen, H., *et al.* ..... (A) 605
Human T-cell responses to secreted antigen fractions of *M. tuberculosis.* Boesen, H., *et al.* ..... (A) 490
Identification of a *M. leprae*-specific T-cell epitope on the 70 kDa heat shock protein. Roche, P. W., *et al.* ..... (A) 154
Immune response to *M. bovis* bacille Calmette Guerin infection in major histocompatibility complex class I-and II deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Ladel, C. H., *et al.* ..... (A) 602
Individuals from different populations identify multiple and diverse T-cell determinants on mycobacterial HSP70. Adams, E., *et al.* ..... (A) 145
Infection of *M. bovis* bacillus Calmette-Guerin in antibody mediated gamma delta T-cell-depleted mice. Nabeshima, S., *et al.* ..... (A) 355
Influence of mouse strain and vaccine viability on T-cell responses induced by *M. bovis* bacillus Calmette-Guerin. Daugelat, S., *et al.* ..... (A) 600
Limited restriction in the TCR-alpha beta V region usage of anti-specific clones–recognition of myelin basic protein (amino acids 84-102) and *M. bovis* 65-kDa heat shock protein (amino acids 3-13) by T cell clones established from PBMC of monozygotic twins and HLA-identical individuals. Hawes, G. E., *et al.* ..... (A) 351
Lysis of human macrophages by cytolytic CD4+ T cells fails to affect survival of intracellular *M. bovis* bacille Calmette Guerin (BCG). Fazal, N., *et al.* ..... (A) 495
Macrophage-T cell interaction in experimental mycobacterial infection; selective regulation of co-stimulatory molecules on *Mycobacterium*-infected macrophages and its implication in the suppression of cell-mediated immune response. Saha, B., *et al.* ... (A) 359
Mapping of T cell epitopes of the 30-kDa ex-antigen of *M. bovis* strain bacillus Calmette-Guerin in purified protein derivative (PPD)-positive individuals. Silver, R. F., *et al.* .... (A) 500
Mapping of multiple HLA class II-restricted T-cell epitopes of the mycobacterial 70-kilodalton heat shock protein. Oftung, F., *et al.* ..... (A) 329
Protection against tuberculosis by passive transfer with T cell clones recognizing mycobacterial heat shock protein 65. Silva, C. L., *et al.* ..... (A) 331
Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. Beckman, E. M., *et al.* ..... (A) 322
Recognition of a unique peptide epitope of the mycobacterial and human heat shock protein 65-60 antigen by T cells of patients with recurrent oral ulcers. Hasan, A., *et al.* ..... (A) 496
Role of T cell subsets in immunity against intracellular bacteria: experimental infections of knock-out mice with *Listeria monocytogenes* and *M. bovis.* Kaufmann, S. H. E. and Ladel, C. H. ..... (A) 326
Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and-dependent phases of *M. avium* infection. Appelberg, R., *et al.* ..... (A) 170
Role of interleukin-6 in the infection of protective T cells during mycobacterial infections in mice. Appelberg, R., *et al.* ..... (A) 145
Study on the roles of CD4+ and CD8+ T cells in the expression of host resistance to *M. leprae* infection induced in athymic nude mice. Maw, W. W., *et al.* ..... (O) 539

Sustained T-cell activity to *M. tuberculosis* specific antigens in "split-anergic" leprosy. Kaleab, B., *et al.* ..... (A) 478
T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infections. Zhang, M., *et al.* ..... (A) 333
T cells bearing Vbeta6 T cell receptors in the cell-mediated immune response to *M. leprae*. Wang, X. H., *et al.* ..... (A) 481
T-cell activity against antigen-85 but not against the 18-kDa and 65-kDa heat shock proteins in the early stages of acquired immunity against *M. leprae*. Launois, P., *et al.* ..... (A) 151
T-cell determinants and antibody binding sites on the major mycobacterial secretory protein MPB59 of *M. bovis*. Roche, P. W., *et al.* ..... (A) 358
T-cell-epitope mapping of the major secreted mycobacterial antigen AG85A in tuberculosis and leprosy. Launois, P., *et al.* ..... (A) 151
Thalidomide and the immune system 4. Down-regulation of the CD26 receptor, probably involved in the binding of HIV components to T cells in primates. Neubert, R., *et al.* ..... (A) 355
The T cell response to secreted antigens of *M. tuberculosis*. Anderson, P. ..... (A) 345
Two novel T cell epitope prediction algorithms based on MHC binding motifs; comparison of predicted and published epitopes from *M. tuberculosis* and HIV protein sequences. Meister, G. E., *et al.* ..... (A) 633

Cell-mediated immunity (CMI),
Cell-mediated immunity in skin tuberculosis. Ramesh, V., *et al.* ..... (C) 293
Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis. Dannenberg, A. M. ..... (A) 348

Chemotherapy (see also **Therapy**),
An international randomized study with long-term follow-up of single versus combination chemotherapy of multibacillary leprosy. Dietrich, M., *et al.* ..... (A) 136
Chemotherapeutic activity of clofazimine and its analogues against *M. tuberculosis*: *in vitro*, intracellular and *in vivo* studies. Jagannath, C., *et al.* ..... (A) 496
Chemotherapy of lepromatous leprosy: recent developments and prospects for the future. Gelber, R. H. ..... (A) 313
Elevated interleukin-2 receptor level in patients with active pulmonary tuberculosis and the changes following antituberculosis chemotherapy. Chan, C. H. S., *et al.* ..... (A) 491
[Histologic study of the eyes of armadillos experimentally infected with *M. leprae* before and after chemotherapy.] Zhou, H.-M., *et al.* ..... (A) 340
Immunotherapy with *M. vaccae* as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Onyebujoh, P. C., *et al.* ..... (A) 498
Implications of multidrug resistance for the future of short course chemotherapy of tuberculosis: a molecular study. Heym, B., *et al.* ..... (A) 176
The past, present and future of chemotherapy of leprosy. Ramu, G. ..... (A) 315
Transient exacerbation of tuberculous lymphadenitis during chemotherapy in patients with AIDS. Hill, A. R., *et al.* ..... (A) 176
Treatment of bacilliferous BL/LL cases with combined chemotherapy and immunotherapy. Katoch, K., *et al.* ..... (O) 202
WHO Chemotherapy of Leprosy; report of a WHO Study Group. ..... (N) 130

Children,
[Analysis of 90 children with leprosy.] Yang, J., *et al.* ..... (A) 620
llowing up of 363 healthy children living in colonies and taking DDS for prevention of leprosy.] Liu, C., *et al.* ..... (A) 618
[Leprosy in children.] Terencio de las Aguas, J. ..... (A) 475
Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Cole, C. H., *et al.* ..... (A) 492
Transmission of health information on leprosy from children to their families in an urban centre. Jacob, M. S., *et al.* ..... (A) 133

China, People's Republic of,
[Analysis of 1493 new cases of leprosy.] Lai, Z., *et al.* ..... (A) 341
[Analysis of 407 new cases of leprosy in Hubei Province.] He, R., *et al.* ..... (A) 340

[Calculating the future development of leprology in China with literature statistics.] Tu, X. ..... (A) 586
[Endemic situation of leprosy recently in Sichuan Province.] Lu, W., *et al.* ..... (A) 343
[Endemicity and control of leprosy in Gansu Province.] Pan, H.-Y., *et al.* ..... (A) 341
[Feasibility of basic eradication of leprosy in Xinjiang.] Yang, Z.-L., *et al.* ..... (A) 342
ILEP members fund Chinese shoe factory. ..... (N) 124
[Leprosy control in Quanzhou City, Fujian.] Huang, Y.-X., *et al.* ..... (A) 340
[Leprosy control in Xinjuang since 1986.] Huang, W.-J., *et al.* .(A) 313
Long-term effect of leprosy control in two prefectures of China, 1955-1993. Li, H.-Y., *et al.* ..... (O) 213
Multidrug therapy and eye disease in leprosy; a cross sectional study in the People's Republic of China. Courtright, P., *et al.* ..... (A) 140
[On antileprosy activity of China-made ofloxacin in nude mice.] Shen, J.-P., *et al.* ..... (A) 340
Prevention of impairment in leprosy; results from a collaborative project in China. Smith, W. C. S., *et al.* ..... (O) 507

Chromatography,
High-performance liquid chromatography determination of dapsone, monoacetyldapsone, and pyrimethamine in filter paper blood spots. Ronn, A. M., *et al.* ..... (A) 316
Isolation of a 32 kDa *M. tuberculosis* protein by lectin affinity chromatography. Montano, L. F., *et al.* ..... (A) 182
Rapid and sensitive determination of thalidomide in human plasma by high performance liquid chromatography. Delon, A., *et al.* ..... (A) 473

Ciprofloxacin,
Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of *Escherichia coli* and MICs. Vila, J., *et al.* ..... (A) 188
Intestinal elimination of sparfloxacin, fleroxacin and ciprofloxacin in rats. Rubenstein, E., *et al.* ..... (A) 317
Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Berning, S. E., *et al.* ..... (A) 625

Classification,
Biopsy of Skin Lesions in Leprosy; Stains, Pathogenesis and Classification by Kyoshi Harada. Scollard, D. M. ..... (B) 578
IAL 1993 MDT workshop. ..... (N) 126

Clinical,
Agreement between histopathological results in clinically diagnosed cases of interdeterminate leprosy in Sao Paulo, Brazil. Lombardi, C., *et al.* ..... (A) 329
Changes in leprosy clinical pattern after multidrug therapy implementation. Martelli, C. M. T., *et al.* ..... (C) 95
Clinical and histological discrepancies in diagnosis of ENL reactions classified by assessment of acute phase proteins SAA and CRP. Hussain, R., *et al.* ..... (O) 222
Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysical studies to detect thalidomide neuropathy. Gardner-Medwin, J. M. M., *et al.* ..... (A) 350
Clinical features and diagnosis of relapses in leprosy. Ramu, G. ..... (A) 591
Clinical utility of LSR/A16 gene for *M. leprae* detection in leprosy tissues using the polymerase chain reaction. Misra, N., *et al.* ..... (O) 35
Critical residues of the *M. leprae* LSR recombinant protein discriminate clinical activity in erythema nodosum leprosum reactions. Singh, S., *et al.* ..... (A) 331
Culture of nocardioform bacilli from leprosy patients and clinical evaluation of nocardioform bacilli-derived antigen. Basak, P. and Banerjee, P. P. ..... (A) 607
Decreased beta-amyloid and increased abnormal tau deposition in the brain of aged patients with leprosy. Chui, D. H., *et al.* ..... (A) 147
Diagnostic problems of early leprosy in field studies. Nagaraju, B. and Gupta, M. D. ..(A) 320
Effect of rhuIFN-gamma treatment in multibacillary leprosy patients. Sampaio, E. P., *et al.* ..... (A) 653
Enhanced response of serum IgG class of anti-PGL-I antibodies in leprosy patients during onset and following clinical remission of type 1 and type 2 reactions. Saha, K., *et al.* ..... (C) 105

Evaluation of sensibility of leprosy–comparison of various clinical methods. van Brakel, W. H., *et al.* ..... (A) 168
Follicular keratoses in leprosy and post-kala-azar dermal leishmaniasis. Dhar, S., *et al.* ..... (C) 111
Intraocular pressure in leprosy patients without clinically apparent anterior segment pathology. Daniel, A. E., *et al.* ..... (A) 140
Nerve damage in leprosy: an epidemiological and clinical study of 396 patients in west Nepal–Part I. Definitions, methods and frequencies. van Brakel, W. H. and Khawas, I. B. ..... (A) 144
Oral zinc therapy and recurrent erythema nodosum leprosum: a clinical study. Mahajan, P. M., *et al.* ..... (A) 142
Persistence of lepromatous granuloma in clinically cured cases of leprosy. Desikan, P. and Desikan, K. V. ..... (O) 417
Relapse of *M. leprae* infection with ocular manifestations. Carus, N. H., *et al.* ..... (A) 472
Rhinosporidiosis in leprosy; a case report. Jayakumar, J., *et al.* ..... (E) 448
Some factors influencing delay in leprosy diagnosis. Rojas, V., *et al.* ..... (A) 472
Treatment of Hansen's disease. Franzblau, S. G. ..... (A) 284

Clofazimine,
Chemotherapeutic activity of clofazimine and its analogues againt *M. tuberculosis*: *in vitro*, intracellular and *in vivo* studies. Jagannath, C., *et al.* ..... (A) 496
Clofazimine induced cardiotoxicity–a case report. Choudhri, S. H., *et al.* ..... (A) 469
Clofazimine: a review of its medical uses and mechanisms of action. Arbiser, J. L. and Moschella, S. L. ..... (A) 468
Reduction of clastogenic effect of clofazimine, an antileprosy drug, by vitamin A and vitamin C in bone marrow cells of mice. Sahu, K. and Das, R. K. ..... (A) 317
The effect of mixed micellar systems, bile salt/fatty acids, on the solubility and intestinal absorption of clofazimine (B663) in the anaesthetised rat. O'Reilly, J. R., *et al.* ..... (A) 137
The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol and rifampin, on *M. avium* complex bacteremia in patients with AIDS. Kemper, C. A., *et al.* ..... (A) 178
The riminophenazine agents clofazimine and B669 reverse acquired multidrug resistance in human lung cancer cell line. van Rensburg, C. E. J., *et al.* ..... (A) 188

Cloning,
Cloning and expression in *Escherichia coli* of DNA encoding a 60 kDa stress protein of *M. paratuberculosis*, the causative agent of Johne's disease. Colston, A., *et al.* ..... (A) 348
Cloning and sequence analysis of the rpsL and rpsG genes of *M. smegmatis* and characterization of mutations causing resistance to streptomycin. Kenney, T. J. and Churchward, G. .(A) 179
Cloning, sequencing and expression in *Escherichia coli* of the gene for alpha antigen from *M. scrofulaceum*. Takano, M., *et al.* ..... (A) 161
Functional heterogeneity among CD4+ T-cell clones from blood and skin lesions of leprosy patients, identification of T cell clones distinct from Th0, Th1 and Th2. Howe, R. C., *et al.* ..... (A) 602
Impact of antigen-presenting cells of cytokine profiles of human Th clones established after stimulation of *M. tuberculosis* antigens. Conradt, P. and Kaufmann, S. H. E. ..(A) 600
Limited restriction in the TCR-alpha beta V region usage of anti-specific clones–recognition of myelin basic protein (amino acids 84-102) and *M. bovis* 65-kDa heat shock protein (amino acids 3-13) by T cell clones established from PBMC of monozygotic twins and HLA-identical individuals. Hawes, G. E., *et al.* ..... (A) 351
Molecular cloning of gyrA and gyrB genes of *M. tuberculosis*: analysis of nucleotide sequence. Madhusudan, K., *et al.* ..... (A) 335
Protection against tuberculosis by passive transfer with T cell clones recognizing mycobacterial heat shock protein 65. Silva, C. L., *et al.* ..... (A) 331

Congresses,
14th International Congress of Tropical Medicine and Malaria. ..... (N) 465
Carville Centennial: International Colloquium on the Future of Hansen's Disease Control and Research. ..... (E) 269
Epidemiology Congresses to be held in April in Brazil. ..... (N) 123
VIII Congres International des Leprologues de Langue Francaise. ..... (N) 303
VIII Congres International des Leprologues de Langue Francaise. ..... (N) 579

Control of leprosy,
A clinician's view of present and future problems in Hansen's disease control. Job, C. K. ..... (A) 274
Carville Centennial: International Colloquium on the Future of Hansen's Disease Control and Research. ..... (E) 269
Carville and Hansen's disease control: past, present and future. Jacobson, R. R. ..... (A) 272
Changing role of voluntary organizations in the context of elimination of leprosy. Walter, C. S. ..... (A) 135
Eliminating leprosy as a public health problem; why the optimism is justified. Noordeen, S. K. ..... (E) 559
Elimination of leprosy as a public health problem: progress and prospects. Noordeen, S. K. ..... (A) 486
Elimination of leprosy: forecasts and projections. Gupte, M. D. ..... (A) 165
[Endemicity and control of leprosy in Gansu Province.] Pan, H.-Y., *et al.* ..... (A) 341
Evaluation of a multidrug therapy programme of leprosy control. Jakeman, P. and Smith, W. C. S. ..... (A) 313
[Evaluation of leprosy control program with strata analysis.] Wu, X.-Q., *et al.* ..... (A) 339
[Experimental project for the control of hanseniasis in the city of Bauru, Sao Paulo, Brazil; evaluation after the first year of implementation.] Bonilha, V. F., *et al.* ..... (A) 617
Fifth Chinese National Conference on Leprosy Control. He, D. ..... (N) 461
Hansen's disease control in India: problems and solutions. Ganapati, R. ..... (A) 279
[Hanseniasis: actual situation.] Talhari, S. ..... (A) 134
Industrial participation in leprosy control. ..... (N) 127
Integrating leprosy control into primary health care: the experience in Ghana. Bainson, K. A. ..... (A) 310
Integration of leprosy control into basic health services; an example from Nepal. Roos, B. R., *et al.* ..... (O) 422
Integration of traditional and modern methods in the control of leprosy and in the study of mycobacterial taxonomy (13th IWGMT Conference). Portaels, F. ..... (A) 483
[Leprosy control in Quanzhou City, Fujian.] Huang, Y.-X., *et al.* ..... (A) 340
[Leprosy control in Xinjuang since 1986.] Huang, W.-J., *et al.* ..... (A) 313
Long-term effect of leprosy control in two prefectures of China, 1955-1993. Li, H.-Y., *et al.* ..... (O) 213
Patient treatment compliance in leprosy; a reply. Vadher, A. ..... (C) 120
Patient treatment compliance in leprosy; an unjustifiably critical review. Ellard, G. A. ..... (C) 117
Prospects for contributions from basic biological research to leprosy control. Brennan, P. J. ..... (A) 285
Some points on the elimination of leprosy. Sansarricq, H. ..... (A) 166
[Status of the integration of leprosy control with the general health services in Senegal.] Sylla, P. M. ..... (A) 586
The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Murray, C. J. L., *et al.* ..... (A) 134
Tuberculosis control strategies: the cost of particulate respirators. Nettleman, M. D., *et al.* ..... (A) 355
Tuberculosis; Pathogenesis, Protection and Control, Barry R. Bloom, ed. ..... (B) 122
Voluntary donor agencies in antileprosy work; present contribution and probable future. Sommerfeld, P. ..... (A) 311
Will there be a need for leprosy control services in the 21st century? Feenstra, P. ..... (A) 310
Will we understand leprosy before it disappears? Fine, P. E. M. ..... (A) 282

Cuba,
[Incidence of leprosy in the city of Camaguey, Cuba, in the years 1978-1993.] Ferra Torres, T. M. and Carrazana Hernandez, G. B. ..... (A) 618
[Leprosy incidence during monotherapy and multidrug therapy in Camaguey, Cuba, 1984-1993.] Carrazana Hernandez, G. B. and Ferra Torres, T. M. ..... (A) 486

Cultivation,
Continuous cultivation of *M. leprae* in primary cell cultures. Walker, L. L., *et al.* ..... (A) 657
Cultivation of *M. leprae* in macrophages. Fukutomi, Y., *et al.* ..... (A) 648
Water soluble palmitic acid in media for cultivation of leprosy derived psychrophlic mycobacteria from *M. leprae* infected tissues. Kato, L. ..... (A) 611

Cutaneous,
Biometals in skin and sera of leprosy patients and their correlation to trace element contents of *M. leprae* and histological types of the disease; a comparative study with cutaneous tuberculosis. Jain, A., *et al.* ..... (O) 249
Differing antibody IgG isotypes in the polar forms of leprosy and cutaneous leishmaniasis characterized by antigen-specific T cell anergy. Ulrich, M., *et al.* ..... (A) 480
Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. Carlesimo, M., *et al.* ..... (A) 626

Dapsone (DDS),
Activity of combinations of dapsone, rifampin, minocycline, clarithromycin, and sparfloxacin against *M. leprae*-infected mice. Gelber, R. H., *et al.* ..... (O) 259
Adverse reactions to dapsone in persons infected with human immunodeficiency virus. Pertel, P. and Hirschtick, R. ..... (A) 138
Cimetide improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. Rhodes, L. E., *et al.* ..... (A) 316
Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated *M. avium* infection in beige mice. Bermudez, L. E., *et al.* ..... (A) 346
Dapsone acetylation by human liver arylamine N acetyltransferases and interaction of antiopportunistic infection drugs. Palamanda, J. R., *et al.* ..... (A) 469
Dapsone agranulocytosis in a leprosy patient. Hiran, S., *et al.* ..... (A) 141
Dapsone attenuates kainic acid-induced seizures in rats. Altagracia, M., *et al.* ..... (A) 135
Dapsone inhibits the generation of 5-lipoxygenase products in human polymorphonuclear leukocytes. Wozel, G. and Lehmann, B. ..... (A) 593
Dapsone syndrome in Goa. Rege, V. L., *et al.* ..... (A) 139
Dapsone-induced hematologic toxicity; comparison of the methemoglobin-forming ability of hydroxylamine metabolites of dapsone in rat and human blood. Vage, C., *et al.* ..... (A) 318
Dapsone-induced hemolytic anemia: effect of dapsone hydroxylamine on sulhydryl status, membrane skeletal proteins and morphology of human and rat erythrocytes. McMillan, D. C., *et al.* ..... (A) 590
Dapsone-induced hemolytic anemia: role of glucose-6-phosphate dehydrogenase in the hemolytic response of rat erythrocytes to N-hydroxydapsone. Grossmann, S., *et al.* ..... (A) 588
Evaluation of effects of gastric pH on absorption of dapsone in healthy volunteers. Breen, G. A., *et al.* ..... (A) 140
Evidence that the biotransformation of dapsone and monoacetyldapsone to their respective hydroxylamine metabolites in rat liver microsomes is mediated by cytochrome P45 2C6/2C11 and 3A1. Vage, C. and Svensson, C. K. ..... (A) 139
[Following up of 363 healthy children living in colonies and taking DDS for prevention of leprosy.] Liu, C., *et al.* ..... (A) 618
[Frequency of chronic plantar ulcers in leprosy patients according to treatment by dapsone monotherapy or multidrug therapy.] Mane, I., *et al.* ..... (A) 589
High-performance liquid chromatography determination of dapsone, monoacetyldapsone, and pyrimethamine in filter paper blood spots. Ronn, A. M., *et al.* ..... (A) 316
Improving patient compliance–a multicentre evaluation of the DDS tile test. Naik, S. S., *et al.* ..... (A) 314
[Relapse of leprosy after MDT and after DDS plus RMP.] Zhou, X. ..... (A) 593

Deformity, disability,
Deformity incidence in leprosy patients treated with multidrug therapy. Rao, P. S., *et al.* ..... (A) 315
Disabilities of hands, feet and eyes in newly diagnosed leprosy patients in eastern Nepal. Schipper, A., *et al.* ..... (A) 142
Disability grading in leprosy: current status. Thappa, D. M. ..... (A) 344
Field evaluation of WHO-MDT of fixed duration at ALERT, Ethiopia: the AMFES project–I. MDT course completion, case holding and another score for disability grading. de Rijk, A. J., *et al.* ..... (A) 312
Low cost disability management project in Bombay. ..... (N) 127
Measurement of dehabilitation in patients of leprosy; a scale. Anandaraj, H. ..... (A) 621
Problems and coping strategies of families having patients with and without deformities. Kopparty, S. N. M., *et al.* ..... (A) 621
Quantifying disability: data, methods and results. Murray, C. J. L. and Lopez, A. D. ..... (A) 134

Quantifying the burden of disease; the technical basis for disability-adjusted life years. Murray, C. J. L. ..... (A) 133
[Seasons of occurrences of leprosy and the disability.] Yang, Z.-M., *et al.* ..... (A) 342
Surgical correction of saddle nose deformity in leprosy–one stage procedure. Malaviya, G. N. and Husain, S. ..... (A) 343
Workshop on Prevention of Disabilities and Physical Rehabilitation of Leprosy Patients. . (N) 465

Dermatology,
IADVL (Indian Association of Dermatologists, Venereologists and Leprologists) Textbook and Atlas of Dermatology, Volumes I and II. Hastings, R. C. ..... (B) 299
[Use of thalidomide in dermatology.] Poenca, N. G. ..... (A) 315

DNA,
A search for mycobacterial DNA in sarcoidosis using the polymerase chain reaction. Ghossein, R. A., *et al.* ..... (A) 174
Amplification of DNA of *M. tuberculosis* from peripheral blood of patients with pulmonary tuberculosis. Schluger, N. W., *et al.* ..... (A) 185
Analysis of the population structure of *M. tuberculosis* in Ethiopia, Tunisia, and The Netherlands; usefulness of DNA typing for global tuberculosis epidemiology. Hermans, P. W. M., *et al.* ..... (A) 631
Application of polymerase chain reaction for the detection of *M. leprae* DNA in specimens from treated leprosy patients. Rafi, A., *et al.* ..... (O) 42
Chromosomal DNA fingerprinting analysis using the insertion sequence IS6110 and the repetitive element DR as strain specific markers for epidemiological study of tuberculosis in French Polynesia. Torrea, G., *et al.* ..... (A) 637
Cloning and expression in *Escherichia coli* of DNA encoding a 60 kDa stress protein of *M. paratuberculosis*, the causative agent of Johne's disease. Colston, A., *et al.* ..... (A) 348
Colorimetric microwell plate hybridization assay for detection of amplified *M. tuberculosis* DNA from sputum samples. Cho, S.-N., *et al.* ..... (A) 492
DNA of *M. tuberculosis* in formalin-fixed, paraffin-embedded tissue in tuberculosis and sarcoidosis detected by polymerase chain reaction. Popper, H. H., *et al.* ..... (A) 184
DNA topoisomerase I from *M. smegmatis*. Bhaduri, T. and Nagaraja, V. ..... (A) 157
Detection of rifampin-resistant bacteria using DNA probes for precursor rRNA. Britschgi, T. B. and Cangelosi, G. A. ..... (A) 607
Ethanol fixation of sputum sediments for DNA-based detection of *M. tuberculosis*. Williams, D. L., *et al.* ..... (A) 615
Evaluation of PCR mediated DNA amplification in non-invasive biological specimens for subclinical detection of *M. leprae*. Santos, A. R., *et al.* ..... (A) 613
Growth-deficient mycobacteria in patients with AIDS: diagnosis by analysis of DNA amplified from blood or tissue. Emler, S., *et al.* ..... (A) 494
Identification of *M. tuberculosis* DNA sequences encoding exported proteins by using phoA gene fusions. Lim, E. M., *et al.* ..... (A) 354
Inactivation of polymerase inhibitors for *M. tuberculosis* DNA amplification in sputum by using capture resin. Amicosante, M., *et al.* ..... (A) 488
M. leprae DNA content, cellular and cytokine patterns in skin lesions of leprosy patients undergoing multidrug therapy (MDT). Flad, H. D., *et al.* ..... (A) 324
Multiplex strand displacement amplifications (SDA) and detection of DNA sequences from *M. tuberculosis* and other mycobacteria. Walker, G. T., *et al.* ..... (A) 163
Preparation of high-molecular-weight DNA: application to mycobacterial cells. Imai, T., *et al.* ..... (A) 335
Rapid *Mycobacterium* species assignment and unambiguous identification of mutations associated with antimicrobial resistance in *M. tuberculosis* by automated DNA sequencing. Kapur, V., *et al.* ..... (A) 352
Rapid discrimination of *M. tuberculosis* strains by random amplified polymorphic DNA analysis. Linton, C. J., *et al.* ..... (A) 159
Sequence analysis of the 18-kDa gene and the 16S-23S rDNA ITS region from strains of *M. leprae*. Gillis, T. P., *et al.* ..... (A) 649
Sequence of conserved region in the A subunit of DNA gyrase from nine species of the genus *Mycobacterium*: phylogenetic analysis and implication for intrinsic susceptibility to quinolones. Guillemin, I., *et al.* ..... (A) 610
Solid-phase hybridization capture of low-abundance target DNA sequences: application

to the polymerase chain reaction detection of *M. paratuberculosis* and *M. avium* subsp. *silvaticum*. Millar, D. S., *et al.* ..... (A) 497

Dominican Republic,
[Scope of the Action Plan for the Elimination of Leprosy in the Dominican Republic.] Isa Isa, R. A. and Castellazzi, Z. ..... (A) 166

Drugs (see also **Multidrug therapy** and specific drugs),
Development of an *in vitro* drug screening system for *M. leprae* based on the determination of the intrabacterial sodium-to-potassium ratio of individual bacterial organisms. Wiese, M., *et al.* ..... (A) 338
Drug-resistant strains of *M. tuberculosis* exhibit a range of virulence for mice. Ordway, D. J., *et al.* ..... (A) 355
[Frequency of chronic plantar ulcers in leprosy patients according to treatment by dapsone monotherapy or multidrug therapy.] Mane, I., *et al.* ..... (A) 589
Implications of multidrug resistance for the future of short course chemotherapy of tuberculosis: a molecular study. Heym, B., *et al.* ..... (A) 176
Intracellular activities of roxithromycin used alone and in association with other drugs against *M. avium* complex in human macrophages. Rastogi, N., *et al.* ..... (A) 499
[Leprosy incidence during monotherapy and multidrug therapy in Camaguey, Cuba, 1984-1993.] Carrazana Hernandez, G. B. and Ferra Torres, T. M. ..... (A) 486
Molecular genetics of drug resistence in *M. tuberculosis*. Zhang, Y. and Young, D. ..... (A) 191
Molecular mechanisms of multiple drug resistance in clinicalisolates of *M. tuberculosis*. Morris, S., *et al.* ..... (A) 497
Ofloxacin-containing combined drug regimens in the treatment of lepromatous leprosy. Rao, P. S., *et al.* ..... (A) 138
Outbreak of multi-drug-resistant tuberculosis in a New York state prison. Valway, S. E., *et al.* ..... (A) 187
Potential drug targets for *M. avium* defined by radiometric drug-inhibitor combination techniques. Rastogi, N., *et al.* ..... (A) 160
Quinolone resistance in veterinary isolates of *Salmonella*. Griggs, D. J., *et al.* ..... (A) 159
[Secondary multiple drug resistance in hanseniasis.] Opromolla, D. V. A., *et al.* ..... (A) 314
Short-course regimens for the treatment of Hansen's disease. Pattyn, S. R. ..... (A) 285
Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: a molecular epidemiologic assessment. Shafer, R. W., *et al.* ..... (A) 360

Ear,
Audiovestibular system, fifth and seventh cranial nerve involvement in leprosy. Koyuncu, M., *et al.* ..... (A) 320
Doppler sonography of vertebral arteries and audiovestibular system investigation in leprosy. Koyuncu, M., *et al.* ..... (O) 23

Electron microscopy (see also **Ultrastructure**),
Antigenic properties and immunoelectron microproperties and immunoelectron microscopic localization of *M. fortuitum* beta lactamase. Wagner, B., *et al.* ..... (A) 365

ELISA (enzyme-linked immunosorbent assay) tests,
[A seroepidemiological study of leprosy in the household contacts with ELISA using ND-O-BSA and PGL as antigens.] Li, W.-Z., *et al.* ..... (A) 341
[Ultramicro-ELISA (UMELISA) for the detection of IgM antibodies to *M. leprae* using eluates of dried blood spots.] Torrella, A., *et al.* ..... (A) 606

Enzyme(s),
The *M. leprae* genome: systematic sequence analysis identifies key catabolic enzymes, ATP-dependent transport systems and a novel polA locus associated with genomic variability. Fsihi, H. and Cole, S. T. ..... (A) 609

Epidemiology,
A case control study on human immunodeficiency virus-1 (HIV-1) infection as a risk factor for tuberculosis and leprosy in western Kenya. Orege, P. A., *et al.* ..... (A) 487
A clinico-epidemiological study of leprosy in arid northwest Rajasthan, Jodhpur. Salodkar, A. D. and Kalla, G. ..... (A) 598

[A seroepidemiological study of leprosy in the household contacts with ELISA using ND-O-BSA and PGL as antigens.] Li, W.-Z., *et al.* ..... (A) 341
[Aggregation property of leprosy in distribution.] Li, X., *et al.* ..... (A) 618
Case finding survey for leprosy in Botswana. Kumaresan, J. A., *et al.* ..... (A) 341
Development of a whole blood assay to measure T cell responses to leprosy: a new tool for immuno-epidemiological field studies of leprosy immunity. Weir, R. E., *et al.* ... (A) 332
[Epidemiologic indicators of the incidence of leprosy in a health district.] Lopez Sifontes, M. E., *et al.* ..... (A) 618
Epidemiological aspects of relapses in leprosy. Ponnighaus, J. M. and Sterne, J. A. .... (A) 591
Epidemiology Congresses to be held in April in Brazil. ..... (N) 123
[Leprosy in New Caledonia from 1983 to 1992; histopathological and epidemiological data.] Monchy, D., *et al.* ..... (A) 619
Nerve damage in leprosy: an epidemiological and clinical study of 396 patients in west Nepal–Part I. Definitions, methods and frequencies. van Brakel, W. H. and Khawas, I. B. ..... (A) 144
Reactions in leprosy: an epidemiological study of 386 patients in west Nepal. van Brakel, W. H., *et al.* ..... (A) 144
Seroepidemiological study of *M. leprae* infection in the inhabitants of endemic villages in South Sulawesi, Indonesia. Izumi, S., *et al.* ..... (A) 650
[Seroepidemiology of leprosy.] Wu, Q.-X., *et al.* ..... (A) 342
Silent neuropathy in leprosy: an epidemiological description. van Brakel, W. H. and Khawas, I. B. ..... (A) 321
The genetic epidemiology of leprosy in a Brazilian population. Feitosa, M. F., *et al.* ... (A) 617
The present status of serological techniques and future perspectives in the study of epidemiology of leprosy. Bharadwaj, V. P. ..... (A) 146
Trends in leprosy in the Kingdom of Bhutan. Jakeman, P., *et al.* ..... (A) 486

Erythema nodosum leprosum (ENL),
Clinical and histological discrepancies in diagnosis of ENL reactions classified by assessment of acute phase proteins SAA and CRP. Hussain, R., *et al.* ..... (O) 222
Critical residues of the *M. leprae* LSR recombinant protein discriminate clinical activity in erythema nodosum leprosum reactions. Singh, S., *et al.* ..... (A) 331
ENL necroticans; report on 5 cases. Salafia, A. and De Geiking, I. ..... (A) 598
Erythema nodosum leprosum in Malaysians. Jayalakshmi, P., *et al.* ..... (C) 109
Erythema nodosum leprosum lymphadenitis. Fiallo, P., et al. ..... (A) 594
Is pentoxifylline a viable alternative in the treatment of ENL? Sarno, E. N., *et al.* ..... (C) 570
Oral zinc therapy and recurrent erythema nodosum leprosum: a clinical study. Mahajan, P. M., *et al.* ..... (A) 142

Escherichia coli,
Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of *Escherichia coli* and MICs. Vila, J., *et al.* ..... (A) 188
Cloning and expression in *Escherichia coli* of DNA encoding a 60 kDa stress protein of *M. paratuberculosis*, the causative agent of Johne's disease. Colston, A., *et al.* ..... (A) 348
Cloning, sequencing and expression in *Escherichia coli* of the gene for alpha antigen from *M. scrofulaceum*. Takano, M., *et al.* ..... (A) 161
Evidence for a ppGpp-binding site on *Escherichia coli* RNA polymerase: proximity relationship with the rifampicin binding domain. Reddy, P. S., *et al.* ..... (A) 358
Identification and characterization of *M. paratuberculosis* recombinant proteins expressed in *E. coli*. Elsaatari, F. A. K., *et al.* ..... (A) 173
Stationery phase induction in *Escherichia coli*–new targets for antimicrobial therapy? Smith, A. W. ..... (A) 484

Ethambutol,
Activities of benzoxazinorifamycin KRM 1648 and ethambutol against *M. avium* complex *in vitro* and in macrophages. Inderlied, C. B., *et al.* ..... (A) 178
Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against *M. simiae* in murine model of disseminated infection. Valero, G., *et al.* ..... (A) 187
Activity of KRM 1648 alone and in combination with ethambutol or clarithromycin against *M. avium* in beige mouse model of disseminated infection. Bermudez, L. E., *et al.* ..... (A) 170

Oral desensitization to rifampin and ethambutol in mycobacterial disease. Matz, J., *et al.* ..... (A) 137
Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelope. Deng, L. Y., *et al.* ..... (A) 493
Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria. Wolucka, B. A., *et al.* ..... (A) 339
The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol and rifampin, on *M. avium* complex bacteremia in patients with AIDS. Kemper, C. A., *et al.* ..... (A) 178

Ethiopia,
ALERT 1996 Training Calendar ..... (N) 462
Analysis of the population structure of *M. tuberculosis* in Ethiopia, Tunisia, and The Netherlands; usefulness of DNA typing for global tuberculosis epidemiology. Hermans, P. W. M., *et al.* ..... (A) 631
Field comparison of 10-g and 1-g filaments for the sensory testing of hands in Ethiopian leprosy patients. de Rijk, A. J. and Byass, P. ..... (A) 319
Field evaluation of WHO-MDT of fixed duration at ALERT, Ethiopia: the AMFES project–I. MDT course completion, case holding and another score for disability grading. de Rijk, A. J., *et al.* ..... (A) 312
Field evaluation of WHO-MDT of fixed duration at ALERT, Ethiopia: the AMFES project–II. Reaction and neuritis during and after MDT in PB and MB leprosy patients. de Rijk, A. J., *et al.* ..... (A) 312
HIV infection and leprosy: a four-year survey in Ethiopia. Frommel, D., *et al.* ..... (A) 141
Inter-observer variability in the assessment of nerve function in leprosy patients in Ethiopia. Lienhardt, C., *et al.* ..... (O) 62

Experimental leprosy,
Experimental animal models and the future. Truman, R. W. ..... (A) 282
Experimental leprosy in monkeys. I. Sooty mangabey monkeys: transmission, susceptibility, clinical and pathological findings. Gormus, B. J., *et al.* ..... (A) 616
Infection of SCID mice with *M. leprae* and control with antigen activated "immune" human peripheral blood mononuclear cells. Converse, P. J., *et al.* ..... (A) 476

Eye(s),
An unusual presentation of recurrent corneal abrasion in a lepromatous patient with impaired corneal sensation. Daniel, E. and Brand, M. E. ..... (E) 450
Disabilities of hands, feet and eyes in newly diagnosed leprosy patients in eastern Nepal. Schipper, A., *et al.* ..... (A) 142
[Effect of a modified temporal muscle transposition on leprous lagophthalmos.] Tan, W.-P. ..... (A) 321
Experimental arthritis and uveitis in rats associated with *M. butyricum.* Petty, R. E., *et al.* ..... (A) 183
Eye disease in newly diagnosed leprosy patients in eastern Nepal. Lubbers, W. J., *et al.* ..... (A) 141
[Histologic study of the eyes of armadillos experimentally infected with *M. leprae* before and after chemotherapy.] Zhou, H.-M., *et al.* ..... (A) 340
Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic *M. avium* complex infection with rifabutin. Saran, B. R., *et al.* ..... (A) 142
Intraocular pressure in leprosy patients without clinically apparent anterior segment pathology. Daniel, A. E., *et al.* ..... (A) 140
Is the leprosy blindness avoidable? The effect of disease type, duration, and treatment on eye damage from leprosy in Uganda. Waddell, K. M. and Saunderson, P. R. ..... (A) 475
Multidrug therapy and eye disease in leprosy; a cross sectional study in the People's Republic of China. Courtright, P., *et al.* ..... (A) 140
Ocular leprosy: do steroids complicate matters? Daniel, E., *et al.* ..... (C) 115
Pupil cycle time in leprosy patients without clincally apparent ocular pathology. Daniel, E. and Rao, P. S. A. ..... (O) 529
Relapse of *M. leprae* infection with ocular manifestations. Carus, N. H., *et al.* ..... (A) 472
[Surgical correction of lagophthalmos in 49 persons.] Yin, Y., *et al.* ..... (A) 344
[The effect of a modified temporal muscle bundle transposition on lagophthalmos in leprosy.] Long, P., *et al.* ..... (A) 622

[The effect of eyebrow transposition with single hairs in 274 cases of leprosy.] Wang, X., *et al.* ..... (A) 623

Face,

An unusual presentation of facial palsy in leprosy; a case report. Thompson, K. ..... (E) 567

[Analysis of the nerve damage in maxillofacial area among 607 leprosy patients.] Qiu, W.-P. ..... (A) 321

[Nerve damage on the face of 89 leprosy patients.] Jing, Z., *et al.* ..... (A) 319

[The effect of eyebrow transposition with single hairs in 274 cases of leprosy.] Wang, X., *et al.* ..... (A) 623

Family,

An RLFP map for 2q33-q37 from multicase mycobacterial and leishmanial disease families: no evidence for an Lsh/Ity/Bcg gene homologue influencing susceptibility to leprosy. Shaw, M. A., *et al.* ..... (A) 487

Case report of leprosy and a trial of screenings for the family members in Ecuador. Hosokawa, A., *et al.* ..... (A) 595

Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene? Levin, M., *et al.* ..... (A) 353

Problems and coping strategies of families having patients with and without deformities. Kopparty, S. N. M., *et al.* ..... (A) 621

Transmission of health information on leprosy from children to their families in an urban centre. Jacob, M. S., *et al.* ..... (A) 133

Finger(s),

Circulation and sensation at the fingertips of claw hands. Abbot, N. C., *et al.* ..... (A) 318

Foot,

A method for texture discrimination in the sole of the foot; a preliminary communication. Narayanakumar, T. S., *et al.* ..... (A) 622

Disabilities of hands, feet and eyes in newly diagnosed leprosy patients in eastern Nepal. Schipper, A., *et al.* ..... (A) 142

[Effect of footwear on insensitive feet in leprosy.] Chen, Q., *et al.* ..... (A) 342

Measurement of pressure walking in footwear used in leprosy. Birke, J. A., *et al.* ..... (A) 167

[Pathology of the feet in leprosy.] Terencio de las Aguas, J. ..... (A) 168

Technology transfer: implementing Carville's diabetic foot program in a community health setting. Shirley, A. ..... (A) 276

[The effect of a comprehensive protection measure on the feet with plantar ulcer and numbness.] Xu, S., *et al.* ..... (A) 623

Tibialis posterior transfer in the correction of footdrop due to leprosy. Soares, D. ..... (A) 622

Workshop on the Podiatric Management of Neuropathic Foot. ..... (N) 581

Foot pad(s),

Comparative assessment of viability of *M. leprae* by mouse foot pad and fluorescent staining techniques. Sreevatsa and Katoch, V. M. ..... (A) 337

Vaccination with pure *M. leprae* proteins inhibits *M. leprae* multiplication in mouse foot pads. Gelber, R. H., *et al.* ..... (A) 148

France,

Diplome Universitaire de Leprologie (1995-1996) ..... (N) 462

Diplome Universitaire de Leprologie, 1994-1995. ..... (N) 124

Genetics,

Activation of the hypothalamic-pituitary-adrenal axis differentially affects the antimycobacterial activity of macrophages from BCG-resistant and-susceptible mice. Brown, D. H. and Zwilling, B. S. ..... (A) 146

An RLFP map for 2q33-q37 from multicase mycobacterial and leishmanial disease families: no evidence for an Lsh/Ity/Bcg gene homologue influencing susceptibility to leprosy. Shaw, M. A., *et al.* ..... (A) 487

Characterization of IS1110 a highly mobile genetic element from *M. avium*. Perez, M. H., *et al.* ..... (A) 183

Detection of a genetic locus encoding resistance to rifampin in mycobacterial cultures in clinical specimens. Hunt, J. M., *et al.* ..... (A) 177

Genetic determination of the meso-diaminopimelate biosynthetic pathway of mycobacteria. Cirillo, J. D., *et al.* ..... (A) 158
Genetic regulation of leishmanial and mycobacterial infections; the Lsh/Ity/Bcg gene story continues. Blackwell, J. M., *et al.* ..... (A) 489
Growth of *M. tuberculosis* in BCG-resistant and-susceptible mice: establishment of latency and reactivation. Brown, D. H., *et al.* ..... (A) 625
In vivo growth characteristics of leucine and methionine auxotrophic mutants of *M. bovis* BCG generated by transposon mutagenesis. McAdam, R. A., *et al.* ..... (A) 483
Molecular genetics of drug resistence in *M. tuberculosis*. Zhang, Y. and Young, D. .... (A) 191
Nucleotide sequence of the 85B-protein gene of *M. bovis* BCG and *M. tuberculosis*. de Wit, M. Y. L., *et al.* ..... (A) 173
Sequence of conserved region in the A subunit of DNA gyrase from nine species of the genus *Mycobacterium*: phylogenetic analysis and implication for intrinsic susceptibility to quinolones. Guillemin, I., *et al.* ..... (A) 610
The genetic epidemiology of leprosy in a Brazilian population. Feitosa, M. F., *et al.* ... (A) 617
The immunogenicity of recombinant *M. smegmatis*-bearing BCG genes. Falcone, V., *et al.* ..... (A) 609
Use of various genetic markers in differentiation of *M. bovis* strains from animals and humans and for studying epidemiology of bovine tuberculosis. van Soolingen, D., *et al.* ..... (A) 188

Genome,
Basic and applied research emerging from the *M. leprae* genome. Gillis, T. P. ..... (A) 286
Genomic fingerprinting of *M. bovis* from cattle by restriction fragment length polymorphism analysis. Skuce, R. A., *et al.* ..... (A) 186
The *M. leprae* genome: systematic sequence analysis identifies key catabolic enzymes, ATP-dependent transport systems and a novel polA locus asociated with genomic variability. Fsihi, H. and Cole, S. T. ..... (A) 609

Germany,
1995 European Conference on Tropical Medicine. ..... (N) 304
European Conference on Tropical Medicine. ..... (N) 463
First European Conference on Tropical Medicine in Hamburg, Germany. ..... (N) 124

Granuloma(s),
Cytokine responses during mycobacterial and shistosomal antigen-induced pulmonary granuloma formation–production of Th1 and Th2 cytokines and relative contribution of tumor necrosis factor. Chensue, S. W., *et al.* ..... (A) 323
Intraoperative electroneurodiagnostics to detect a second granuloma in the cubital area of median nerves affected by leprosy: a new approach to prevent incomplete surgery. Turkof, E., *et al.* ..... (O) 409
Persistence of lepromatous granuloma in clinically cured cases of leprosy. Desikan, P. and Desikan, K. V. ..... (O) 417
Ultraviolet radiation decreases the granulomatous response to lepromin in humans. Cestari, T. F., *et al.* ..... (A) 599

Hand(s),
Circulation and sensation at the fingertips of claw hands. Abbot, N. C., *et al.* ..... (A) 318
Disabilities of hands, feet and eyes in newly diagnosed leprosy patients in eastern Nepal. Schipper, A., *et al.* ..... (A) 142
Field comparison of 10-g and 1-g filaments for the sensory testing of hands in Ethiopian leprosy patients. de Rijk, A. J. and Byass, P. ..... (A) 319
Hand wounds in leprosy patients. Soares, D. and Desar N. ..... (A) 623
The predictive value of sensation testing in the development of neuropathic ulceration on the hands of leprosy patients. Kuipers, M. and Schreuders, T. ..... (A) 167

Histopathology,
Agreement between histopathological results in clinically diagnosed cases of indeterminate leprosy in Sao Paulo, Brazil. Lombardi, C., *et al.* ..... (A) 329
Effects of treatment on the histopathology of leprosy. Cree, I. A., *et al.* ..... (A) 476
Histopathological features of relapsed leprosy. Job, C. K. ..... (A) 589
Histopathology of C57BL/6 mice inoculated orally with *M. paratuberculosis*. Veasey, R. S., *et al.* ..... (A) 638

[Histopathology of the skin in LL patients after completion of treatment.] Zhou, X.-T., *et al.* ..... (A) 333
[Leprosy in New Caledonia from 1983 to 1992; histopathological and epidemiological data.] Monchy, D., *et al.* ..... (A) 619

History of leprosy,
Prevalence of maxillary sinusitis in leprous individuals from a medieval leprosy hospital. Boocock, P. A., *et al.* ..... (O) 265

HLA (see also **Genetics**),
An HLA-DRw53-restricted T-cell epitope from a novel *M. leprae* protein antigen important to the human memory T-cell repertoire against *M. leprae*. Mustafa, A. S., *et al.* ..... (A) 328
CD4+ T-cell responses to recombinant hsp65 and hsp18 of *M. leprae* and their trypsin-digested fragments in leprosy: diversity in HLA-DR restriction. Mitra, D. K., *et al.* .... (O) 518
Delayed hypersensitivity and HLA in smear-positive pulmonary tuberculosis. Bothamley, G. H., *et al.* ..... (A) 490
Limited restriction in the TCR-alpha beta V region usage of anti-specific clones–recognition of myelin basic protein (amino acids 84-102) and *M. bovis* 65-kDa heat shock protein (amino acids 3-13) by T cell clones established from PBMC of monozygotic twins and HLA-identical individuals. Hawes, G. E., *et al.* ..... (A) 351
Mapping of multiple HLA class II-restricted T-cell epitopes of the mycobacterial 70-kilodalton heat shock protein. Oftung, F., *et al.* ..... (A) 329
Thalidomide does not perturb CD2, CD4, CD5, CD8, HLA-DR, or HLA-A, B, C molecules *in vitro* on the membranes of cells with immune potential. Shannon, E. J., *et al.* ..... (A) 330
Variants of HLA-DR2/DR51 group haplotypes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis in Asian Indians. Mehra, N. K., *et al.* ..... (O) 241

Human immunodeficiency virus (HIV),
A case control study on human immunodeficiency virus-1 (HIV-1) infection as a risk factor for tuberculosis and leprosy in western Kenya. Orege, P. A., *et al.* ..... (A) 487
Adverse reactions to dapsone in persons infected with human immunodeficiency virus. Pertel, P. and Hirschtick, R. ..... (A) 138
Cellular immune responses to *M. leprae* infection in human immunodeficiency virus-infected individuals. Sampaio, E. P., *et al.* ..... (A) 605
Environmental risk factors for acquisition of *M. avium* complex in persons with human immunodeficiency virus infection. Horsburgh, C. R., *et al.* ..... (A) 177
HIV infection and leprosy: a four-year survey in Ethiopia. Frommel, D., *et al.* ..... (A) 141
Human immunodeficiency virus and leprosy. Naafs, B., *et al.* ..... (A) 474
Interleukin-12 enhances antigen-specific proliferation of peripheral blood mononuclear cells from HIV-positive and negative donors in response to *M. avium*. Newman, G. W., *et al.* ..... (A) 182
Isolation of nontuberculous, non-avium mycobacteria from patients infected with human immunodeficiency virus. Raszaka, W. V., *et al.* ..... (A) 357
[Kaposi's sarcoma in an HIV-negative patient with lepromatous leprosy.] Drateln, C. R. ..... (A) 594
Leprosy in five human immunodeficiency virus-affected patients. Moran, C. A., *et al.* ..... (A) 596
M. avium complex in water, food, and soil samples collected from the environment of HIV-infected individuals. Yajko, D. M., *et al.* ..... (A) 639
M. tuberculosis enhances human immunodeficiency virus-1 replication of transcriptional activation at the long terminal repeat. Zhang, Y. H., *et al.* ..... (A) 640
Prevalence of human T cell lymphotrophic virus (HTLV) types I and II and human immunodeficiency virus type 1 infections among persons with Hansen's disease in New York City. Glaser, J. B., *et al.* ..... (A) 141
T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infections. Zhang, M., *et al.* ..... (A) 333
Tat protein from HIV-1 binds to *M. avium* via a bacterial integrin–effects on extracellular and intracellular growth. Denis, M. ..... (A) 173
Testing for antibody to human immunodeficiency virus type 1 in a population in which mycobacterial diseases are endemic. Sterne, J. A. C., *et al.* ..... (A) 620
Thalidomide and the immune system 4. Down-regulation of the CD26 receptor, prob-

ably involved in the binding of HIV components to T cells in primate. Neubert, R., *et al.* ..... (A) 355
Thalidomide as treatment of refractory aphthous ulceration to human immunodeficient virus infection. Paterson, D. L., *et al.* ..... (A) 356
Thalidomide-resistant HIV-associated aphthae successfully treated with granulocyte colony-stimulating factor. Manders, S. M., *et al.* ..... (A) 632
Two novel T cell epitope prediction algorithms based on MHC binding motifs; comparison of predicted and published epitopes from *M. tuberculosis* and HIV protein sequences. Meister, G. E., *et al.* ..... (A) 633
Type 1 reactions in leprosy, neuritis and steroid therapy: the impact of the human immunodeficiency virus. Bwire, R. and Kawuma, H. J. S. ..... (A) 135
Why disease due to *M. tuberculosis* is less common than expected in HIV-positive patients in Edinburgh. Leitch, A. G., *et al.* ..... (A) 632

Hypersensitivity,
Delayed hypersensitivity and HLA in smear-positive pulmonary tuberculosis. Bothamley, G. H., *et al.* ..... (A) 490
Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Fine, P. E. M., *et al.* ..... (A) 324
Immunogenic properties of the *M. leprae* recombinant 18-kDa antigen purified from *Saccharomyces cerevisiae*; enhancement of delayed-type hypersensitivity after gamma-irradiation. Pinho, J. R. R., *et al.* ..... (O) 381
Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis. Dannenberg, A. M. ..... (A) 348
The delayed-type hypersensitivity reaction is dependent on IL-8; inhibition of a tuberculin skin reaction by an anti-IL-8 monoclonal antibody. Larsen, C. G., *et al.* ..... (A) 603

ILEP (International Federation of Anti-Leprosy Associations),
ILEP looks to the future. ..... (N) 584
ILEP members fund Chinese shoe factory. ..... (N) 124
ILEP statement: elimination of leprosy as a public health problem. ..... (A) 468

Immune complexes,
Circulating immune complexes in patients with advanced tuberculosis and their association with autoantibodies and reduced CD4+ lymphocytes. Dlugovitzky, D., *et al.* ..... (A) 628
[Glomerulonephritis due to immune complexes associated with pulmonary tuberculosis.] Villar, I., *et al.* ..... (A) 189

Immune responses,
Cellular and humoral immune responses to recombinant 65-kDa antigen of *M. leprae* in leprosy patients and healthy controls. Ilangumaran, S., *et al.* ..... (A) 150
Cellular immune response to common mycobacterial antigens in subjects seropositive for *Trypanosoma cruzi*. Bottasso, O. A., *et al.* ..... (A) 322
Cellular immune responses to *M. leprae* infection in human immunodeficiency virus-infected individuals. Sampaio, E. P., *et al.* ..... (A) 605
Comparison of the immune response against *M. tuberculosis* antigens between a group of patients with active pulmonary tuberculosis and healthy household contacts. Torres, M., *et al.* ..... (A) 155
Effect of thalidomide on the cellular immune response in experimental tuberculosis in mice. Moreira, A. L., *et al.* ..... (A) 651
Identification and purification of armadillo (*Dasypus novemcinctus*) immunoglobulins: preparation of specific antisera to evaluate the immune response in these animals. Santos-Argumedo, L., *et al.* ..... (O) 56
Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes; antibody responses to mycobacterial and leishmanial antigens. Sharples, C. E., *et al.* ..... (A) 360
Immune response of armadillos (*Dasypus novemcinctus*). I. Use of lectins to identify lymphocyte subpopulations and to evaluate cell proliferation. Santos-Argumedo, L., *et al.* ..... (O) 546
Immune response to *M. bovis* bacille Calmette Guerin infection in major histocompatibility complex class I-and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Ladel, C. H., *et al.* ..... (A) 602

Immune responses of heat-shock protein 65 on *M. leprae* inoculated mice. Nomaguchi, H., *et al.* ....(A) 652
Macrophage-T cell interaction in experimental mycobacterial infection; selective regulation of co-stimulatory molecules on *Mycobacterium*-infected macrophages and its implication in the suppression of cell-mediated immune response. Saha, B., *et al.* ....(A) 359
Regulation by arachidonic acid metabolites of the immune response toward pathogenic mycobacteria. Adams, L. B., *et al.* ....(A) 644
T cells bearing Vbeta6 T cell receptors in the cell-mediated immune response to *M. leprae*. Wang, X. H., *et al.* ....(A) 481
The effect of prostaglandin E(2) and indomethacin on the cytotoxic response to mycobacterial antigens. Yuan, S. N., *et al.* ....(A) 191
Tumor necrosis factor-alpha is required in the protective immune response against *M. tuberculosis*. Flynn, J. L., *et al.* ....(A) 629

Immunoglobulins,
Differing antibody IgG isotypes in the polar forms of leprosy and cutaneous leishmaniasis characterized by antigen-specific T cell anergy. Ulrich, M., *et al.* ....(A) 480
Enhanced response of serum IgG class of anti-PGL-I antibodies in leprosy patients during onset and following clinical remission of type 1 and type 2 reactions. Saha, K., *et al.* ....(C) 105
Identification and purification of armadillo (*Dasypus novemcinctus*) immunoglobulins: preparation of specific antisera to evaluate the immune response in these animals. Santos-Argumedo, L., *et al.* ....(O) 56
Identification of IgM as the leprosy patient serum factor responsible for rapid sedimentation of formolized sheep erythrocytes. Panunto-Castelo, A. and Roque-Barreira, M.-C. ....(O) 231
IgG humoral response against the antigen 85 complex homologues in leprosy. Drowart, A., *et al.* ....(A) 324
IgG subclass antibodies to mycobacterial sonicate and recombinant antigens in leprosy. Sheela, R., *et al.* ....(A) 480
IgG subclass antibody to *M. leprae* 18,000 MW antigen is restricted to IgG1 and IgG3 in leprosy. Hussain, R., *et al.* ....(A) 325
Immunoglobulin G1 (IgG1) and IgG3 antibodies are markers for progressive disease in leprosy. Hussain, R., *et al.* ....(A) 325
Recognition of *M. leprae* recombinant 18,000 MW epitopes by IgG subclasses in leprosy. Hussain, R., *et al.* ....(A) 326
The role of IgM antiphenolic glycolipid-I antibodies in assessing household contacts of leprosy patients in a low endemic area. Soares, D. J., *et al.* ....(A) 332
[Ultramicro-ELISA (UMELISA) for the detection of IgM antibodies to *M. leprae* using eluates of dried blood spots.] Torrella, A., *et al.* ....(A) 606

Immunology,
A *M. leprae*-specific gene encoding an immunologically recognized 45 kDa protein. De Wit, T. F. R., *et al.* ....(A) 477
Biochemical and immunological characterization of ribosomal fraction and culture filtrate from BCG. Yamada, T., *et al.* ....(A) 658
Immunological aspects of relapse in leprosy. Sengupta, U. ....(A) 592
Immunology research at Carville. Krahenbuhl, J. L. ....(A) 282
Indeterminate leprosy: a serioimmunological and histochemical evaluation. Sekar, B., *et al.* ....(A) 143
Infection of SCID mice with *M. leprae* and control with antigen activated "immune" human peripheral blood mononuclear cells. Converse, P. J., *et al.* ....(A) 476
Molecular and immunological characterization of the highly conserved antigen 84 from *M. tuberculosis* and *M. leprae*. Hermans, P. W. M., *et al.* ....(A) 482
Overview of the immunology of leprosy. Nath, I. ....(A) 281
Th1-Th2 paradigm: insights from leprosy. Modlin, R. L. ....(A) 152
[The immunology of leprosy 1993.] Castells Rodellas, A., *et al.* ....(A) 147
The immunology of leprosy; unraveling an enigma. Choudhuri, K. .(E) 430
Type 2 cytokines and negative immune regulation in human infections. Modlin, R. L. and Nutman, T. B. ....(A) 328

Immunotherapy,
Effective application of modern immunotherapeutic measures in the treatment of leprosy. Kaplan, G. ..... (A) 280
Immunotherapy with *M. vaccae* as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Onyebujoh, P. C., *et al.* ..... (A) 498
Treatment of bacilliferous BL/LL cases with combined chemotherapy and immunotherapy. Katoch, K., *et al.* ..... (O) 202

Indeterminate leprosy,
Agreement between histopathological results in clinically diagnosed cases of indeterminate leprosy in Sao Paulo, Brazil. Lombardi, C., *et al.* ..... (A) 329
Indeterminate leprosy: a serioimmunological and histochemical evaluation. Sekar, B., *et al.* ..... (A) 143

India,
16th Anniversary of leprosy research in Red Cross Hospital. ..... (N) 580
1994 ILEF Awards for Excellence. ..... (N) 304
1995 Leprosy training courses at RLT&RI. ..... (N) 463
1996 International Gandhi Award. ..... (N) 579
CLT&RI research project. ..... (N) 125
Dapsone syndrome in Goa. Rege, V. L., *et al.* ..... (A) 139
Dr. Mukherjee, DGHS, applauds leprosy research in Bombay. ..... (N) 580
Hansen's disease control in India: problems and solutions. Ganapati, R ..... (A) 279
IADVL (Indian Association of Dermatologists, Venereologists and Leprologists) Textbook and Atlas of Dermatology, Volumes I and II. Hastings, R. C. ..... (B) 299
IAL 1993 MDT workshop. ..... (N) 126
ICMR Annual Report excerpts. ..... (N) 305
Industrial participation in leprosy control. ..... (N) 127
Infection amongst leprosy patients in South India. Jayasheela, M., *et al.* ..... (A) 319
Karigiri staff news. ..... (N) 127
Low cost disability management project in Bombay. ..... (N) 127
National Seminar on Public Health Aspects of Fixed Duration Treatment in Leprosy. ..... (N) 464
New Director of Gandhi Memorial Leprosy Foundation is Wele. ..... (N) 128
Schieffelin course schedule for 1995. ..... (N) 128
Tare gives 1994 Erwin Stindl Memorial Oration. ..... (N) 129
Tare retires from GMLF. ..... (N) 129
The influence of operational factors in the profile of monolesional leprosy cases in South India. Krishnamurthy, P., *et al.* ..... (A) 166
Variants of HLA-DR2/DR51 group haplotypes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis in Asian Indians. Mehra, N. K., *et al.* ..... (O) 241
Workshop on health education and training materials held. ..... (N) 464
Workshop on the Podiatric Management of Neuropathic Foot. ..... (N) 581
World Bank support to India. ..... (N) 129

Indonesia,
Protective effect of BCG against leprosy in South Sulawesi, Indonesia. Boelens, J. J., *et al.* ..... (C) 456
Seroepidemiological study of *M. leprae* infection in the inhabitants of endemic villages in South Sulawesi, Indonesia. Izumi, S., *et al.* ..... (A) 650

Interferon,
Antigen provoking gamma interferon production in response to *M. bovis* BCG and functional difference in T-cell responses to this antigen between viable and killed BCG-immunized mice. Kawamura, I., *et al.* ..... (A) 150
Cellular target of *in vitro*-induced suppressor cells derived from the spleen of *M. lepraemurium* infected mice and role of IFN-gamma in their development. Gosselin, D., *et al.* ..... (A) 484
Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. Flesch, I. E. A., *et al.* ..... (A) 600
Growth inhibition of *M. bovis* by IFN-gamma stimulated macrophages–regulation by

endogenous tumor necrosis factor alpha and by IL-10. Flesch, I. E. A., *et al.* .....(A) 148
Role of gamma interferon and tumor necrosis factor alpha suring T-cell-independent and-dependent phases of *M. avium* infection. Appelberg, R., *et al.* .....(A) 170

Interleukin(s),
Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. Flesch, I. E. A., *et al.* ...(A) 600
Effect of interleukin-1 alpha on the growth of *M. microti* within J774A.1 cells. Majumder, S. and Gupta, R. .....(A) 181
Endogenously produced IL-12 is required for the induction of protective T cells during *M. avium* infections in mice. Castro, A. G., *et al.* .....(A) 599
Enhanced interleukin-8 release and gene expression in macrophages after exposure to *M. tuberculosis* and its components. Zhong, Y.-H., *et al.* .....(A) 366
Growth inhibition of *M. bovis* by IFN-gamma stimulated macrophages–regulation by endogenous tumor necrosis factor alpha and by IL-10. Flesch, I. E. A., *et al.* .....(A) 148
IL-12 increases resistance of BALB/c mice to *M. tuberculosis* infection. Flynn, J. L., *et al.* .....(A) 601
Interleukin-12 (IL-12) augments cytolytic activity of natural killer cell toward *M. tuberculosis*-infected human monocytes. Denis, M. .....(A) 147
Interleukin-12 enhances antigen-specific proliferation of peripheral blood mononuclear cells from HIV-positive and negative donors in response to *M. avium*. Newman, G. W., *et al.* .....(A) 182
Mycobacterial 65-kilodalton heat shock protein induced tumor necrosis factor alpha and interleukin 6, reactive nitrogen intermediates, and toxoplasmastatic activity in murine peritoneal macrophages. Peetermans, W. E., *et al.* .....(A) 604
Mycobacterial cell wall components induce the production of TNF-alpha, IL-1 and IL-6 by bovine monocytes and the murine macrophage cell line RAW 264.7. Adams, J. L. and Czuprynski, C. J. .....(A) 169
Role of interleukin-6 in the infection of protective T cells during mycobacterial infections in mice. Appelberg, R., *et al.* .....(A) 145
Secretion of human interleukin 2 by recombinant *M. bovis* BCG. Kong, D. Q. and Kunimoto, D. Y. .....(A) 483
Thalidomide is agonistic to the synthesis of IL-2 and it can be agonistic or antagonistic to the synthesis of TNF-alpha. Shannon, E. J. and Sandoval, F. .....(A) 654
The role of interleukin-12 in acquired immunity to *M. tuberculosis* infection. Cooper, A. M., *et al.* .....(A) 493

International Journal of Leprosy (IJL),
1994 Damien-Dutton Award to IJL. .....(N) 300
Reviewers. ..... (-) 660
Statement of financial condition. ..... (-) 502
Statement of Ownership, Management, and Circulation. ..... (-) 661

Isoniazid,
Crystal structure and function of the isoniazid target of *M. tuberculosis*. Dessen, A., *et al.* .....(A) 494
Effect of inhA and katG on isoniazid resistance and virulence of *M. bovis*. Wilson, T. M., *et al.* .....(A) 500
Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance to *M. tuberculosis*. Heym, B., *et al.* .....(A) 351
Mutations in the catalase-peroxidase gene from isoniazid resistant *M. tuberculosis* isolates. Altamirano, M., *et al.* .....(A) 170

Japan,
14th International Congress of Tropical Medicine and Malaria. .....(N) 465
$50 million donated to global leprosy program. .....(N) 130
Neuropathological analysis of dementia in a Japanese leprosarium. Goto, M., *et al.* ...(A) 594
U.S.-Japan Cooperative Medical Science Program, Thirtieth U.S.-Japan Tuberculosis Research Conference and Tuberculosis/Leprosy Symposium, Fort Collins, Colorado, 1995. .....(A) 641

Kenya,
A case control study on human immunodeficiency virus-1 (HIV-1) infection as a risk factor for tuberculosis and leprosy in western Kenya. Orege, P. A., *et al.* .....(A) 487

Kidney(s),
Activation of the hypothalamic-pituitary-adrenal axis differentially affects the antimycobacterial activity of macrophages from BCG-resistant and-susceptible mice. Brown, D. H. and Zwilling, B. S. ..... (A) 146
Leprosy-associated renal disease: case report and review of the literature. Ahsan, N. and Palmer, B. F. ..... (A) 471

Leishmaniasis,
Differing antibody IgG isotypes in the polar forms of leprosy and cutaneous leishmaniasis characterized by antigen-specific T cell anergy. Ulrich, M., *et al.* ..... (A) 480
Follicular keratoses in leprosy and post-kala-azar dermal leishmaniasis. Dhar, S., *et al.* .... (C) 111
Thiols of intracellular pathogens–identification of ovothiol A in *Leishmania donovani* and structural analysis of a novel thiol from *M. bovis*. Spies, H. S. C. and Steenkamp, D. J. ..... (A) 186

Lepromatous leprosy,
Androgenic status in patients with lepromatous leprosy. Saporta, L. and Yuksel, A. ... (A) 598
Chemotherapy of lepromatous leprosy: recent developments and prospects for the future. Gelber, R. H. ..... (A) 313
[Comparative evaluation of AAFB from the nose and skin of LL patients.] Prabhakar, M. C. ..... (A) 336
Eustachian tube functions in lepromatous leprosy; a tympanometric study. Soni, N. K. .... (A) 143
Evaluation of chemiluminescence, procoagulant activity and antigen presentation by monocytes from lepromatous leprosy patients with or without reactional episodes. Santos, D. O., *et al.* ..... (A) 154
[Histopathology of the skin in LL patients after completion of treatment.] Zhou, X.-T., *et al.* ..... (A) 333
[Kaposi's sarcoma in an HIV-negative patient with lepromatous leprosy.[Drateln, C. R. ..... (A) 594
Mast cells in lepromatous leprosy. Jayalakshmi, P. and Lian, T. K. ..... (C) 291
Minocycline in lepromatous leprosy. Fajardo, T. T., Jr., *et al.* ..... (O) 8
Neuropathy as the only sign of borderline lepromatous leprosy for 13 years. Mizuno, K., *et al.* ..... (A) 596
Ofloxacin-containing combined drug reigmens in the treatment of lepromatous leprosy. Rao, P. S., *et al.* ..... (A) 138
Palatal palsy in a case of lepromatous leprosy. Pavithran, K. ..... (A) 142
Persistence of lepromatous granuloma in clinically cured cases of leprosy. Desikan, P. and Desikan, K. V. ..... (O) 417
Successful treatment of a lepromatous patients with clarithromycin. Gelber, R. H. .... (C) 113

Lepromin,
Ultraviolet radiation decreases the granulomatous response to lepromin in humans. Cestari, T. F., *et al.* ..... (A) 599

Lesion(s),
A clinico-pathological study of macular lesions in leprosy. Kar, P. K., *et al.* ..... (A) 320
Biopsy of Skin Lesions in Leprosy; Stains, Pathogenesis and Classification by Kyoshi Harada. Scollard, D. M. ..... (B) 578
[Dimorphous leprosy with a lesion of the radial nerve; a case report.] Lora Robles, M. and Gonzalez, K. ..... (A) 141
[Early lesions in disseminated reactional cases.] Opromolla, D. V. A. and Brasil Filho, A. A. ..... (A) 597
[Evolution of lesions induced by mycobacteria, BCG and H37Rv in hampsters.] Roxo, E., *et al.* ..... (A) 605
Functional heterogeneity among CD4+ T-cell clones from blood and skin lesions of leprosy patients, identification of T cell clones distinct from Th0, Th1 and Th2. Howe, R. C., *et al.* ..... (A) 602
M. leprae DNA content, cellular and cytokine patterns in skin lesions of leprosy patients undergoing multidrug therapy (MDT). Flad, H. D., *et al.* ..... (A) 324
Response of leprosy patients with single lesions to MDT. Katoch, K., *et al.* ..... (A) 595
The influence of operational factors in the profile of monolesional leprosy cases in South India. Krishnamurthy, P., *et al.* ..... (A) 166

Lipid(s),

Induction of immunity against experimental tuberculosis with mycobacterial mannophosphoinositides encapsulated in liposomes containing lipid A. Singh, A. P. and Khuller, G. K. ..... (A) 361

Interactions of mycobacterial clycopeptidolipids with membranes: influence of carbohydrate on inducted alterations. Lopez Marin, L. M., *et al.* ..... (A) 160

Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. Beckman, E. M., *et al.* ..... (A) 322

Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria. Wolucka, B. A., *et al.* ..... (A) 339

Lipoarabinomannan (LAM),

CD1-restricted T-cell recognition of *M. leprae* lipoarabinomannan. Sieling, P. A., *et al.* ..... (A) 656

Inositol phosphate capping of the nonreducing termini of lipoarabinomannan from rapidly growing strains of *Mycobacterium.* Khoo, K. H., *et al.* ..... (A) 611

Integration of mycobacterial lipoarabinomannans into glycosylphosphatidylinositol-rich domains of lymphomonocytic cell plasma membranes. Ilangumaran, S., *et al.* ..... (A) 610

Lipoarabinomannan inhibits nonopsonic binding of *M. tuberculosis* to murine macrophages. Stokes, R. W. and Speert, D. P. ..... (A) 636

Structural analysis of the mannan region of lipoarabinomannan from *M. bovis* BCG. Venisse, A., *et al.* ..... (A) 614

Structural definition of acylated phosphatidylinositol mannosides from *M. tuberculosis*: definition of a common anchor for lipomannan and lipoarabinomannan. Khoo, K. H., *et al.* ..... (A) 482

Liposome,

Glycoside-bearing liposomal delivery systems against macrophage-associated disorders involving *M. leprae* and *M. tuberculosis.* Medda, S., *et al.* ..... (A) 590

Induction of immunity against experimental tuberculosis with mycobacterial mannophosphoinositides encapsulated in liposomes containing lipid A. Singh, A. P. and Khuller, G. K. ..... (A) 361

Liver,

Dapsone acetylation by human liver arylamine N acetyltransferases and interaction of antiopportunistic infection drugs. Palamanda, J. R., *et al.* ..... (A) 469

Evidence that the biotransformation of dapsone and monoacetyldapsone to their respective hydroxylamine metabolites in rat liver microsomes is mediated by cytochrome P45 2C6/2C11 and 3A1. Vage, C. and Svensson, C. K. ..... (A) 139

Exacerbation of acetaminophen hepatotoxicity by thalidomide and protection by nicotinic acid amide. Kroger, H., *et al.* ..... (A) 632

Lymphocyte(s),

Circulating immune complexes in patients with advanced tuberculosis and their association with autoantibodies and reduced CD4+ lymphocytes. Dlugovitzky, D., *et al.* ..... (A) 628

Contribution of alpha/beta and gamma/delta T lymphocytes to immunity against *M. bovis* bacillus Calmette Guerin: studies with T cell receptor-deficient mutant mice. Ladel, C. H., *et al.* ..... (A) 603

Crossrecognition of CD7 T cell receptor alpha beta cytotoxic T lymphocytes of peptides in the self and the mycobacterial hsp60 with shared intermediate sequence homology. Zugel, U., *et al.* ..... (A) 606

Immune response of armadillos (*Dasypus novemcinctus*). I. Use of lectins to identify lymphocyte subpopulations and to evaluate cell proliferation. Santos-Argumedo, L., *et al.* ..... (O) 546

Increased gamma-delta T-lymphocyte response to *M. bovis* BCG in major histocompatibility complex class I-deficient mice. Muller, D., *et al.* ..... (A) 603

Induction of the autoantigen proliferating cell nuclear antigen in T lymphocytes by a mycobacterial antigen. Haftel, H. M., *et al.* ..... (A) 149

Phosphate is essential for stimulation of V gamma 9V delta 2 T lymphocytes by mycobacterial low molecular weight ligand. Schoel, B., *et al.* ..... (A) 154

Suppression of cytokine production by supernatants from CD8+ lymphocytes activated by mycobacterial fractions: the role of interleukins 4 and 6. Wadee, A. A., *et al.* ..... (A) 156

Macrophage(s),
Activation of the hypothalamic-pituitary-adrenal axis differentially affects the antimycobacterial activity of macrophages from BCG-resistant and-susceptible mice. Brown, D. H. and Zwilling, B. S. ..... (A) 146
Activities of benzoxazinorifamycin KRM 1648 and ethambutol against *M. avium* complex *in vitro* and in macrophages. Inderlied, C. B., *et al.* ..... (A) 178
Actvities of roxithromycin against *M. avium* infections in human macrophages and C57BL/6 mice. Struillou, L., *et al.* ..... (A) 500
Bacteriostatic activity of BCG/PPD-activated macrophages against *M. fortuitum* does not involve reactive nitrogen or oxygen intermediates. Nibbering, P. H., *et al.* ..... (A) 182
Comparison of activities of rifapentine and rifampin against *M. tuberculosis* residing in human macrophages. Mor, N., *et al.* ..... (A) 633
Cultivation of *M. leprae* in macrophages. Fukutomi, Y., *et al.* ..... (A) 648
Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. Flesch, I. E. A., *et al.* ..... (A) 600
Enhanced interleukin-8 release and gene expession in macrophages after exposure to *M. tuberculosis* and its components. Zhong, Y.-H., *et al.* ..... (A) 366
Glycoside-bearing liposomal delivery systems against macrophage-associated disorders involving *M. leprae* and *M. tuberculosis.* Medda, S., *et al.* ..... (A) 590
Growth inhibition of *M. bovis* by IFN-gamma stimulated macrophages–regulation by endogenous tumor necrosis factor alpha and by IL-10. Flesch, I. E. A., *et al.* ..... (A) 148
Hypertriglyceridemic serum, a very low density lipoprotein, and iron enhance *M. avium* replication in human macrophages. Douvas, G. S., *et al.* ..... (A) 349
Identification of macrophage and stress-induced proteins of *M. tuberculosis.* Lee, B.-Y. and Horwitz, M. A. ..... (A) 612
Intracellular activities of roxithromycin used alone and in association with other drugs against *M. avium* complex in human macrophages. Rastogi, N., *et al.* ..... (A) 499
Intracellular trafficking in *M. tuberculosis* and *M. avium* infected macrophages. Xu, S. M., *et al.* ..... (A) 156
Lipoarabinomannan inhibits nonopsonic binding of *M. tuberculosis* to murine macrophages. Stokes, R. W. and Speert, D. P. ..... (A) 636
Lysis of human macrophages by cytolytic CD4+ T cells fails to affect survival of intracellular *M. bovis* bacille Calmette Guerin (BCG). Fazal, N., *et al.* ..... (A) 495
Macrophage-T cell interaction in experimental mycobacterial infection; selective regulation of co-stimulatory molecules on *Mycobacterium*-infected macrophages and its implication in the suppression of cell-mediated immune response. Saha, B., *et al.* ..... (A) 359
Mycobacterial 65-kilodalton heat shock protein induced tumor necrosis factor alpha and interleukin 6, reactive nitrogen intermediates, and toxoplasmastatic activity in murine peritoneal macrophages. Peetermans, W. E., *et al.* ..... (A) 604
Mycobacterial cell wall components induce the production of TNF-alpha, IL-1 and IL-6 by bovine monocytes and the murine macrophage cell line RAW 264.7. Adams, J. L. and Czuprynski, C. J. ..... (A) 169
Mycotin: a lectin involved in the adherence of mycobacteria to macrophages. Goswami, S., *et al.* ..... (A) 334
Nitric oxide production and mycobacterial growth inhibition by murine alveolar macrophages: the sequence of rIFN-gamma stimulation and *M. bovis* BCG infection determines macrophage activation. Hanano, R. and Kaufmann, S. H. E. ..... (A) 495
Pentoxifylline aggravates impairment in tumor necrosis factor alpha secretion and increases mycobacterial load in macrophages from AIDS patients with disseminated *M. avium intracellulare* complex infection. Sathe, S. S., *et al.* ..... (A) 184
Plasminogen activator inhibitor type 2 prevents programmed cell death of human macrophages infected with *M. avium*, serovar 4. Gan, H. X., *et al.* ..... (A) 629
Rapid induction of mRNA for nitric oxide synthase II in rat alveolar macrophages by intratracheal administration of *M. tuberculosis* and *M. avium.* Greenburg, S. S., *et al.* ..... (A) 495
Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis. Dannenberg, A. M. ..... (A) 348
Selective *M. avium*-induced production of nitric oxide by human monocyte-derived macrophages. Dumarey, C. H., *et al.* ..... (A) 148

Malawi,
Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi. Ponnighaus, J. M. and Boerrigter, G. ..... (O) 1

Malaysia,
A longitudinal study of alveolar bone loss around maxillary central incisors in patients with leprosy in Malaysia. Subramaniam, K., *et al.* ..... (A) 143
Erythema nodosum leprosum in Malaysians. Jayalakshmi, P., *et al.* ..... (C) 109

Mali,
[Factors determining the irregularity of multidrug therapy patients in Bamako district.] Sylla, P. M., *et al.* ..... (A) 317
Workshop on Prevention of Disabilities and Physical Rehabilitation of Leprosy Patients. . (N) 465

Metabolism,
Dapsone-induced hematologic toxicity; comparison of the methemoglobin-forming ability of hydroxylamine metabolites of dapsone in rat and human blood. Vage, C., *et al.* ..... (A) 318
Evidence that the biotransformation of dapsone and monoacetyldapsone to their respective hydroxylamine metabolites in rat liver microsomes is mediated by cytochrome P45 2C6/2C11 and 3A1. Vage, C. and Svensson, C. K. ..... (A) 139
Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelope. Deng, L. Y., *et al.* ..... (A) 493
Regulation by arachidonic acid metabolites of the immune response toward pathogenic mycobacteria. Adams, L. B., *et al.* ..... (A) 644

Mice, murine,
Acquired resistance in *M. avium* complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. Doucet-Populaire, F., *et al.* ..... (A) 587
Activation of protein kinase C by mycobacterial cord factor, trehalose 6-monomycolate, resulting in tumor necrosis factor alpha release in mouse lung tissues. Sueoka, E., *et al.* ..... (A) 636
Activation of the hypothalamic-pituitary-adrenal axis differentially affects the antimycobacterial activity of macrophages from BCG-resistant and-susceptible mice. Brown, D. H. and Zwilling, B. S. ..... (A) 146
Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against *M. simiae* in murine model of disseminated infection. Valero, G., *et al.* ..... (A) 187
Activity of KRM 1648 alone and in combination with ethambutol or clarithromycin against *M. avium* in beige mouse model of disseminated infection. Bermudez, L. E., *et al.* ..... (A) 170
Activity of KRM-1648, a new benzoxazinorifamycin, against *M. tuberculosis* in a murine model. Klemens, S. P., *et al.* ..... (A) 180
Activity of combinations of dapsone, rifampin, minocycline, clarithromycin, and sparfloxacin against *M. leprae*-infected mice. Gelber, R. H., *et al.* ..... (O) 259
Actvities of roxithromycin against *M. avium* infections in human macrophages and C57BL/6 mice. Struillou, L., *et al.* ..... (A) 500
Antigen provoking gamma interferon production in response to *M. bovis* BCG and functional difference in T-cell responses to this antigen between viable and killed BCG-immunized mice. Kawamura, I., *et al.* ..... (A) 150
Beige mice infected with *M. leprae*. Gelber, R. H., *et al.* ..... (C) 295
Cellular target of *in vitro*-induced suppressor cells derived from the spleen of *M. lepraemurium* infected mice and role of IFN-gamma in their development. Gosselin, D., *et al.* ..... (A) 484
Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated *M. avium* infection in beige mice. Bermudez, L. E., *et al.* ..... (A) 346
Contribution of alpha/beta and gamma/delta T lymphocytes to immunity against *M. bovis* bacillus Calmette Guerin: studies with T cell receptor-deficient mutant mice. Ladel, C. H., *et al.* ..... (A) 603
Differences in *M. leprae*-induced nerve damage in Swiss white and C57BL/6 mice. Birdi, T. J., *et al.* ..... (C) 573
Drug-resistant strains of *M. tuberculosis* exhibit a range of virulence for mice. Ordway, D. J., *et al.* ..... (A) 355
Effect of thalidomide on the cellular immune response in experimental tuberculosis in mice. Moreira, A. L., *et al.* ..... (A) 651
Effective vaccination of mice against *M. leprae* with density gradient subfractions of soluble *M. leprae* proteins: clues to active protein epitopes. Gelber, R. H., *et al.* ....(A) 164

Effectiveness of various antimicrobial agents against *M. avium* complex in the beige mouse model. Ji, B., *et al.* ..... (A) 178
Effects of nitric oxide synthase inhibitors on murine infection with *M. tuberculosis*. Chan, J., *et al.* ..... (A) 491
Endogenously produced IL-12 is required for the induction of protective T cells during *M. avium* infections in mice. Castro, A. G., *et al.* ..... (A) 599
Exacerbation of acute and chronic murine tuberculosis by administration of tumor necrosis factor receptor-expressing adenovirus. Adams, L. B., *et al.* ..... (A) 488
Growth of *M. tuberculosis* in BCG-resistant and-susceptible mice: establishment of latency and reactivation. Brown, D. H., *et al.* ..... (A) 625
Histopathology of C57BL/6 mice inoculated orally with *M. paratuberculosis*. Veasey, R. S., *et al.* ..... (A) 638
IL-12 increases resistance of BALB/c mice to *M. tuberculosis* infection. Flynn, J. L., *et al.* ..... (A) 601
Immune response to *M. bovis* bacille Calmette Guerin infection in major histocompatibility complex class I-and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Ladel, C. H., *et al.* ..... (A) 602
Immune responses of heat-shock protein 65 on *M. leprae* inoculated mice. Nomaguchi, H., *et al.* ..... (A) 652
Immunostimulatory effect of thalidomide in normal C57BL/6 mice is compatible with stimulation of a highly connected central immune system. Arala Chaves, M., *et al.* .(A) 345
Increased gamma-delta T-lymphocyte response to *M. bovis* BCG in major histocompatibility complex class I-deficient mice. Muller, D., *et al.* ..... (A) 603
Infection of *M. bovis* bacillus Calmette-Guerin in antibody mediated gamma delta T-cell-depleted mice. Nabeshima, S., *et al.* ..... (A) 355
Infection of SCID mice with *M. leprae* and control with antigen activated "immune" human peripheral blood mononuclear cells. Converse, P. J., *et al.* ..... (A) 476
Influence of mouse strain and vaccine viability on T-cell responses induced by *M. bovis* bacillus Calmette-Guerin. Daugelat, S., *et al.* ..... (A) 600
Intermittent azithromycin for treatment of *M. avium* infection in beige mice. Klemens, S. P. and Cynamon, M. H. ..... (A) 179
Lipoarabinomannan inhibits nonopsonic binding of *M. tuberculosis* to murine macrophages. Stokes, R. W. and Speert, D. P. ..... (A) 636
Mouse cell lines expressing *M. leprae* heat-shock protein 65 kDa gene: lymphoproliferative responses to the cell lines. Nakanaga, K., *et al.* ..... (A) 651
Mycobacterial 65-kilodalton heat shock protein induced tumor necrosis factor alpha and interleukin 6, reactive nitrogen intermediates, and toxoplasmastatic activity in murine peritoneal macrophages. Peetermans, W. E., *et al.* ..... (A) 604
Mycobacterial cell wall components induce the production of TNF-alpha, IL-1 and IL-6 by bovine monocytes and the murine macrophage cell line RAW 264.7. Adams, J. L. and Czuprynski, C. J. ..... (A) 169
Nitric oxide production and mycobacterial growth inhibition by murine alveolar macrophages: the sequence of rIFN-gamma stimulation and *M. bovis* BCG infection determines macrophage activation. Hanano, R. and Kaufmann, S. H. E. ..... (A) 495
Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Chapuis, L., *et al.* ..... (A) 347
Reduction of clastogenic effect of clofazimine, an antileprosy drug, by vitamin A and vitamin C in bone marrow cells of mice. Sahu, K. and Das, R. K. ..... (A) 317
Role of T cell subsets in immunity against intracellular bacteria: experimental infections of knock-out mice with *Listeria monocytogenes* and *M. bovis*. Kaufmann, S. H. E. and Ladel, C. H. ..... (A) 326
Role of interleukin-6 in the infection of protective T cells during mycobacterial infections in mice. Appelberg, R., *et al.* ..... (A) 145
Selection of clarithromycin-resistant *M. avium* complex during combined therapy using the beige mouse model. Lounis, N., *et al.* ..... (A) 354
Susceptibility of beige mice to *M. avium*; role of neutrophils. Appelberg, R., *et al.* ....(A) 624
The effects of thalidomide treatment on autoimmune-prone NZB and MRL mice are consistent with stimulation of the central immune system. 2. Vilanova, M., *et al.* ...(A) 364

Mice, nude,
Inhibition of the multiplication of *M. leprae* in nude mice by intermittent administration

of a new rifamycin derivative, 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin (KRM-1648) combined with sparfloxacin. Gidoh, M., *et al.* ....(A) 484
[On antileprosy activity of China-made ofloxacin in nude mice.] Shen, J.-P., *et al.* ....(A) 340
Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Chapuis, L., *et al.* ....(A) 347
Study on the roles of CD4+ and CD8+ T cells in the expression of host resistance to *M. leprae* infection induced in athymic nude mice. Maw, W. W., *et al.* ....(O) 539

Microbiology,
Repeated isolation of dermatophilus-like organism from leprosy material. Bhatia, V. A. ...(A) 158

Minocycline,
Activity of combinations of dapsone, rifampin, minocycline, clarithromycin, and sparfloxacin against *M. leprae*-infected mice. Gelber, R. H., *et al.* ....(O) 259
Minocycline in lepromatous leprosy. Fajardo, T. T., Jr., *et al.* ....(O) 8

Molecular biology (see also **DNA** and **Genetics**),
Comparison of thermostable macromolecular antigens from leprosy-associated bacteria. Baelden, M. C., *et al.* ....(A) 157
Implications of multidrug resistance for the future of short course chemotherapy of tuberculosis: a molecular study. Heym, B., *et al.* ....(A) 176
Molecular and immunological characterization of the highly conserved antigen 84 from *M. tuberculosis* and *M. leprae*. Hermans, P. W. M., *et al.* ....(A) 482
Molecular basis of rifampin resistance in *M. leprae*. Honore, N. and Cole, S. T. ....(A) 334
Molecular biology, virulence, and pathogenicity of mycobacteria. Shinnick, T. M., *et al.* ....(A) 337
Molecular cloning of gyrA and gyrB genes of *M. tuberculosis*: analysis of nucleotide sequence. Madhusudan, K., *et al.* ....(A) 335
Molecular composition of the outermost capsular material of the tubercle bacillus. Ortalo-Magne, A., *et al.* ....(A) 633
Molecular genetics of drug resistence in *M. tuberculosis*. Zhang, Y. and Young, D. ....(A) 191
Molecular mechanisms of multiple drug resistance in clinical isolates of *M. tuberculosis*. Morris, S., *et al.* ....(A) 497
Molecular mechanisms of natural resistance to mycobacterial infections. Radzioch, D., *et al.* ....(A) 613
Molecular mimicry: histone H3 and mycobacterial protein epitopes. Eriksen, N., *et al.* ....(A) 494
Putative functional domain within ORF2 on the mycobacterium insertion sequences. Doran, T. J., *et al.* ....(A) 349
Rendering of mycobacteria safe for molecular diagnostic studies and development of a lysis method for strand displacement amplification and PCR. Zwadyk, P., Jr., *et al.* ....(A) 164
Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: a molecular epidemiologic assessment. Shafer, R. W., *et al.* ....(A) 360
The molecular biology of *M. leprae*. Colston, M. J. ....(A) 158

Monkey(s),
Experimental leprosy in monkeys. I. Sooty mangabey monkeys: transmission, susceptibility, clinical and pathological findings. Gormus, B. J., *et al.* ....(A) 616

Monocyte(s),
Antigen 85C on *M. bovis*, BCG and *M. tuberculosis* promotes monocyte-CR3-mediated uptake of microbeads coated with mycobacterial products. Hetland, G. and Wiker, H. G. ....(A) 150
Enhancement of intracellular growth of *M. tuberculosis* in human monocytes by transforming growth factor-beta. Hirsch, C. S., *et al.* ....(A) 351
Evaluation of chemiluminescence, procoagulant activity and antigen presentation by monocytes from lepromatous leprosy patients with or without reactional episodes. Santos, D. O., *et al.* ....(A) 154
Interleukin-12 (IL-12) augments cytolytic activity of natural killer cell toward *M. tuberculosis*-infected human monocytes. Denis, M. ....(A) 147
Mycobacterial cell wall components induce the production of TNF-alpha, IL-1 and IL-6 by bovine monocytes and the murine macrophage cell line RAW 264.7. Adams, J. L. and Czuprynski, C. J. ....(A) 169

Selective *M. avium*-induced production of nitric oxide by human monocyte-derived macrophages. Dumarey, C. H., *et al.* ..... (A) 148

Morbidity,

Global and regional cause-of-death patterns in 1990. Murray, C. J. L. and Lopez, A. D. ..... (A) 133

Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. Raviglione, M. C., *et al.* ..... (A) 357

Psychiatric morbidity in displaced leprosy patients. Verma, K. K. and Gautam, S. ..... (A) 344

Morphology,

Dapsone-induced hemolytic anemia: effect of dapsone hydroxylamine on sulhydryl status, membrane skeletal proteins and morphology of human and rat erythrocytes. McMillan, D. C., *et al.* ..... (A) 590

Morphology of cystic structures seen in leprosy biopsy suspensions kept at cooler temperatures. Bhatia, V. N. ..... (A) 334

Mouth,

[On stomatologic disorder and its treatment in persons with leprosy.] Qiu, W.-P. ..... (A) 320

Palatal palsy in a case of lepromatous leprosy. Pavithran, K. ..... (A) 142

Multidrug therapy (MDT),

Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi. Ponnighaus, J. M. and Boerrigter, G. ..... (O) 1

Changes in leprosy clinical pattern after multidrug therapy implementation. Martelli, C. M. T., *et al.* ..... (C) 95

Deformity incidence in leprosy patients treated with multidrug therapy. Rao, P. S., *et al.* ..... (A) 315

[Effect of MDT on endemicity of leprosy.] Guo, Q., *et al.* ..... (A) 313

Effect of blister calendar packs in enhancing compliance with MDT; the Kaduna State (Nigeria) experience. Awofeso, N., *et al.* ..... (E) 453

Evaluation of a multidrug therapy programme of leprosy control. Jakeman, P. and Smith, W. C. S. ..... (A) 313

[Evolution of borderline tuberculoid hanseniasis during multidrug therapy.] de Carvalho, M. L. R., *et al.* ..... (A) 593

[ctors determining the irregularity of multidrug therapy patients in Bamako district.] Sylla, P. M., *et al.* ..... (A) 317

Features of relapse in paucibacillary leprosy after multidrug therapy. Naafs, B. ..... (A) 590

Field evaluation of WHO-MDT of fixed duration at ALERT, Ethiopia: the AMFES project–I. MDT course completion, case holding and another score for disability grading. de Rijk, A. J., *et al.* ..... (A) 312

Field evaluation of WHO-MDT of fixed duration at ALERT, Ethiopia: the AMFES project–II. Reaction and neuritis during and after MDT in PB and MB leprosy patients. de Rijk, A. J., *et al.* ..... (A) 312

[Frequency of chronic plantar ulcers in leprosy patients according to treatment by dapsone monotherapy or multidrug therapy.] Mane, I., *et al.* ..... (A) 589

IAL 1993 MDT workshop. ..... (N) 126

Incidence of late lepra reaction among multibacillary leprosy patients after MDT. Vijayakumaran, P., *et al.* ..... (O) 18

[Leprosy incidence during monotherapy and multidrug therapy in Camaguey, Cuba, 1984-1993.] Carrazana Hernandez, G. B. and Ferra Torres, T. M. ..... (A) 486

M. leprae DNA content, cellular and cytokine pattersn in skin lesions of leprosy patients undergoing multidrug therapy (MDT). Flad, H. D., *et al.* ..... (A) 324

[MDT for leprosy in Member States of OCCGE: a ten-year implementation (1983-1993).] Tiendrebeogo, A., *et al.* ..... (A) 620

Multidrug therapy and eye disease in leprosy; a cross sectional study in the People's Republic of China. Courtright, P., *et al.* ..... (A) 140

Relapse following various types of multidrug therapy in multibacillary leprosy. Waters, M. F. R. ..... (A) 470

[Relapse of leprosy after MDT and after DDS plus RMP.] Zhou, X. ..... (A) 593

Relapse with multibacillary leprosy caused by rifampicin sensitive organisms following paucibacillary multidrug therapy. Soares, D., *et al.* ..... (A) 591

Relapses during long-term follow up with drug-susceptible *M. leprae* among multibacillary leprosy patients treated with multidrug therapy regimens; case reports. Thomas, A., *et al.* ..... (O) 391
Response of leprosy patients with single lesions to MDT. Katoch, K., *et al.* ..... (A) 595
[The factors of impact on examination of the persons under suveillance after MDT.] Qiao, J., *et al.* ..... (A) 591
[Traits of leprosy cases detected after implementation of MDT scheme.] Hong, B.-Y., *et al.* ..... (A) 588
[Type 1 reactions in borderline tuberculoid hanseniasis during multidrug therapy: time of appearance of nerve involvement.] de Carvalho, M. L. R., *et al.* ..... (A) 594

Muscle(s),
[Effect of a modified temporal muscle transposition on leprous lagophthalmos.] Tan, W.-P. ..... (A) 321
[The effect of a modified temporal muscle bundle transposition on lagophthalmos in leprosy.] Long, P., *et al.* ..... (A) 622

Mycobacteria (see also individual species),
A search for mycobacterial DNA in sarcoidosis using the polymerase chain reaction. Ghossein, R. A., *et al.* ..... (A) 174
Activation of the hypothalamic-pituitary-adrenal axis differentially affects the antimycobacterial activity of macrophages from BCG-resistant and-susceptible mice. Brown, D. H. and Zwilling, B. S. ..... (A) 146
Activity of mycobacterial promoters during intracellular and extracellular growth. Dellagostin, O. A., *et al.* ..... (A) 608
Amplification reactions in mycobacteriology. Klatser, P. R. ..... (A) 612
An RLFP map for 2q33-q37 from multicase mycobacterial and leishmanial disease families: no evidence for an Lsh/Ity/Bcg gene homologue influencing susceptibility to leprosy. Shaw, M. A., *et al.* ..... (A) 487
An improved method for the species-specific assessment of mycobacteria in routinely formalin-fixed and paraffin embedded tissues. Richter, E., *et al.* ..... (A) 336
Animal and cell-culture models for the study of mycobacterial infections and treatment. Orme, I. M., *et al.* ..... (A) 356
Antibody reactivity to mycobacterial 65 kDa heat shock protein: relevance to autoimmunity. Karopoulos, C., *et al.* ..... (A) 479
Antigen 85C on *M. bovis*, BCG and *M. tuberculosis* promotes monocyte-CR3-mediated uptake of microbeads coated with mycobacterial products. Hetland, G. and Wiker, H. G. ..... (A) 150
Assessment of mycobacterial viability by RNA amplification. van der Vliet, G. M. E., *et al.* ..... (A) 162
Cellular immune response to common mycobacterial antigens in subjects seropositive for *Trypanosoma cruzi*. Bottasso, O. A., *et al.* ..... (A) 322
Characterization of rifampin resistance in pathogenic mycobacteria. Williams, D. L., *et al.* ..... (A) 163
Crossrecognition of CD7 T cell receptor alpha beta cytotoxic T lymphocytes of peptides in the self and the mycobacterial hsp60 with shared intermediate sequence homology. Zugel, U., *et al.* ..... (A) 606
Cytokine patterns at the site of mycobacterial infection. Sieling, P. A. and Modlin, R. L. ..... (A) 331
Cytokine responses during mycobacterial and shistosomal antigen-induced pulmonary granuloma formation–production of Th1 and Th2 cytokines and relative contribution of tumor necrosis factor. Chensue, S. W., *et al.* ..... (A) 323
Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Fine, P. E. M., *et al.* ..... (A) 324
Demonstration of mycobacterial antigens in skin biopsies from suspected leprosy cases in the absence of bacilli. Barbosa, A. D., *et al.* ..... (A) 146
Detection of a genetic locus encoding resistance to rifampin in mycobacterial cultures in clinical specimens. Hunt, J. M., *et al.* ..... (A) 177
Development of a 23S rRNA-based PCR assay for the detection of mycobacteria. Verma, A., *et al.* ..... (A) 162
Differential T cell responses to mycobacteria-secreted proteins distinguish vaccination

with bacille Calmette Guerin from infection with *M. tuberculosis*. Roche, P. W., *et al.* ..... (A) 330
Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. Flesch, I. E. A., *et al.* ... (A) 600
Epitope specificity and isoforms of the mycobacterial 19 kilodalton antigen. Harris, D. P., *et al.* ..... (A) 174
[Evolution of lesions induced by mycobacteria, BCG and H37Rv in hampsters.] Roxo, E., *et al.* ..... (A) 605
Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene? Levin, M., *et al.* ..... (A) 353
Fine needle aspiration cytology of mycobacterial spindle cell pseudotumor. Corkill, M., *et al.* ..... (A) 493
Gene expression in mycobacteria: transcriptional fusions based on xylE and analysis of the promoter region of the response regulator mtrA from *M. tuberculosis*. Curcic, R., *et al.* ..... (A) 172
Genetic determination of the meso-diaminopimelate biosynthetic pathway of mycobacteria. Cirillo, J. D., *et al.* ..... (A) 158
Genetic regulation of leishmanial and mycobacterial infections; the Lsh/Ity/Bcg gene story continues. Blackwell, J. M., *et al.* ..... (A) 489
Growth-deficient mycobacteria in patients with AIDS: diagnosis by analysis of DNA amplified from blood or tissue. Emler, S., *et al.* ..... (A) 494
Human CD4-, CD8-, alpha beta+ T-cell receptor T cells recognize different mycobacteria strains in the context of CD1b. Thomssen, H., *et al.* ..... (A) 605
Identification of genes involved in the sequestration of iron in mycobacteria: the ferric exochelin biosynthetic and uptake pathways. Fiss, E. H., *et al.* ..... (A) 334
IgG subclass antibodies to mycobacterial sonicate and recombinant antigens in leprosy. Sheela, R., *et al.* ..... (A) 480
Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes; antibody responses to mycobacterial and leishmanial antigens. Sharples, C. E., *et al.* ..... (A) 360
Immunohistological localization of mycobacterial antigens with the peripheral nerves of treated leprosy patients and their significance to nerve damage in leprosy. Shetty, V. P., *et al.* ..... (A) 155
Immunoprecipitation of mycobacterial antigens with sera from patients with leprosy. Kode, J. A., *et al.* ..... (A) 327
In vitro antimycobacterial activities of pyrazinamide analogs. Yamamoto, S., *et al.* ... (A) 640
In-vitro activity of quinolones and macrolides against mycobacteria. Yew, W. W., *et al.* ... (A) 190
Individuals from different populations identify multiple and diverse T-cell determinants on mycobacterial HSP70. Adams, E., *et al.* ..... (A) 145
Induction of immunity against experimental tuberculosis with mycobacterial mannophosphoinositides encapsulated in liposomes containing lipid A. Singh, A. P. and Khuller, G. K. ..... (A) 361
Induction of the autoantigen proliferating cell nuclear antigen in T lymphocytes by a mycobacterial antigen. Haftel, H. M., *et al.* ..... (A) 149
Integration of mycobacterial lipoarabinomannans into glycosylphosphatidylinositol-rich domains of lymphomonocytic cell plasma membranes. Ilangumaran, S., *et al.* ..... (A) 610
Integration of traditional and modern methods in the control of leprosy and in the study of mycobacterial taxonomy (13th IWGMT Conference). Portaels, F. ..... (A) 483
Interactions of mycobacterial clycopeptidolipids with membranes: influence of carbohydrate on inducted alterations. Lopez Marin, L. M., *et al.* ..... (A) 160
Isolation of mycobacteria from acidic forest soil samples; comparison of culture methods. Iivanainen, E. ..... (A) 610
Isolation of nontuberculous, non-avium mycobacteria from patients infected with human immunodeficiency virus. Raszaka, W. V., *et al.* ..... (A) 357
Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Berning, S. E., *et al.* ..... (A) 625
Macrophage-T cell interaction in experimental mycobacterial infection; selective regulation of co-stimulatory molecules on *Mycobacterium*-infected macrophages and its implication in the suppression of cell-mediated immune response. Saha, B., *et al.* ... (A) 359
Mapping of multiple HLA class II-restricted T-cell epitopes of the mycobacterial 70-

kilodalton heat shock protein. Oftung, F., *et al.* ..... (A) 329
Marked conservation of complementarity-determining region 3 of the beta-chain of TCRs recognizing a mycobacterial heat shock protein 60-derived peptide with strong sequence similarity to human heat shock protein 60. Goodall, J. C., *et al.* ..... (A) 601
Mercury resistance as a selective marker for recombinant mycobacteria. Baulard, A., *et al.* ..... (A) 607
Molecular biology, virulence, and pathogenicity of mycobacteria. Shinnick, T. M., *et al.* ..... (A) 337
Molecular mechanisms of natural resistance to mycobacterial infections. Radzioch, D., *et al.* ..... (A) 613
Molecular mimicry: histone H3 and mycobacterial protein epitopes. Eriksen, N., *et al.* ..... (A) 494
Multiplex strand displacement amplifications (SDA) and detection of DNA sequences from *M. tuberculosis* and other mycobacteria. Walker, G. T., *et al.* ..... (A) 163
Mycobacterial 65-kilodalton heat shock protein induced tumor necrosis factor alpha and interleukin 6, reactive nitrogen intermediates, and toxoplasmastatic activity in murine peritoneal macrophages. Peetermans, W. E., *et al.* ..... (A) 604
Mycobacterial cell wall components induce the production of TNF-alpha, IL-1 and IL-6 by bovine monocytes and the murine macrophage cell line RAW 264.7. Adams, J. L. and Czuprynski, C. J. ..... (A) 169
Mycobacterial heat-shock protein 65 induces proinflammatory cytokines but does not activate human mononuclear phagocytes. Peetermans, W. E., *et al.* ..... (A) 153
Mycobacterial taxonomy. Shinnick, T. M. and Good, R. C. ..... (A) 337
Mycotin: a lectin involved in the adherence of mycobacteria to macrophages. Goswami, S., *et al.* ..... (A) 334
Nitric oxide production and mycobacterial growth inhibition by murine alveolar macrophages: the sequence of rIFN-gamma stimulation and *M. bovis* BCG infection determines macrophage activation. Hanano, R. and Kaufmann, S. H. E. ..... (A) 495
Non-major histocompatibility complex-restricted cytotoxic activity of blood mononuclear cells stimulated with secreted mycobacterial proteins and other mycobacterial antigens. Ravn, P. and Pedersen, B. K. ..... (A) 357
Nucleotide sequences of the spacer-1, spacer-2 and trailer regions of the rrn operons and the secondary sructures of precursor 23S rRNAs and precursor 5S rRNAs of slow-growing mycobacteria. Ji, Y., *et al.* ..... (A) 159
Oral desensitization to rifampin and ethambutol in mycobacterial disease. Matz, J., *et al.* ..... (A) 137
PCR amplification and restriction endonuclease analysis of a 65-kDa heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria. Steingrube, V. A., *et al.* ..... (A) 362
Pentoxifylline aggravates impairment in tumor necrosis factor alpha secretion and increases mycobacterial load in macrophages from AIDS patients with disseminated *M. avium intracellulare* complex infection. Sathe, S. S., *et al.* ..... (A) 184
Phenolic acridine orange fluorescent stain for mycobacteria. Smithwick, R. W., *et al.* ..... (A) 636
Phosphate is essential for stimulation of V gamma 9V delta 2 T lymphocytes by mycobacterial low molecular weight ligand. Schoel, B., *et al.* ..... (A) 154
Preparation of high-molecular-weight DNA: application to mycobacterial cells. Imai, T., *et al.* ..... (A) 335
Protection against tuberculosis by passive transfer with T cell clones recognizing mycobacterial heat shock protein 65. Silva, C. L., *et al.* ..... (A) 331
Pulmonary infections caused by less frequently encountered slow-growing environmental mycobacteria. Hoffner, S. E. ..... (A) 352
Recent changes in taxonomy and disease manifestations of the rapidly growing mycobacteria. Wallace, R. J. ..... (A) 365
Recognition of a unique peptide epitope of the mycobacterial and human heat shock protein 65-60 antigen by T cells of patients with recurrent oral ulcers. Hasan, A., *et al.* ..... (A) 496
Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelope. Deng, L. Y., *et al.* ..... (A) 493
Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria. Wolucka, B. A., *et al.* ..... (A) 339

Regulation by arachidonic acid metabolites of the immune response toward pathogenic mycobacteria. Adams, L. B., *et al.* ..... (A) 644
Rendering of mycobacteria safe for molecular diagnostic studies and development of a lysis method for strand displacement amplification and PCR. Zwadyk, P., Jr., *et al.* ..... (A) 164
Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation. Dabbs, E. R., *et al.* ..... (A) 482
Role of interleukin-6 in the infection of protective T cells during mycobacterial infections in mice. Appelberg, R., *et al.* ..... (A) 145
Suppression of cytokine production by supernatants from CD8+ lymphocytes activated by mycobacterial fractions: the role of interleukins 4 and 6. Wadee, A. A., *et al.* ..... (A) 156
Susceptibilities of nontuberculosis mycobacterial species to amoxicillin-clavulanic acid alone and in combination with antimycobacterial agents. Utrup, L. J., *et al.* ..... (A) 638
T and B cell responses to mycobacterial 65-kDa heat-shock protein in sheep infected with *maedi visna* virus. Harkiss, G. D., *et al.* ..... (A) 478
T-cell determinants and antibody binding sites on the major mycobacterial secretory protein MPB59 of *M. bovis*. Roche, P. W., *et al.* ..... (A) 358
T-cell-epitope mapping of the major secreted mycobacterial antigen AG85A in tuberculosis and leprosy. Launois, P., *et al.* ..... (A) 151
Testing for antibody to human immunodeficiency virus type 1 in a population in which mycobacterial diseases are endemic. Sterne, J. A. C., *et al.* ..... (A) 620
The effect of prostglandin E(2) and indomethacin on the cytotoxic response to mycobacterial antigens. Yuan, S. N., *et al.* ..... (A) 191
The envelope of mycobacteria. Brennan, P. J. and Nikaido, H. ..... (A) 607
The role of cytokines in mycobacterial infection. Champsi, J. H., *et al.* ..... (A) 322
The superoxide dismutase gene, a target for detection and identification of mycobacteria by PCR. Zolg, J. W. and Philippi-Schulz, S. ..... (A) 191
Tumour necrosis factor-alpha in the host resistance to mycobacteria of distinct virulence. Appelberg, R., *et al.* ..... (A) 599
Water soluble palmitic acid in media for cultivation of leprosy derived psychrophlic mycobacteria from *M. leprae* infected tissues. Kato, L. ..... (A) 611

Mycobacterium avium,

Activity of KRM 1648 alone and in combination with ethambutol or clarithromycin against *M. avium* in beige mouse model of disseminated infection. Bermudez, L. E., *et al.* ..... (A) 170
Actvities of roxithromycin against *M. avium* infections in human macrophages and C57BL/6 mice. Struillou, L., *et al.* ..... (A) 500
Bioluminescence method to evaluate antimicrobial agents against *M. avium*. Cooksey, R. C., *et al.* ..... (A) 628
Characterization of IS1110 a highly mobile genetic element from *M. avium*. Perez, M. H., *et al.* ..... (A) 183
Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated *M. avium* infection in beige mice. Bermudez, L. E., *et al.* ..... (A) 346
Complete sequence of the gene encoding the bacterioferritin subunit of *M. avium* subspecies *silvaticum*. Inglis, N. F., *et al.* ..... (A) 335
Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of *M. avium*. Mor, N., *et al.* ..... (A) 353
Endogenously produced IL-12 is required for the induction of protective T cells during *M. avium* infections in mice. Castro, A. G., *et al.* ..... (A) 599
Extra and intracellular activities of dirithromycin against *M. avium*. Gevaudan, M. J. and Demicco, P. ..... (A) 630
Hypertriglyceridemic serum, a very low density lipoprotein, and iron enhance *M. avium* replication in human macrophages. Douvas, G. S., *et al.* ..... (A) 349
In vitro anti-*M. avium* activities of quinolones: predicted active structures and mechanistic considerations. Klopman, G., *et al.* ..... (A) 180
Interleukin-12 enhances antigen-specific proliferation of peripheral blood mononuclear cells from HIV-positive and negative donors in response to *M. avium*. Newman, G. W., *et al.* ..... (A) 182
Intermittent azithromycin for treatment of *M. avium* infection in beige mice. Klemens, S. P. and Cynamon, M. H. ..... (A) 179

Intracellular trafficking in *M. tuberculosis* and *M. avium* infected macrophages. Xu, S. M., *et al.* ..... (A) 156
Loci of *M. avium* ser2 gene cluster and their functions. Mills, J. A., *et al.* ..... (A) 181
Novel extracellular mycobactins, the carboxymycobactins from *M. avium*. Lane, S. J., *et al.* ..... (A) 612
Plasminogen activator inhibitor type 2 prevents programmed cell death of human macrophages infected with *M. avium*, serovar 4. Gan, H. X., *et al.* ..... (A) 629
Polyclonal *M. avium* infections in patients with AIDS: variations in antimicrobial susceptibilities of different strains of *M. avium* isolated from the same patient. Van Reyn, C. F., *et al.* ..... (A) 500
Potential drug targets for *M. avium* defined by radiometric drug-inhibitor combination techniques. Rastogi, N., *et al.* ..... (A) 160
Rapid induction of mRNA for nitric oxide synthase II in rat alveolar macrophages by intratracheal administration of *M. tuberculosis* and *M. avium*. Greenburg, S. S., *et al.* ...(A) 495
Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and-dependent phases of *M. avium* infection. Appelberg, R., *et al.* ..... (A) 170
Selective *M. avium*-induced production of nitric oxide by human monocyte-derived macrophages. Dumarey, C. H., *et al.* ..... (A) 148
Solid-phase hybridization capture of low-abundance target DNA sequences: aplication to the polymerase chain reaction detection of *M. paratuberculosis* and *M. avium* subsp. *silvaticum*. Millar, D. S., *et al.* ..... (A) 497
Susceptibility of beige mice to *M. avium*; role of neutrophils. Appelberg, R., *et al.* ....(A) 624
Tat protein from HIV-1 binds to *M. avium* via a bacterial integrin–effects on extracellular and intracellular growth. Denis, M. ..... (A) 173

***Mycobacterium avium* complex,**

Acquired resistance in *M. avium* complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. Doucet-Populaire, F., *et al.* ..... (A) 587
Activities of benzoxazinorifamycin KRM 1648 and ethambutol against *M. avium* complex *in vitro* and in macrophages. Inderlied, C. B., *et al.* ..... (A) 178
Effectiveness of various antimicrobial agents against *M. avium* complex in the beige mouse model. Ji, B., *et al.* ..... (A) 178
Evironmental risk factors for acquisition of *M. avium* complex in persons with human immunodeficiency virus infection. Horsburgh, C. R., *et al.* ..... (A) 177
Hypopyon uveitis in patients with acquired immunodeficiency syndrom treated for systemic *M. avium* complex infection with rifabutin. Saran, B. R., *et al.* ..... (A) 142
In vitro activity of oxazolidinones against *M. avium* complex. Peters, J., *et al.* ..... (A) 591
Initial clarithromycin monotherapy for *M. avium-intracellulare* complex lung disease. Wallace, R. J., *et al.* ..... (A) 190
Intracellular activities of roxithromycin used alone and in association with other drugs against *M. avium* complex in human macrophages. Rastogi, N., *et al.* ..... (A) 499
Low-dose desamethasone as adjunctive therapy for disseminated *M. avium* complex infections in AIDS patients. Wormser, G. P., *et al.* ..... (A) 190
M. avium complex in water, food, and soil samples collected from the environment of HIV-infected individuals. Yajko, D. M., *et al.* ..... (A) 639
M. avium complex: advances in therapy. Havlir, D. V. ..... (A) 350
Pentoxifylline aggravates impairment in tumor necrosis factor alpha secretion and increases mycobacterial load in macrophages from AIDS patients with disseminated *M. avium intracellulare* complex infection. Sathe, S. S., *et al.* ..... (A) 184
Predictors of survival in patients with AIDS and disseminated *M. avium* complex disease. Horsburgh, C. R., *et al.* ..... (A) 177
Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for *M. avium-intracellulare* infection. Wallace, R. J., *et al.* ..... (A) 470
Selection of clarithromycin-resistant *M. avium* complex during combined therapy using the beige mouse model. Lounis, N., *et al.* ..... (A) 354
The impact of *M. avium* complex bacteremia and its treatment on survival of AIDS patients–a prospective study. Chin, D. P., *et al.* ..... (A) 172
The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol and rifampin, on *M. avium* complex bacteremia in patients with AIDS. Kemper, C. A., *et al.* ..... (A) 178

***Mycobacterium bovis* (see also BCG),**
Antigen 85C on *M. bovis*, BCG and *M. tuberculosis* promotes monocyte-CR3-mediated uptake of microbeads coated with mycobacterial products. Hetland, G. and Wiker, H. G. ..... (A) 150
Effect of inhA and katG on isoniazid resistance and virulence of *M. bovis*. Wilson, T. M., *et al.* ..... (A) 500
Genomic fingerprinting of *M. bovis* from cattle by restriction fragment length polymorphism analysis. Skuce, R. A., *et al.* ..... (A) 186
Growth inhibition of *M. bovis* by IFN-gamma stimulated macrophages–regulation by endogenous tumor necrosis factor alpha and by IL-10. Flesch, I. E. A., *et al.* ..... (A) 148
Limited restriction in the TCR-alpha beta V region usage of anti-specific clones–recognition of myelin basic protein (amino acids 84-102) and *M. bovis* 65-kDa heat shock protein (amino acids 3-13) by T cell clones established from PBMC of monozygotic twins and HLA-identical individuals. Hawes, G. E., *et al.* ..... (A) 351
Role of T cell subsets in immunity against intracellular bacteria: experimental infections of knock-out mice with *Listeria monocytogenes* and *M. bovis*. Kaufmann, S. H. E. and Ladel, C. H. ..... (A) 326
T-cell determinants and antibody binding sites on the major mycobacterial secretory protein MPB59 of *M. bovis*. Roche, P. W., *et al.* ..... (A) 358
Thiols of intracellular pathogens–identification of ovothiol A in *Leishmania donovani* and structural analysis of a novel thiol from *M. bovis*. Spies, H. S. C. and Steenkamp, D. J. ..... (A) 186
Use of various genetic markers in differentiation of *M. bovis* strains from animals and humans and for studying epidemiology of bovine tuberculosis. van Soolingen, D., *et al.* ..... (A) 188

***Mycobacterium butyricum*,**
Experimental arthritis and uveitis in rats associated with *M. butyricum*. Petty, R. E., *et al.* ..... (A) 183

***Mycobacterium celatum*,**
Isolation of the newly described species *M. celatum* from AIDS patients. Tortoli, E., *et al.* ..... (A) 363

***Mycobacterium cheloni (chelonae)*,**
Evaluation of Etest for rapid susceptibility testing of *M. chelonae* and *M. fortuitum*. Hoffner, S. E., *et al.* ..... (A) 176
In vitro evaluation of clarithromycin alone and in combination against *M. chelonae* complex. Gevaudan, M. J., *et al.* ..... (A) 173
Rapid development of resistance to clarithromycin following monotherapy for disseminated *M. chelonae* infection in a heart transplant patient. Tebas, P., *et al.* ..... (A) 363

***Mycobacterium fortuitum*,**
Antigenic properties and immunoelectron microproperties and immunoelectron microscopic localization of *M. fortuitum* beta lactamase. Wagner, B., *et al.* ..... (A) 365
Bacteriostatic activity of BCG/PPD-activated macrophages against *M. fortuitum* does not involve reactive nitrogen or oxygen intermediates. Nibbering, P. H., *et al.* ..... (A) 182
Evaluation of Etest for rapid susceptibility testing of *M. chelonae* and *M. fortuitum*. Hoffner, S. E., *et al.* ..... (A) 176

***Mycobacterium genavense*,**
M. genavense: an emerging pathogen. Bottger, E. C. ..... (A) 347

***Mycobacterium gordonae*,**
Cross-reactivity of anti-*M. gordonae* antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. Vilagut, L., *et al.* ..... (A) 189

***Mycobacterium habana*,**
Immunoreactive antigens of a candidate leprosy vaccine: *M. habana*. Chaturvedi, V., *et al.* ..... (A) 481

***Mycobacterium haemophilum*,**
M. haemophilum: an emerging pathogen. Kiehn, T. E. and White, M. ..... (A) 353
Treatment of *M. haemophilum* infection with an antibotic regimen including clarithromycin. Darling, T. N., *et al.* ..... (A) 172

Mycobacterium leprae,

A 46-kDa integral membrane protein from *M. leprae* resembles a number of bacterial and mammalian membrane transport proteins. Oskam, L., *et al.* ..... (A) 613

A *M. leprae* gene encoding a fibronectin binding protein is used for efficient invasion of epithelial cells and Schwann cells. Schorey, J. S., *et al.* ..... (A) 614

A *M. leprae*-specific gene encoding an immunologically recognized 45 kDa protein. De Wit, T. F. R., *et al.* ..... (A) 477

A morphological and functional assessment of *M. leprae*-induced nerve damage in a guinea-pig model of leprous neuritis. De Blaquiere, G. E., *et al.* ..... (A) 164

Acid-fast bacilli from former leprosy regions in coastal Norway showing PCR positivity for *M. leprae*. Mostafa, H. M., *et al.* ..... (C) 97

An HLA-DRw53-restricted T-cell epitope from a novel *M. leprae* protein antigen important to the human memory T-cell repertoire against *M. leprae*. Mustafa, A. S., *et al.* ..... (A) 328

An unusual spreading phenomenon in an artifical medium inoculated with *M. leprae*. Sticht-Groh, V., *et al.* ..... (C) 100

Analysis of T-cell and B-cell responses to recombinant *M. leprae* antigens in leprosy patients and in healthy contacts: significant T-cell responses to antigens in *M. leprae* nonresponders. Thole, J. E. R., *et al.* ..... (O) 369

Analysis of vaccines prepared from armadillo-derived *M. leprae*; results of an interlaboratory study coordinated by the World Health Organization. IMMYC Steering Committee. ..... (O) 48

Application of polymerase chain reaction for the detection of *M. leprae* DNA in specimens from treated leprosy patients. Rafi, A., *et al.* ..... (O) 42

Application of recombinant 85 complex of *M. leprae* for the serodiagnosis of leprosy. Suzuki, Y., *et al.* ..... (A) 657

Association of antibodies to *M. leprae* and nerve antigens with lepra reactions in leprosy patients. Cho, S.-N., *et al.* ..... (A) 647

Basic and applied research emerging from the *M. leprae* genome. Gillis, T. P. ..... (A) 286

Beige mice infected with *M. leprae*. Gelber, R. H., *et al.* ..... (C) 295

Biometals in skin and sera of leprosy patients and their correlation to trace element contents of *M. leprae* and histological types of the disease; a comparative study with cutaneous tuberculosis. Jain, A., *et al.* ..... (O) 249

CD1-restricted T-cell recognition of *M. leprae* lipoarabinomannan. Sieling, P. A., *et al.* ..... (A) 656

CD4+ T-cell responses to recombinant hsp65 and hsp18 of *M. leprae* and their trypsin-digested fragments in leprosy: diversity in HLA-DR restriction. Mitra, D. K., *et al.* ..... (O) 518

Cellular and humoral immune responses to recombinant 65-kDa antigen of *M. leprae* in leprosy patients and healthy controls. Ilangumaran, S., *et al.* ..... (A) 150

Cellular immune responses to *M. leprae* infection in human immunodeficiency virus-infected individuals. Sampaio, E. P., *et al.* ..... (A) 605

Characterization of the gene encoding the immunodominant 35 kDa protein of *M. leprae*. Winter, N., *et al.* ..... (A) 615

Clinical utility of LSR/A16 gene for *M. leprae* detection in leprosy tissues using the polymerase chain reaction. Misra, N., *et al.* ..... (O) 35

Comparative assessment of viability of *M. leprae* by mouse foot pad and fluorescent staining techniques. Sreevatsa and Katoch, V. M. ..... (A) 337

Continuous cultivation of *M. leprae* in primary cell cultures. Walker, L. L., *et al.* ..... (A) 657

Critical residues of the *M. leprae* LSR recombinant protein discriminate clinical activity in erythema nodosum leprosum reactions. Singh, S., *et al.* ..... (A) 331

Cultivation of *M. leprae* in macrophages. Fukutomi, Y., *et al.* ..... (A) 648

Detection of *M. leprae* by three-primer PCR. Richter, E., *et al.* ..... (A) 336

Detection of *M. leprae* infection by PCR. Wichitwechkarn, J., *et al.* ..... (A) 338

Detection of antibodies against phenolic glycolipid-I (PGL-I), 35-kDa and 30-40-kDa components of *M. leprae* on the cerebrospinal fluid of leprosy patients. Patil, S. A., *et al.* ..... (A) 604

[Determination of distribution and density of *M. leprae* in the skin of leprosy patients.] Xie, Y.-L., *et al.* ..... (A) 333

Development of an *in vitro* drug screening system for *M. leprae* based on the determination of the intrabacterial sodium-to-potassium ratio of individual bacterial organisms. Wiese, M., *et al.* ..... (A) 338
Differences in *M. leprae*-induced nerve damage in Swiss white and C57BL/6 mice. Birdi, T. J., *et al.* ..... (C) 573
Effective vaccination of mice against *M. leprae* with density gradient subfractions of soluble *M. leprae* proteins: clues to active protein epitopes. Gelber, R. H., *et al.* ..... (A) 164
[Establishment of a PCR method by using the terminal repeated sequence of the gene encoded for 65 kDa antigen of *M. leprae*.] Li, T., *et al.* ..... (A) 612
Evaluation of PCR mediated DNA amplification in non-invasive biological specimens for subclinical detection of *M. leprae*. Santos, A. R., *et al.* ..... (A) 613
Expression of the 18-kDa protein of *M. leprae* in *Saccharomyces cerevisiae*. Pinho, J. R. R., *et al.* ..... (A) 336
Glycoside-bearing liposomal delivery systems against macrophage-associated disorders involving *M. leprae* and *M. tuberculosis*. Medda, S., *et al.* ..... (A) 590
[Histologic study of the eyes of armadillos experimentally infected with *M. leprae* before and after chemotherapy.] Zhou, H.-M., *et al.* ..... (A) 340
Identification of a *M. leprae*-specific T-cell epitope on the 70 kDa heat shock protein. Roche, P. W., *et al.* ..... (A) 154
Identification of an antigenic domain on *M. leprae* protein antigen 85B, which is specifically recognized by antibodies from patients with leprosy. Filley, E., *et al.* ..... (A) 477
IgG subclass antibody to *M. leprae* 18,000 MW antigen is restricted to IgG1 and IgG3 in leprosy. Hussain, R., *et al.* ..... (A) 325
Immune responses of heat-shock protein 65 on *M. leprae* inoculated mice. Nomaguchi, H., *et al.* ..... (A) 652
Immunoaffinity chromatographic isolation of a high molecular weight seroreactive protein from *M. leprae* cell sonicate. Deshpande, R. G., *et al.* ..... (A) 608
Immunogenic properties of the *M. leprae* recombinant 18-kDa antigen purified from *Saccharomyces cerevisiae*; enhancement of delayed-type hypersensitivity after gamma-irradiation. Pinho, J. R. R., *et al.* ..... (O) 381
In vitro activities of 2, 2'-bipyridyl analogs against *M. leprae*. Dhople, A. M., *et al.* ..... (A) 312
In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against *M. leprae*. Dhople, A. M. and Ibanez, M. A. ..... (A) 608
Infection of SCID mice with *M. leprae* and control with antigen activated "immune" human peripheral blood mononuclear cells. Converse, P. J., *et al.* ..... (A) 476
Inhibition of the multiplication of *M. leprae* in nude mice by intermittent administration of a new rifamycin derivative, 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin (KRM-1648) combined with sparfloxacin. Gidoh, M., *et al.* ..... (A) 484
Lack of cytotoxic activity against *M. leprae* 65-kD heat shock protein (hsp) in multibacillary leprosy patients. Delabarrera, S., *et al.* ..... (A) 476
M. leprae DNA content, cellular and cytokine patterns in skin lesions of leprosy patients undergoing multidrug therapy (MDT). Flad, H. D., *et al.* ..... (A) 324
M. leprae in the epidermis: ultrastructural study I. Seo, Y. H., *et al.* ..... (C) 101
M. leprae iron nutrition: bacterioferritin, mycobactin, exochelin and intracellular growth. Morrison, N. E. ..... (E) 86
M. leprae isolates from different sources have identical sequences of the spacer region between the 16S and 23S ribosomal RNA genes. de Wit, M. Y. L. and Klatser, P. R. ..... (A) 158
Mapping the *in vivo*-expressed proteins of *M. leprae*. Pessolani, M. C. V., *et al.* ..... (A) 652
Molecular and immunological characterization of the highly conserved antigen 84 from *M. tuberculosis* and *M. leprae*. Hermans, P. W. M., *et al.* ..... (A) 482
Molecular basis of rifampin resistance in *M. leprae*. Honore, N. and Cole, S. T. ..... (A) 334
Mouse cell lines expressing *M. leprae* heat-shock protein 65 kDa gene: lymphoproliferative responses to the cell lines. Nakanaga, K., *et al.* ..... (A) 651
Optimal pH for preserving the activity of *M. leprae* during incubation of cells in a cell-free liquid medium. Nakamura, M. ..... (O) 28
Purification, characterization, gene sequence, and significance of a bacterioferritin from *M. leprae*. Pessolani, M. C. V., *et al.* ..... (A) 160
Recognition of *M. leprae* recombinant 18,000 MW epitopes by IgG subclasses in leprosy. Hussain, R., *et al.* ..... (A) 326

Relapses during long-term follow up with drug-susceptible *M. leprae* among multibacillary leprosy patients treated with multidrug therapy regimens; case reports. Thomas, A., *et al.* ..... (O) 391
Sequence analysis of the 18-kDa gene and the 16S-23S rDNA ITS region from strains of *M. leprae*. Gillis, T. P., *et al.* ..... (A) 649
Seroepidemiological study of *M. leprae* infection in the inhabitants of endemic villages in South Sulawesi, Indonesia. Izumi, S., *et al.* ..... (A) 650
Study on the roles of CD4+ and CD8+ T cells in the expression of host resistance to *M. leprae* infection induced in athymic nude mice. Maw, W. W., *et al.* ..... (O) 539
T cells bearing Vbeta6 T cell receptors in the cell-mediated immune response to *M. leprae*. Wang, X. H., *et al.* ..... (A) 481
T-cell activity against antigen-85 but not against the 18-kDa and 65-kDa heat shock proteins in the early stages of acquired immunity against *M. leprae*. Launois, P., *et al.* ..... (A) 151
The *M. leprae* genome: systematic sequence analysis identifies key catabolic enzymes, ATP-dependent transport systems and a novel po1A locus asociated with genomic variability. Fsihi, H. and Cole, S. T. ..... (A) 609
The *in vitro* activities of novel benzoaxinorifamycins against *M. leprae*. Dhople, A. M. and Ibanez, M. A. ..... (A) 587
The molecular biology of *M. leprae*. Colston, M. J. ..... (A) 158
Titration of numbers of human-derived *M. leprae* required to progressively oxidize ^{14}C-palmitic acid and release $^{14}CO_2$. Shannon, E. J., *et al.* ..... (A) 161
[Ultramicro-ELISA (UMELISA) for the detection of IgM antibodies to *M. leprae* using eluates of dried blood spots.] Torrella, A., *et al.* ..... (A) 606
Ultrastructural changes in *M. leprae* passed to laboratory animals. Maslov, A. K., *et al.* ..... (C) 457
Unique gene organization of thioredoxin and thioredoxin reductase in *M. leprae*. Wieles, B., *et al.* ..... (A) 615
Vaccination with pure *M. leprae* proteins inhibits *M. leprae* multiplication in mouse foot pads. Gelber, R. H., *et al.* ..... (A) 148
Water soluble palmitic acid in media for cultivation of leprosy derived psychrophlic mycobacteria from *M. leprae* infected tissues. Kato, L. ..... (A) 611

Mycobacterium lepraemurium,
Cellular target of *in vitro*-induced suppressor cells derived from the spleen of *M. lepraemurium* infected mice and role of IFN-gamma in their development. Gosselin, D., *et al.* ..... (A) 484

Mycobacterium malmoense,
Infection with *M. malmoense* in Sweden; report of 221 cases. Henriques, B., *et al.* ..... (A) 175

Mycobacterium marinum,
M. marinum persists in cultured mammalian cells in a temperature-restricted fashion. Ramakrishnan, L. and Falkow, S. ..... (A) 165
Septic arthritis due to *M. marinum*. Harth, M., *et al.* ..... (A) 175

Mycobacterium microti,
Effect of interleukin-1 alpha on the growth of *M. microti* within J774A.1 cells. Majumder, S. and Gupta, R. ..... (A) 181

Mycobacterium neoaurum,
Determination of the structure of exochelin MN, the extracellular siderophore from *M. neoaurum*. Sharman, G. J., *et al.* ..... (A) 614

Mycobacterium paratuberculosis,
Cloning and expression in *Escherichia coli* of DNA encoding a 60 kDa stress protein of *M. paratuberculosis*, the causative agent of Johne's disease. Colston, A., *et al.* ..... (A) 348
Histopathology of C57BL/6 mice inoculated orally with *M. paratuberculosis*. Veasey, R. S., *et al.* ..... (A) 638
Identification and characterization of *M. paratuberculosis* recombinant proteins expressed in *E. coli*. Elsaatari, F. A. K., *et al.* ..... (A) 173
Solid-phase hybridization capture of low-abundance target DNA sequences: aplication to the polymerase chain reaction detection of *M. paratuberculosis* and *M. avium* subsp. *silvaticum*. Millar, D. S., *et al.* ..... (A) 497

Mycobacterium scrofulaceum,
Cloning, sequencing and expression in *Escherichia coli* of the gene for alpha antigen from *M. scrofulaceum*. Takano, M., *et al.* ..... (A) 161

Mycobacterium simiae,
Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against *M. simiae* in murine model of disseminated infection. Valero, G., *et al.* ..... (A) 187

Mycobacterium smegmatis,
Characterization of mutations in *M. smegmatis* involved in resistance to fluoroquinolones. Revel, V., *et al.* ..... (A) 161
Cloning and sequence analysis of the rpsL and rpsG genes of *M. smegmatis* and characterization of mutations causing resistance to streptomycin. Kenney, T. J. and Churchward, G. ..... (A) 179
DNA topoisomerase I from *M. smegmatis*. Bhaduri, T. and Nagaraja, V. ..... (A) 157
Iron storage in *M. smegmatis* grown under iron-sufficient and iron-overload conditions. Kikuchi, K., *et al.* ..... (A) 179
Permeability of the cell wall of *M. smegmatis*. Trias, J. and Benz, R. ..... (A) 162
Sequence and analysis of the rpoB gene of *M. smegmatis*. Hetherington, S. V., *et al.* ..... (A) 631
The immunogenicity of recombinant *M. smegmatis*-bearing BCG genes. Falcone, V., *et al.* ..... (A) 609

Mycobacterium tuberculosis,
Activities of poloxamer CRL8131 against *M. tuberculosis in vitro* and *in vivo*. Jagannath, C., *et al.* ..... (A) 589
Activity of KRM-1648, a new benzoxazinorifamycin, against *M. tuberculosis* in a murine model. Klemens, S. P., *et al.* ..... (A) 180
Activity of n-propyl pyrazinoate against pyrazinamide resistant *M. tuberculosis*: investigations into mechanism of action of and mechanism of resistance to pyrazinamide. Speirs, R. J., *et al.* ..... (A) 592
Amplification of DNA of *M. tuberculosis* from peripheral blood of patients with pulmonary tuberculosis. Schluger, N. W., *et al.* ..... (A) 185
Analysis of the population structure of *M. tuberculosis* in Ethiopia, Tunisia, and The Netherlands; usefulness of DNA typing for global tuberculosis epidemiology. Hermans, P. W. M., *et al.* ..... (A) 631
Antigen 85C on *M. bovis*, BCG and *M. tuberculosis* promotes monocyte-CR3-mediated uptake of microbeads coated with mycobacterial products. Hetland, G. and Wiker, H. G. ..... (A) 150
CD4+ alpha beta T cell and gamma delta T cell responses to *M. tuberculosis*–similarities and differences in Ag recognition, cytotoxic effector function, and cytokine production. Tsukaguchi, K., *et al.* ..... (A) 363
Characterization of a 10- to 14-kilodalton protease-sensitive *M. tuberculosis* H37Ra antigen that stimulates human gamma delta T cells. Boom, W. H., *et al.* ..... (A) 346
Characterization of fluoroquinolone-resistant mutant strains of *M. tuberculosis* selected in the laboratory and isolated from patients. Alangaden, G. J., *et al.* ..... (A) 624
Characterization of the *M. tuberculosis* phagosome and evidence that phagosomal maturation is inhibited. Clemens, D. L. and Horwitz, M. A. ..... (A) 323
Chemotherapeutic activity of clofazimine and its analogues againt *M. tuberculosis*: *in vitro*, intracellular and *in vivo* studies. Jagannath, C., *et al.* ..... (A) 496
Colorimetric method for determining MICs of antimicrobial agents for *M. tuberculosis*. Yajko, D. M., *et al.* ..... (A) 639
Colorimetric microwell plate hybridization assay for detection of amplified *M. tuberculosis* DNA from sputum samples. Cho, S.-N., *et al.* ..... (A) 492
Comparison of activities of rifapentine and rifampin against *M. tuberculosis* residing in human macrophages. Mor, N., *et al.* ..... (A) 633
Comparison of polymerase chain reaction with standard methods in the diagnosis of *M. tuberculosis* infection. Pietrzak, J., *et al.* ..... (A) 356
Comparison of the immune response against *M. tuberculosis* antigens between a group of patients with active pulmonary tuberculosis and healthy household contacts. Torres, M., *et al.* ..... (A) 155
Crystal structure and function of the isoniazid target of *M. tuberculosis*. Dessen, A., *et al.* ..... (A) 494

DNA of *M. tuberculosis* in formalin-fixed, paraffin-embedded tissue in tuberculosis and sarcoidosis detected by polymerase chain reaction. Popper, H. H., *et al.* ..... (A) 184
Detection of *M. tuberculosis* directly from spiked human sputum by Q-beta replicase-amplified assay. Shah, J. S., *et al.* ..... (A) 360
Differential T cell responses to mycobacteria-secreted proteins distinguish vaccination with bacille Calmette Guerin from infection with *M. tuberculosis*. Roche, P. W., *et al.* ..... (A) 330
Direct genotypic detection of *M. tuberculosis* rifampin resistance in clinical specimens by using single-tube heminested PCR. Whelen, A. C., *et al.* ..... (A) 366
Dormancy of *M. tuberculosis* and latency of disease. Wayne, L. G. ..... (A) 337
Drug-resistant strains of *M. tuberculosis* exhibit a range of virulence for mice. Ordway, D. J., *et al.* ..... (A) 355
Effects of nitric oxide synthase inhibitors on murine infection with *M. tuberculosis*. Chan, J., *et al.* ..... (A) 491
Enhanced interleukin-8 release and gene expession in macrophages after exposure to *M. tuberculosis* and its components. Zhong, Y.-H., *et al.* ..... (A) 366
Enhancement of intracellular growth of *M. tuberculosis* in human monocytes by transforming growth factor-beta. Hirsch, C. S., *et al.* ..... (A) 351
Ethanol fixation of sputum sediments for DNA-based detection of *M. tuberculosis*. Williams, D. L., *et al.* ..... (A) 615
Evidence for glycosylation sites on the 45-kilodalton glycoprotein of *M. tuberculosis*. Dobos, K. M., *et al.* ..... (A) 629
[Evolution of lesions induced by mycobacteria, BCG and H37Rv in hampsters.] Roxo, E., *et al.* ..... (A) 605
Gene expression in mycobacteria: transcriptional fusions based on xylE and analysis of the promoter region of the response regulator mtrA from *M. tuberculosis*. Curcic, R., *et al.* ..... (A) 172
Genotypic detection of *M. tuberculosis* rifampin resistance: comparison of single-strand conformation polymorphism and dideoxy fingerprinting. Felmlee, T. A., *et al.* ..... (A) 609
Glutamine synthetase of *M. tuberculosis*: extracellular release and characterization of its enzymatic activity. Harth, G., *et al.* ..... (A) 175
Glycoside-bearing liposomal delivery systems against macrophage-associated disorders involving *M. leprae* and *M. tuberculosis*. Medda, S., *et al.* ..... (A) 590
Growth of *M. tuberculosis* in BCG-resistant and-susceptible mice: establishment of latency and reactivation. Brown, D. H., *et al.* ..... (A) 625
Human T-cell responses to secreted antigen fractions of *M. tuberculosis*. Boesen, H., *et al.* ..... (A) 490
IL-12 increases resistance of BALB/c mice to *M. tuberculosis* infection. Flynn, J. L., *et al.* ..... (A) 601
Identification of *M. tuberculosis* DNA sequences encoding exported proteins by using phoA gene fusions. Lim, E. M., *et al.* ..... (A) 354
Identification of macrophage and stress-induced proteins of *M. tuberculosis*. Lee, B.-Y. and Horwitz, M. A. ..... (A) 612
Impact of antigen-presenting cells of cytokine profiles of human Th clones established after stimulation of *M. tuberculosis* antigens. Conradt, P. and Kaufmann, S. H. E. ..(A) 600
In vitro activity of roxithromycin against the *M. tuberculosis* complex. Rastogi, N., *et al.* ..... (A) 499
In vitro and *in vivo* activities of levofloxacin against *M. tuberculosis*. Ji, B., *et al.* ..... (A) 631
In vitro experiments with *Centella asiatica*: investigation to elucidate the effect of an indigenously prepared powder of this plant on the acid-fastness and variability of *M. tuberculosis*. Herbert, D., *et al.* ..... (A) 136
Inactivation of polymerase inhibitors for *M. tuberculosis* DNA amplification in sputum by using capture resin. Amicosante, M., *et al.* ..... (A) 488
Induction of transforming growth factor beta 1 by purified protein derivative of *M. tuberculosis*. Toossi, Z., *et al.* ..... (A) 363
Interleukin-12 (IL-12) augments cytolytic activity of natural killer cell toward *M. tuberculosis*-infected human monocytes. Denis, M. ..... (A) 147
Intracellular trafficking in *M. tuberculosis* and *M. avium* infected macrophages. Xu, S. M., *et al.* ..... (A) 156
Iron acquisition by *M. tuberculosis*; isolation and characterization of a family of iron-binding exochelins. Gobin, J., *et al.* ..... (A) 630

Isolation of a 32 kDa *M. tuberculosis* protein by lectin affinity chromatography. Montano, L. F., *et al.* ..... (A) 182
Isolation of the gene for the beta subunit of RNA polymerase from rifampicin-resistant *M. tuberculosis* and identification of new mutations. Donnabella, V., *et al.* ..... (A) 349
Lipoarabinomannan inhibits nonopsonic binding of *M. tuberculosis* to murine macrophages. Stokes, R. W. and Speert, D. P. ..... (A) 636
M. tuberculosis enhances human immunodeficiency virus-1 replication of transcriptional activation at the long terminal repeat. Zhang, Y. H., *et al.* ..... (A) 640
Metronidazole is bactericidal to dormant cells of *M. tuberculosis*. Wayne, L. G. and Sramek, H. A. ..... (A) 163
Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance to *M. tuberculosis*. Heym, B., *et al.* ..... (A) 351
Molecular and immunological characterization of the highly conserved antigen 84 from *M. tuberculosis* and *M. leprae*. Hermans, P. W. M., *et al.* ..... (A) 482
Molecular cloning of gyrA and gyrB genes of *M. tuberculosis*: analysis of nucleotide sequence. Madhusudan, K., *et al.* ..... (A) 335
Molecular genetics of drug resistence in *M. tuberculosis*. Zhang, Y. and Young, D. ..... (A) 191
Molecular mechanisms of multiple drug resistance in clinical isolates of *M. tuberculosis*. Morris, S., *et al.* ..... (A) 497
Multiplex strand displacement amplifications (SDA) and detection of DNA sequences from *M. tuberculosis* and other mycobacteria. Walker, G. T., *et al.* ..... (A) 163
Mutation of the principal sigma factor causes loss of virulence in a strain of the *M. tuberculosis* complex. Collins, D. M., *et al.* ..... (A) 628
Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence *in-vitro* activity of rifamycins in rifampicin-resistant *M. tuberculosis*. Bodmer, T., *et al.* ..... (A) 468
Mutations in the catalase-peroxidase gene from isoniazid resistant *M. tuberculosis* isolates. Altamirano, M., *et al.* ..... (A) 170
Novel mutation in 16S rRNA associated with streptomycin dependence in *M. tuberculosis*. Honore, N., *et al.* ..... (A) 352
Nucleotide sequence of the 85B-protein gene of *M. bovis* BCG and *M. tuberculosis*. de Wit, M. Y. L., *et al.* ..... (A) 173
Protective immunity against tuberculosis induced by baccination with major extracellular proteins of *M. tuberculosis*. Horwitz, M. A., *et al.* ..... (A) 496
Rapid *Mycobacterium* species assignment and unambiguous identification of mutations associated with antimicrobial resistance in *M. tuberculosis* by automated DNA sequencing. Kapur, V., *et al.* ..... (A) 352
Rapid discrimination of *M. tuberculosis* strains by random amplified polymorphic DNA analysis. Linton, C. J., *et al.* ..... (A) 159
Rapid induction of mRNA for nitric oxide synthase II in rat alveolar macrophages by intratracheal administration of *M. tuberculosis* and *M. avium*. Greenburg, S. S., *et al.* ..... (A) 495
Rapid susceptibility testing of *M. tuberculosis* (H37Ra) by flow cytometry. Norden, M. A., *et al.* ..... (A) 498
Restriction fragment length polymorphism of *M. tuberculosis* strains isolated from Greenland during 1992: evidence of tuberculosis transmission between Greenland and Denmark. Yang, Z. H., *et al.* ..... (A) 366
Routine identification of *M. tuberculosis* complex isolated by automated hybridization. Mabilat, C., *et al.* ..... (A) 180
Selection of a gyrA mutant of *M. tuberculosis* resistant to fluoroquinolones during treatment with ofloxacin. Cambau, E., *et al.* ..... (A) 171
Spindle cell pseudotumors in the lungs due to *M. tuberculosis* in a transplant patient. Sekosan, M., *et al.* ..... (A) 185
Strains of *M. tuberculosis* differ in susceptibility to reactive nitrogen intermediates *in vitro*. O'Brien, L., *et al.* ..... (A) 355
Structural definition of acylated phosphatidylinositol mannosides from *M. tuberculosis*: definition of a common anchor for lipomannan and lipoarabinomannan. Khoo, K. H., *et al.* ..... (A) 482
Sustained T-cell activity to *M. tuberculosis* specific antigens in "split-anergic" leprosy. Kaleab, B., *et al.* ..... (A) 478
Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant *M. tuberculosis*. Cavalieri, S. J., *et al.* ..... (A) 626

The T cell response to secreted antigens of *M. tuberculosis*. Anderson, P. ..... (A) 345
The role of interleukin-12 in acquired immunity to *M. tuberculosis* infection. Cooper, A. M., *et al.* ..... (A) 493
Tumor necrosis factor-alpha is required in the protective immune response against *M. tuberculosis*. Flynn, J. L., *et al.* ..... (A) 629
Two novel T cell epitope prediction algorithms based on MHC binding motifs; comparison of predicted and published epitopes from *M. tuberculosis* and HIV protein sequences. Meister, G. E., *et al.* ..... (A) 633
Why disease due to *M. tuberculosis* is less common than expected in HIV-positive patients in Edinburgh. Leitch, A. G., *et al.* ..... (A) 632

Mycobacterium vaccae,
Immunotherapy with *M. vaccae* as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Onyebujoh, P. C., *et al.* ..... (A) 498

Mycobactin,
M. leprae iron nutrition: bacterioferritin, mycobactin, exochelin and intracellular growth. Morrison, N. E. ..... (E) 86
Novel extracellular mycobactins, the carboxymycobactins from *M. avium*. Lane, S. J., *et al.* ..... (A) 612

Nepal,
Changing of Director of INF LCP. ..... (N) 130
Disabilities of hands, feet and eyes in newly diagnosed leprosy patients in eastern Nepal. Schipper, A., *et al.* ..... (A) 142
Eye disease in newly diagnosed leprosy patients in eastern Nepal. Lubbers, W. J., *et al.* ..... (A) 141
Integration of leprosy control into basic health services; an example from Nepal. Roos, B. R., *et al.* ..... (O) 422
Nerve damage in leprosy: an epidemiological and clinical study of 396 patients in west Nepal–Part I. Definitions, methods and frequencies. van Brakel, W. H. and Khawas, I. B. ..... (A) 144
Reactions in leprosy: an epidemiological study of 386 patients in west Nepal. van Brakel, W. H., *et al.* ..... (A) 144
Use of a facility-based assessment in the evaluation of a comprehensive leprosy training program in Nepal. Roos, B. R. and van Brakel, W. H. ..... (O) 552

Nerve(s) (see also **Neuritis** and **Neuropathy**),
A morphological and functional assessment of *M. leprae*-induced nerve damage in a guinea-pig model of leprous neuritis. De Blaquiere, G. E., *et al.* ..... (A) 164
[Analysis of the nerve damage in maxillofacial area among 607 leprosy patients.] Qiu, W.-P. ..... (A) 321
Association of antibodies to *M. leprae* and nerve antigens with lepra reactions in leprosy patients. Cho, S.-N., *et al.* ..... (A) 647
Audiovestibular system, fifth and seventh cranial nerve involvement in leprosy. Koyuncu, M., *et al.* ..... (A) 320
[Comparison of techniques for monitoring the neuropathy of hanseniasis; tests of sensibilities and nerve conduction studies.] Marciano, L. H. S. C. and Garbino, J. A. ..(A) 622
Depletion of nerve growth factor in leprosy. Anand, P., *et al.* ..... (A) 145
Differences in *M. leprae*-induced nerve damage in Swiss white and C57BL/6 mice. Birdi, T. J., *et al.* ..... (C) 573
[Dimorphous leprosy with a lesion of the radial nerve; a case report.] Lora Robles, M. and Gonzalez, K. ..... (A) 141
Early detection of rifampin in human nerve tissue after an oral dose of 600 milligrams. Guebre Xabier, M., *et al.* ..... (A) 588
Immunohistological localization of mycobacterial antigens with the peripheral nerves of treated leprosy patients and their significance to nerve damage in leprosy. Shetty, V. P., *et al.* ..... (A) 155
Infected trophic ulcers and tenderness of posterior tibial nerve in cured leprosy patients. Srinivasan, H. ..... (C) 291
Inter-observer variability in the assessment of nerve function in leprosy patients in Ethiopia. Lienhardt, C., *et al.* ..... (O) 62

Intraoperative electroneurodiagnostics to detect a second granuloma in the cubital area of median nerves affected by leprosy: a new approach to prevent incomplete surgery. Turkof, E., *et al.* ..... (O) 409
Nerve damage in leprosy: an epidemiological and clinical study of 396 patients in west Nepal–Part I. Definitions, methods and frequencies. van Brakel, W. H. and Khawas, I. B. ..... (A) 144
[Nerve damage on the face of 89 leprosy patients.] Jing, Z., *et al.* ..... (A) 319
[Palpation of peripheral nerves (affected in hanseniasis) and their anatomical pathways.] Martins, C. F. ..... (A) 596
Polyaxonal myelination in a human leprous nerve. Shetty, V. ..... (C) 104
Segmental ulnar nerve conduction velocities in Hansen's disease. Grimaud, J., *et al.* ..... (A) 473
[The results of neurolysis of the ulnar nerve in the neuritis of hanseniasis.] Virmond, M., *et al.* ..... (A) 623
The role of antiperipheral nerve antibodies in nerve damage in leprosy. Desikan, P., *et al.* ..... (A) 148
Tumour necrosis factor-alpha synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Khanolkar Young, S., *et al.* ..... (A) 327
[Type 1 reactions in borderline tuberculoid hanseniasis during multidrug therapy: time of appearance of nerve involvement.] de Carvalho, M. L. R., *et al.* ..... (A) 594

Netherlands, The,
Analysis of the population structure of *M. tuberculosis* in Ethiopia, Tunisia, and The Netherlands; usefulness of DNA typing for global tuberculosis epidemiology. Hermans, P. W. M., *et al.* ..... (A) 631
INFOLEP preparing new TALMILEP supplement. ..... (N) 581

Neuritis (see also **Nerve(s)** and **Neuropathy**),
A morphological and functional assessment of *M. leprae*-induced nerve damage in a guinea-pig model of leprous neuritis. De Blaquiere, G. E., *et al.* ..... (A) 164
Field evaluation of WHO-MDT of fixed duration at ALERT, Ethiopia: the AMFES project–II. Reaction and neuritis during and after MDT in PB and MB leprosy patients. de Rijk, A. J., *et al.* ..... (A) 312
Intraoperative spinal root stimulation to detect most proximal site of leprous ulnar neuritis. Turkof, E., *et al.* ..... (A) 143
Neuritis and rifampicin. Salafia, A. and De Geiking, I. ..... (A) 475
[The results of neurolysis of the ulnar nerve in the neuritis of hanseniasis.] Virmond, M., *et al.* ..... (A) 623
Tuberculous optic neuritis histologically resembling leprous neuritis. Arora, V. K., *et al.* ..... (C) 454
Type 1 reactions in leprosy, neuritis and steroid therapy: the impact of the human immunodeficiency virus. Bwire, R. and Kawuma, H. J. S. ..... (A) 135

Neuropathy (see also **Nerve(s)** and **Neuritis**),
Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysical studies to detect thalidomide neuropathy. Gardner-Medwin, J. M. M., *et al.* ..... (A) 350
[Comparison of techniques for monitoring the neuropathy of hanseniasis; tests of sensibilities and nerve conduction studies.] Marciano, L. H. S. C. and Garbino, J. A. ..... (A) 622
Neuropathy as the only sign of borderline lepromatous leprosy for 13 years. Mizuno, K., *et al.* ..... (A) 596
Screening for peripheral neuropathy in patients with leprosy. Grimaud, J., *et al.* ..... (A) 473
Silent neuropathy in leprosy: an epidemiological description. van Brakel, W. H. and Khawas, I. B. ..... (A) 321

New Caledonia,
[Leprosy in New Caledonia from 1983 to 1992; histopathological and epidemiological data.] Monchy, D., *et al.* ..... (A) 619

Nigeria,
AIDS and tuberculosis/leprosy in Nigeria: the urbanisation factor. Awofeso, N. ..... (A) 617
Effect of blister calendar packs in enhancing compliance with MDT; the Kaduna State (Nigeria) experience. Awofeso, N., *et al.* ..... (E) 453

Norway,
Acid-fast bacilli from former leprosy regions in coastal Norway showing PCR positivity for *M. leprae*. Mostafa, H. M., *et al.* ..... (C) 97

Nose,
[Comparative evaluation of AAFB from the nose and skin of LL patients.] Prabhakar, M. C. ..... (A) 336
Surgical correction of saddle nose deformity in leprosy–one stage procedure. Malaviya, G. N. and Husain, S. ..... (A) 343

Obituaries,
Leiker, Dick L. Faber, W., *et al.* ..... (Ob) 298

Ofloxacin,
Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against *M. simiae* in murine model of disseminated infection. Valero, G., *et al.* ..... (A) 187
Kinetics of ofloxacin and its metabolites in cerebrospinal fluid after a single intravenous infusion of 300 milligrams of ofloxacin. Nau, R., *et al.* ..... (A) 137
Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Berning, S. E., *et al.* ..... (A) 625
Ofloxacin-containing combined drug reigmens in the treatment of lepromatous leprosy. Rao, P. S., *et al.* ..... (A) 138
[On antileprosy activity of China-made ofloxacin in nude mice.] Shen, J.-P., *et al.* ..... (A) 340
Oral absorption of ofloxacin administered together with aluminum. Sanchez Navarro, A., *et al.* ..... (A) 184
Selection of a gyrA mutant of *M. tuberculosis* resistant to fluoroquinolones during treatment with ofloxacin. Cambau, E., *et al.* ..... (A) 171

Pathology,
Effects of treatment on the histopathology of leprosy. Cree, I. A., *et al.* ..... (A) 476
Expression of a neurotrophic factor midkine in the spinal cord of leprosy. Goto, M., *et al.* ..... (A) 650
Intraocular pressure in leprosy patients without clinically apparent anterior segment pathology. Daniel, A. E., *et al.* ..... (A) 140
[Pathology of the feet in leprosy.] Terencio de las Aguas, J. ..... (A) 168
Persistence of lepromatous granuloma in clinically cured cases of leprosy. Desikan, P. and Desikan, K. V. ..... (O) 417
Pupil cycle time in leprosy patients without clincally apparent ocular pathology. Daniel, E. and Rao, P. S. A. ..... (O) 529
Tumour necrosis factor-alpha synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Khanolkar Young, S., *et al.* ..... (A) 327

Pefloxacin,
Pefloxacin in leprosy. Bharti, R. ..... (A) 311

Peroxidase,
Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance to *M. tuberculosis*. Heym, B., *et al.* ..... (A) 351
Mutations in the catalase-peroxidase gene from isoniazid resistant *M. tuberculosis* isolates. Altamirano, M., *et al.* ..... (A) 170

Persisters,
M. marinum persists in cultured mammalian cells in a temperature-restricted fashion. Ramakrishnan, L. and Falkow, S. ..... (A) 165

Phagocyte(s),
Altered expression of CD11/CD18 on the peripheral blood phagocytes of patients with tuberculosis. Yassin, R. J. and Hamblin, A. S. ..... (A) 157
Mycobacterial heat-shock protein 65 induces proinflammatory cytokines but does not activate human mononuclear phagocytes. Peetermans, W. E., *et al.* ..... (A) 153

Pharmacokinetic(s),
Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. Child, J., *et al.* ..... (A) 491

Stereospecific determination, chiral inversion *in vitro* and pharmacokinetics in humans of the enantiomers of thalidomide. Eriksen, T., *et al.* ..... (A) 469

Phenolic glycolipid(s),

[A seroepidemiological study of leprosy in the household contacts with ELISA using ND-O-BSA and PGL as antigens.] Li, W.-Z., *et al.* ..... (A) 341

Detection of antibodies against phenolic glycolipid-I (PGL-I), 35-kDa and 30-40-kDa components of *M. leprae* on the cerebrospinal fluid of leprosy patients. Patil, S. A., *et al.* ..... (A) 604

Enhanced response of serum IgG class of anti-PGL-I antibodies in leprosy patients during onset and following clinical remission of type 1 and type 2 reactions. Saha, K., *et al.* ..... (C) 105

The role of IgM antiphenolic glycolipid-I antibodies in assessing household contacts of leprosy patients in a low endemic area. Soares, D. J., *et al.* ..... (A) 332

Polymerase chain reaction (PCR),

[A case of tuberculosis verrucosa cutis diagnosed by polymerase chain reaction.] Ran, Y. P., *et al.* ..... (A) 356

A search for mycobacterial DNA in sarcoidosis using the polymerase chain reaction. Ghossein, R. A., *et al.* ..... (A) 174

Acid-fast bacilli from former leprosy regions in coastal Norway showing PCR positivity for *M. leprae*. Mostafa, H. M., *et al.* ..... (C) 97

Application of polymerase chain reaction for the detection of *M. leprae* DNA in specimens from treated leprosy patients. Rafi, A., *et al.* ..... (O) 42

Clinical utility of LSR/A16 gene for *M. leprae* detection in leprosy tissues using the polymerase chain reaction. Misra, N., *et al.* ..... (O) 35

Comparison of polymerase chain reaction with standard methods in the diagnosis of *M. tuberculosis* infection. Pietrzak, J., *et al.* ..... (A) 356

DNA of *M. tuberculosis* in formalin-fixed, paraffin-embedded tissue in tuberculosis and sarcoidosis detected by polymerase chain reaction. Popper, H. H., *et al.* ..... (A) 184

Detection of *M. leprae* by three-primer PCR. Richter, E., *et al.* ..... (A) 336

Detection of *M. leprae* infection by PCR. Wichitwechkarn, J., *et al.* ..... (A) 338

Development of a 23S rRNA-based PCR assay for the detection of mycobacteria. Verma, A., *et al.* ..... (A) 162

Direct genotypic detection of *M. tuberculosis* rifampin resistance in clinical specimens by using single-tube heminested PCR. Whelen, A. C., *et al.* ..... (A) 366

[Establishment of a PCR method by using the terminal repeated sequence of the gene encoded for 65 KDd antigen of *M. leprae*.] Li, T., *et al.* ..... (A) 612

Evaluation of PCR mediated DNA amplification in non-invasive biological specimens for subclinical detection of *M. leprae*. Santos, A. R., *et al.* ..... (A) 613

PCR amplification and restriction endonuclease analysis of a 65-kDa heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria. Steingrube, V. A., *et al.* ..... (A) 362

Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis. Kennedy, N., *et al.* ..... (A) 179

Rendering of mycobacteria safe for molecular diagnostic studies and development of a lysis method for strand displacement amplification and PCR. Zwadyk, P., Jr., *et al.* ..... (A) 164

Solid-phase hybridization capture of low-abundance target DNA sequences: aplication to the polymerase chain reaction detection of *M. paratuberculosis* and *M. avium* subsp. *silvaticum*. Millar, D. S., *et al.* ..... (A) 497

The superoxide dismutase gene, a target for detection and identification of mycobacteria by PCR. Zolg, J. W. and Philippi-Schulz, S. ..... (A) 191

Polynesia,

Chromosomal DNA fingerprinting analysis using the insertion sequence IS6110 and the repetitive element DR as strain specific markers for epidemiological study of tuberculosis in French Polynesia. Torrea, G., *et al.* ..... (A) 637

Prostaglandin,

The effect of prostaglandin E(2) and indomethacin on the cytotoxic response to mycobacterial antigens. Yuan, S. N., *et al.* ..... (A) 191

Prosthetic(s),
[Following up of 80 amputees of leprosy after fitting with artificial limbs.] Yu, B., *et al.* ...(A) 623

Protein(s),
A 46-kDa integral membrane protein from *M. leprae* resembles a number of bacterial and mammalian membrane transport proteins. Oskam, L., *et al.* ...(A) 613
A *M. leprae* gene encoding a fibronectin binding protein is used for efficient invasion of epithelial cells and Schwann cells. Schorey, J. S., *et al.* ...(A) 614
A *M. leprae*-specific gene encoding an immunologically recognized 45 kDa protein. De Wit, T. F. R., *et al.* ...(A) 477
Activation of protein kinase C by mycobacterial cord factor, trehalose 6-monomycolate, resulting in tumor necrosis factor alpha release in mouse lung tissues. Sueoka, E., *et al.* ...(A) 636
An HLA-DRw53-restricted T-cell epitope from a novel *M. leprae* protein antigen important to the human memory T-cell repertoire against *M. leprae*. Mustafa, A. S., *et al.* ...(A) 328
Antibody reactivity to mycobacterial 65 kDa heat shock protein: relevance to autoimmunity. Karopoulos, C., *et al.* ...(A) 479
Characterization of the gene encoding the immunodominant 35 kDa protein of *M. leprae*. Winter, N., *et al.* ...(A) 615
Clinical and histological discrepancies in diagnosis of ENL reactions classified by assessment of acute phase proteins SAA and CRP. Hussain, R., *et al.* ...(O) 222
Cloning and expression in *Escherichia coli* of DNA encoding a 60 kDa stress protein of *M. paratuberculosis*, the causative agent of Johne's disease. Colston, A., *et al.* ...(A) 348
Critical residues of the *M. leprae* LSR recombinant protein discriminate clinical activity in erythema nodosum leprosum reactions. Singh, S., *et al.* ...(A) 331
Dapsone-induced hemolytic anemia: effect of dapsone hydroxylamine on sulhydryl status, membrane skeletal proteins and morphology of human and rat erythrocytes. McMillan, D. C., *et al.* ...(A) 590
Differential T cell responses to mycobacteria-secreted proteins distinguish vaccination with bacille Calmette Guerin from infection with *M. tuberculosis*. Roche, P. W., *et al.* ...(A) 330
Effective vaccination of mice against *M. leprae* with density gradient subfractions of soluble *M. leprae* proteins: clues to active protein epitopes. Gelber, R. H., *et al.* ...(A) 164
Expression of the 18-kDa protein of *M. leprae* in *Saccharomyces cerevisiae*. Pinho, J. R. R., *et al.* ...(A) 336
Fibronectin-binding antigen 85 and the 10-kDa groES-related heat shock protein are the predominant Th-1 response inducers in leprosy contacts. Launois, P., *et al.* ...(A) 329
Identification and characterization of *M. paratuberculosis* recombinant proteins expressed in *E. coli*. Elsaatari, F. A. K., *et al.* ...(A) 173
Identification of *M. tuberculosis* DNA sequences encoding exported proteins by using phoA gene fusions. Lim, E. M., *et al.* ...(A) 354
Identification of a *M. leprae*-specific T-cell epitope on the 70 kDa heat shock protein. Roche, P. W., *et al.* ...(A) 154
Identification of an antigenic domain on *M. leprae* protein antigen 85B, which is specifically recognized by antibodies from patients with leprosy. Filley, E., *et al.* ...(A) 477
Identification of macrophage and stress-induced proteins of *M. tuberculosis*. Lee, B.-Y. and Horwitz, M. A. ...(A) 612
Immune responses of heat-shock protein 65 on *M. leprae* inoculated mice. Nomaguchi, H., *et al.* ...(A) 652
Immunoaffinity chromatographic isolation of a high molecular weight seroreactive protein from *M. leprae* cell sonicate. Deshpande, R. G., *et al.* ...(A) 608
Isolation of a 32 kDa *M. tuberculosis* protein by lectin affinity chromatography. Montano, L. F., *et al.* ...(A) 182
Isolation of a fibronectin-binding tryptic peptide from the antigen 85A protein of *M. bovis* BCG. Klegerman, M. E., *et al.* ...(A) 496
Isolation of a fibronectin-binding tryptic peptide from the antigen 85A protein of *M. bovis*. Klegerman, M. E., *et al.* ...(A) 335
Lack of cytotoxic activity against *M. leprae* 65-kD heat shock protein (hsp) in multibacillary leprosy patients. Delabarrera, S., *et al.* ...(A) 476

Limited restriction in the TCR-alpha beta V region usage of anti-specific clones–recognition of myelin basic protein (amino acids 84-102) and *M. bovis* 65-kDa heat shock protein (amino acids 3-13) by T cell clones established from PBMC of monozygotic twins and HLA-identical individuals. Hawes, G. E., *et al.* ..... (A) 351
Mapping of multiple HLA class II-restricted T-cell epitopes of the mycobacterial 70-kilodalton heat shock protein. Oftung, F., *et al.* ..... (A) 329
Mapping the *in vivo*-expressed proteins of *M. leprae*. Pessolani, M. C. V., *et al.* ..... (A) 652
Marked conservation of complementarity-determining region 3 of the beta-chain of TCRs recognizing a mycobacterial heat shock protein 60-derived peptide with strong sequence similarity to human heat shock protein 60. Goodall, J. C., *et al.* ..... (A) 601
Molecular mimicry: histone H3 and mycobacterial protein epitopes. Eriksen, N., *et al.* ..... (A) 494
Mouse cell lines expressing *M. leprae* heat-shock protein 65 kDa gene: lymphoproliferative responses to the cell lines. Nakanaga, K., *et al.* ..... (A) 651
Mycobacterial 65-kilodalton heat shock protein induced tumor necrosis factor alpha and interleukin 6, reactive nitrogen intermediates, and toxoplasmastatic activity in murine peritoneal macrophages. Peetermans, W. E., *et al.* ..... (A) 604
Mycobacterial heat-shock protein 65 induces proinflammatory cytokines but does not activate human mononuclear phagocytes. Peetermans, W. E., *et al.* ..... (A) 153
Non-major histocompatibility complex-restricted cytotoxic activity of blood mononuclear cells stimulated with secreted mycobacterial proteins and other mycobacterial antigens. Ravn, P. and Pedersen, B. K. ..... (A) 357
Nucleotide sequence of the 85B-protein gene of *M. bovis* BCG and *M. tuberculosis*. de Wit, M. Y. L., *et al.* ..... (A) 173
On the serum antibody against beta-glucuronidase binding protein (BGBP) among normal individuals and leprosy patients. Matsuo, E., *et al.* ..... (A) 650
PCR amplification and restriction endonuclease analysis of a 65-kDa heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria. Steingrube, V. A., *et al.* ..... (A) 362
Protection against tuberculosis by passive transfer with T cell clones recognizing mycobacterial heat shock protein 65. Silva, C. L., *et al.* ..... (A) 331
Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of *M. tuberculosis*. Horwitz, M. A., *et al.* ..... (A) 496
Recognition of a unique peptide epitope of the mycobacterial and human heat shock protein 65-60 antigen by T cells of patients with recurrent oral ulcers. Hasan, A., *et al.* ..... (A) 496
Rifampicin prevents the aggregation of neurotoxicity of amyloid beta protein *in vitro*. Tomiyama, T., *et al.* ..... (A) 187
T and B cell responses to mycobacterial 65-kDa heat-shock protein in sheep infected with *maedi visna* virus. Harkiss, G. D., *et al.* ..... (A) 478
T-cell activity against antigen-85 but not against the 18-kDa and 65-kDa heat shock proteins in the early stages of acquired immunity against *M. leprae*. Launois, P., *et al.* ..... (A) 151
T-cell determinants and antibody binding sites on the major mycobacterial secretory protein MPB59 of *M. bovis*. Roche, P. W., *et al.* ..... (A) 358
Tat protein from HIV-1 binds to *M. avium* via a bacterial integrin–effects on extracellular and intracellular growth. Denis, M. ..... (A) 173
[The use of S-100 protein to diagnosis of leprosy.] Shen, J. P., *et al.* ..... (A) 330
Two novel T cell epitope prediction algorithms based on MHC binding motifs; comparison of predicted and published epitopes from *M. tuberculosis* and HIV protein sequences. Meister, G. E., *et al.* ..... (A) 633
Vaccination with pure *M. leprae* proteins inhibits *M. leprae* multiplication in mouse foot pads. Gelber, R. H., *et al.* ..... (A) 148

Psychosocial,
[Changes of mood and mentality among leprosy patients.] Liao, J., *et al.* ..... (A) 320
Social problems of women leprosy patients–a study conducted in 2 urban leprosy centres in Delhi. Kaur, H. and Ramesh, V. .(A) 310
Sociocultural dimensions of leprosy in northwestern Botswana. Kumaresan, J. A. and Maganu, E. T. ..... (A) 586
[The importance of socio-cultural data concerning the accessibility of health care and

the observance of treatment in leprosy; the example of the Zarma in Niger.] Jaffre, Y. and Moumouni, A. ..... (A) 486
The psychosocial challenge: integration, dignity, and economic advancement. Law, A. S. ..... (A) 277

Rat(s),
Dapsone-induced hematologic toxicity; comparison of the methemoglobin-forming ability of hydroxylamine metabolites of dapsone in rat and human blood. Vage, C., *et al.* ..... (A) 318
Dapsone-induced hemolytic anemia: effect of dapsone hydroxylamine on sulhydryl status, membrane skeletal proteins and morphology of human and rat erythrocytes. McMillan, D. C., *et al.* ..... (A) 590
Dapsone-induced hemolytic anemia: role of glucose-6-phosphate dehydrogenase in the hemolytic response of rat erythrocytes to N-hydroxydapsone. Grossmann, S., *et al.* ..... (A) 588
Evidence that the biotransformation of dapsone and monoacetyldapsone to their respective hydroxylamine metabolites in rat liver microsomes is mediated by cytochrome P45 2C6/2C11 and 3A1. Vage, C. and Svensson, C. K. ..... (A) 139
Rapid induction of mRNA for nitric oxide synthase II in rat alveolar macrophages by intratracheal administration of *M. tuberculosis* and *M. avium*. Greenburg, S. S., *et al.* ..... (A) 495
The effect of mixed micellar systems, bile salt/fatty acids, on the solubility and intestinal absorption of clofazimine (B663) in the anaesthetised rat. O'Reilly, J. R., *et al.* ..... (A) 137

Reaction, leprosy,
Association of antibodies to *M. leprae* and nerve antigens with lepra reactions in leprosy patients. Cho, S.-N., *et al.* ..... (A) 647
Clinical and histological discrepancies in diagnosis of ENL reactions classified by assessment of acute phase proteins SAA and CRP. Hussain, R., *et al.* ..... (O) 222
Critical residues of the *M. leprae* LSR recombinant protein discriminate clinical activity in erythema nodosum leprosum reactions. Singh, S., *et al.* ..... (A) 331
Cyclosporin A treatment in reversal reaction. Chin-A-Lien, R. A. M., *et al.* ..... (A) 472
[Early lesions in disseminated reactional cases.] Opromolla, D. V. A. and Brasil Filho, A. A. ..... (A) 597
Enhanced response of serum IgG class of anti-PGL-I antibodies in leprosy patients during onset and following clinical remission of type 1 and type 2 reactions. Saha, K., *et al.* ..... (C) 105
Evaluation of chemiluminescence, procoagulant activity and antigen presentation by monocytes from lepromatous leprosy patients with or without reactional episodes. Santos, D. O., *et al.* ..... (A) 154
Field evaluation of WHO-MDT of fixed duration at ALERT, Ethiopia: the AMFES project–II. Reaction and neuritis during and after MDT in PB and MB leprosy patients. de Rijk, A. J., *et al.* ..... (A) 312
Incidence of late lepra reaction among multibacillary leprosy patients after MDT. Vijayakumaran, P., *et al.* ..... (O) 18
[On tuberculoid reactions.] Opromolla, D. V. A., *et al.* ..... (A) 597
Pathogenesis of generalized nodular type I reaction in a borderline leprosy patient. Jayakumar, J., *et al.* ..... (A) 319
Reactions in leprosy: an epidemiological study of 386 patients in west Nepal. van Brakel, W. H., *et al.* ..... (A) 144
[Relapse or reversal reaction?]. Opromolla, D. V. A. ..... (A) 596
[Sulfone syndrome and reversal reaction.] Opromolla, D. V. A. and Fleury, R. N. ..... (A) 597
Tumour necrosis factor-alpha synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Khanolkar Young, S., *et al.* ..... (A) 327
[Type 1 reactions in borderline tuberculoid hanseniasis during multidrug therapy: time of appearance of nerve involvement.] de Carvalho, M. L. R., *et al.* ..... (A) 594
Type 1 reactions in leprosy, neuritis and steroid therapy: the impact of the human immunodeficiency virus. Bwire, R. and Kawuma, H. J. S. ..... (A) 135

Rehabilitation,
Advantages, indications and the manifesting of melted PVC waterpipe splints. Theuvenet, W. J., *et al.* ..... (A) 344
Changing horizon of rehabilitation. Gokhale, S. D. ..... (A) 343
Electrophysiological correlates of hanseniasis. Ramakrishnan, A. G. and Srinivasan, T. M. ..... (O) 395

Rehabilitation of the Hansen's disease patient: past, present and future. Brand, P. W. .....(A) 272
Rehabilitation research at Carville today. Giurintano, D. J. .....(A) 275
Workshop on Prevention of Disabilities and Physical Rehabilitation of Leprosy Patients. . (N) 465

Relapse(s),
Clinical features and diagnosis of relapses in leprosy. Ramu, G. .....(A) 591
Epidemiological aspects of relapses in leprosy. Ponnighaus, J. M. and Sterne, J. A. ....(A) 591
Features of relapse in paucibacillary leprosy after multidrug therapy. Naafs, B. .....(A) 590
Histopathological features of relapsed leprosy. Job, C. K. .....(A) 589
Immunological aspects of relapse in leprosy. Sengupta, U. .....(A) 592
Issues in evaluating information on relapse in leprosy. Daumerie, D. and Pannikar, V. ....(A) 587
Microbiological aspects of relapse in leprosy. Katoch, V. M. .....(A) 611
Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Jamet, P., *et al.* .....(O) 195
Relapse following various types of multidrug therapy in multibacillary leprosy. Waters, M. F. R. .....(A) 470
Relapse of *M. leprae* infection with ocular manifestations. Carus, N. H., *et al.* .....(A) 472
[Relapse of leprosy after MDT and after DDS plus RMP.] Zhou, X. .....(A) 593
[Relapse or reversal reaction?] Opromolla, D. V. A. .....(A) 596
Relapse with multibacillary leprosy caused by rifampicin sensitive organisms following paucibacillary multidrug therapy. Soares, D., *et al.* .....(A) 591
Relapse, reactivation or reinfection? Desikan, K. V. .....(A) 587
Relapses during long-term follow up with drug-sysceptible *M. leprae* among multibacillary leprosy patients treated with multidrug therapy regimens; case reports. Thomas, A., *et al.* .....(O) 391
Risk of relapse in leprosy. WHO Leprosy Unit. .....(A) 592
Treatment of relapsed leprosy. Jacobson, R. R. .....(A) 589

Rifampin,
Activity of combinations of dapsone, rifampin, minocycline, clarithromycin, and sparfloxacin against *M. leprae*-infected mice. Gelber, R. H., *et al.* .....(O) 259
Characterization of rifampin resistance in pathogenic mycobacteria. Williams, D. L., *et al.* .....(A) 163
Comparison of activities of rifapentine and rifampin against *M. tuberculosis* residing in human macrophages. Mor, N., *et al.* .....(A) 633
Detection of a genetic locus encoding resistance to rifampin in mycobacterial cultures in clinical specimens. Hunt, J. M., *et al.* .....(A) 177
Detection of rifampin-resistant bacteria using DNA probes for precursor rRNA. Britschgi, T. B. and Cangelosi, G. A. .....(A) 607
Direct genotypic detection of *M. tuberculosis* rifampin resistance in clinical specimens by using single-tube heminested PCR. Whelen, A. C., *et al.* .....(A) 366
Early detection of rifampin in human nerve tissue after an oral dose of 600 milligrams. Guebre Xabier, M., *et al.* .....(A) 588
Evidence for a ppGpp-binding site on *Escherichia coli* RNA polymerase: proximity relationship with the rifampicin binding domain. Reddy, P. S., *et al.* .....(A) 358
"Flu" syndrome due to rifampin; experience with four cases. Dhar, S., *et al.* .....(E) 92
"Flu" syndrome on monthly rifampin dose; first case reported from Yemen. Al-Samie, A. R. and Al-Qubati, Y. .....(C) 574
Genotypic detection of *M. tuberculosis* rifampin resistance: comparison of single-strand conformation polymorphism and dideoxy fingerprinting. Felmlee, T. A., *et al.* .....(A) 609
Isolation of the gene for the beta subunit of RNA polymerase from rifampicin-resistant *M. tuberculosis* and identification of new mutations. Donnabella, V., *et al.* .....(A) 349
Misdiagnosis of Cushing's syndrome in a patient receiving rifampicin therapy for tuberculosis. Terzolo, M., *et al.* .....(A) 475
Molecular basis of rifampin resistance in *M. leprae*. Honore, N. and Cole, S. T. .....(A) 334
Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence *in-vitro* activity of rifamycins in rifampicin-resistant *M. tuberculosis*. Bodmer, T., *et al.* .....(A) 468
Neuritis and rifampicin. Salafia, A. and De Geiking, I. .....(A) 475
Oral desensitization to rifampin and ethambutol in mycobacterial disease. Matz, J., *et al.* .....(A) 137

Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for *M. avium-intracellulare* infection. Wallace, R. J., *et al.* ..... (A) 470

Relapse with multibacillary leprosy caused by rifampicin sensitive organisms following paucibacillary multidrug therapy. Soares, D., *et al.* ..... (A) 591

Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation. Dabbs, E. R., *et al.* ..... (A) 482

Rifabutin for the treatment of a newly diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Gonzalez-Montaner, L. J., *et al.* ..... (A) 631

Rifampicin prevents the aggregation of neurotoxicity of amyloid beta protein *in vitro*. Tomiyama, T., *et al.* ..... (A) 187

The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol and rifampin, on *M. avium* complex bacteremia in patients with AIDS. Kemper, C. A., *et al.* ..... (A) 178

Rifamycin(s),

Activities of benzoxazinorifamycin KRM 1648 and ethambutol against *M. avium* complex *in vitro* and in macrophages. Inderlied, C. B., *et al.* ..... (A) 178

Activity of KRM-1648, a new benzoxazinorifamycin, against *M. tuberculosis* in a murine model. Klemens, S. P., *et al.* ..... (A) 180

In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against *M. leprae*. Dhople, A. M. and Ibanez, M. A. ..... (A) 608

In vitro and *in vivo* anti-*M. leprae* activity of benzoxazinorifamycin, KRM-1648, in combination with other antimicrobials and biological response modifiers. Saito, H., *et al.* ..... (A) 653

Inhibition of the multiplication of *M. leprae* in nude mice by intermittent administration of a new rifamycin derivative, 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin (KRM-1648) combined with sparfloxacin. Gidoh, M., *et al.* ..... (A) 484

Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence *in-vitro* activity of rifamycins in rifampicin-resistant *M. tuberculosis*. Bodmer, T., *et al.* ..... (A) 468

The *in vitro* activities of novel benzoaxinorifamycins against *M. leprae*. Dhople, A. M. and Ibanez, M. A. ..... (A) 587

Sarcoidosis,

A search for mycobacterial DNA in sarcoidosis using the polymerase chain reaction. Ghossein, R. A., *et al.* ..... (A) 174

DNA of *M. tuberculosis* in formalin-fixed, paraffin-embedded tissue in tuberculosis and sarcoidosis detected by polymerase chain reaction. Popper, H. H., *et al.* ..... (A) 184

Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. Carlesimo, M., *et al.* ..... (A) 626

Screening,

[A preliminary study on screening antileprosy Chinese herbs with CAMS-A as an indicator.] Wu, Q.-X., *et al.* ..... (A) 339

Case report of leprosy and a trial of screenings for the family members in Ecuador. Hosokawa, A., *et al.* ..... (A) 595

Community-based tuberculin screening in Montreal: a cost outcome description. Adhikari, N. and Menzies, R. ..... (A) 623

Development of an *in vitro* drug screening system for *M. leprae* based on the determination of the intrabacterial sodium-to-potassium ratio of individual bacterial organisms. Wiese, M., *et al.* ..... (A) 338

Evaluation of modified lepro-aggultination as screening test for leprosy. Thawani, G., *et al.* ..... (A) 332

Screening for peripheral neuropathy in patients with leprosy. Grimaud, J., *et al.* ..... (A) 473

Senegal,

[Status of the integration of leprosy control with the general health services in Senegal.] Sylla, P. M. ..... (A) 586

5th Annual course offered by Institut de Leprologie Appliquee de Dakar. ..... (N) 308

Sensation(s),
An unusual presentation of recurrent corneal abrasion in a lepromatous patient with impaired corneal sensation. Daniel, E. and Brand, M. E. ..... (E) 450
Assessment of the methods available for testing sensation in leprosy patients in a rural setting. Owen, B. M. and Stratford, C. J. ..... (A) 474
Circulation and sensation at the fingertips of claw hands. Abbot, N. C., *et al.* ..... (A) 318
Sensory functions in limbs of normal persons and leprosy patients with peripheral trunk damage. Malaviya, G. N. *et al.* ..... (A) 168
The predictive value of sensation testing in the development of neuropathic ulceration on the hands of leprosy patients. Kuipers, M. and Schreuders, T. ..... (A) 167
Toward restoring sensibility in anesthetic extremities of leprosy patients. Malaviya, G. N. ..... (A) 622

Serodiagnosis,
Application of recombinant 85 complex of *M. leprae* for the serodiagnosis of leprosy. Suzuki, Y., *et al.* ..... (A) 657
Comment: the serodiagnosis of leprosy. Gonzalez, A. B. and Gonzalez-Abreu, E. ..... (A) 478
Serology of leprosy. Klatser, P. R. ..... (A) 479

Serum,
[A preliminary study of SDS-PAGE standardization and serum spectrum of patients with leprosy.] Xia, L.-P., *et al.* ..... (A) 332
Biometals in skin and sera of leprosy patients and their correlation to trace element contents of *M. leprae* and histological types of the disease; a comparative study with cutaneous tuberculosis. Jain, A., *et al.* ..... (O) 249
Enhanced response of serum IgG class of anti-PGL-I antibodies in leprosy patients during onset and following clinical remission of type 1 and type 2 reactions. Saha, K., *et al.* ..... (C) 105
Hypertriglyceridemic serum, a very low density lipoprotein, and iron enhance *M. avium* replication in human macrophages. Douvas, G. S., *et al.* ..... (A) 349
Identification and purification of armadillo (*Dasypus novemcinctus*) immunoglobulins: preparation of specific antisera to evaluate the immune response in these animals. Santos-Argumedo, L., *et al.* ..... (O) 56
Identification of IgM as the leprosy patient serum factor responsible for rapid sedimentation of formolized sheep erythrocytes. Panunto-Castelo, A. and Roque-Barreira, M.-C. ..... (O) 231
Immunoprecipitation of mycobacterial antigens with sera from patients with leprosy. Kode, J. A., *et al.* ..... (A) 327
On the serum antibody against beta-glucuronidase binding protein (BGBP) among normal individuals and leprosy patients. Matsuo, E., *et al.* ..... (A) 650
Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for *M. avium-intracellulare* infection. Wallace, R. J., *et al.* ..... (A) 470

Skin,
Biometals in skin and sera of leprosy patients and their correlation to trace element contents of *M. leprae* and histological types of the disease; a comparative study with cutaneous tuberculosis. Jain, A., *et al.* ..... (O) 249
Biopsy of Skin Lesions in Leprosy; Stains, Pathogenesis and Classification by Kyoshi Harada. Scollard, D. M. ..... (B) 578
Cell-mediated immunity in skin tuberculosis. Ramesh, V., *et al.* ..... (C) 293
[Comparative evaluation of AAFB from the nose and skin of LL patients.] Prabhakar, M. C. ..... (A) 336
Demonstration of mycobacterial antigens in skin biopsies from suspected leprosy cases in the absence of bacilli. Barbosa, A. D., *et al.* ..... (A) 146
[Determination of distribution and density of *M. leprae* in the skin of leprosy patients.] Xie, Y.-L., *et al.* ..... (A) 333
Functional heterogeneity among CD4+ T-cell clones from blood and skin lesions of leprosy patients, identification of T cell clones distinct from Th0, Th1 and Th2. Howe, R. C., *et al.* ..... (A) 602
[Histopathology of the skin in LL patients after completion of treatment.] Zhou, X.-T., *et al.* ..... (A) 333

The delayed-type hypersensitivity reaction is dependent on IL8; inhibition of a tuberculin skin reaction by an anti-IL-8 monoclonal antibody. Larsen, C. G., *et al.* .....(A) 603
Tumour necrosis factor-alpha synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Khanolkar Young, S., *et al.* .....(A) 327

Skin smear(s),
Classification of leprosy cases under field conditions in Bangladesh. I. Usefulness of skin-smear examinations. Groenen, G., *et al.* .....(A) 595

Skin test(s),
Boosting of tuberculin sensitivity among Southeast Asian refugees. Cauthen, C. M., *et al.* .....(A) 171
Community-based tuberculin screening in Montreal: a cost outcome description. Adhikari, N. and Menzies, R. .....(A) 623
Evaluation of tuberculin reactivity in BCG-immunized siblings. Sepulveda, R. L., *et al.* ...(A) 185
The delayed-type hypersensitivity reaction is dependent on IL8; inhibition of a tuberculin skin reaction by an anti-IL-8 monoclonal antibody. Larsen, C. G., *et al.* .....(A) 603
Ultraviolet radiation decreases the granulomatous response to lepromin in humans. Cestari, T. F., *et al.* .....(A) 599

Southeast Asia,
Boosting of tuberculin sensitivity among Southeast Asian refugees. Cauthen, C. M., *et al.* .....(A) 171

Spain,
1995 Fontilles coursos. .....(N) 308

Stain(s),
Biopsy of Skin Lesions in Leprosy; Stains, Pathogenesis and Classification by Kyoshi Harada. Scollard, D. M. .....(B) 578
Comparative assessment of viability of *M. leprae* by mouse foot pad and fluorescent staining techniques. Sreevatsa and Katoch, V. M. .....(A) 337
Phenolic acridine orange fluorescent stain for mycobacteria. Smithwick, R. W., *et al.* ..(A) 636

Steroid(s),
Diabetic ketoacidosis following steroid therapy in a rural leprosy hospital. Edward, V. K. .....(C) 289
Ocular leprosy: do steroids complicate matters? Daniel, E., *et al.* .....(C) 115
Thalidomide as replacement for steroids in immunosuppression after lung transplantation. Uthoff, K., *et al.* .....(A) 364
Type 1 reactions in leprosy, neuritis and steroid therapy: the impact of the human immunodeficiency virus. Bwire, R. and Kawuma, H. J. S. .....(A) 135

Streptomycin,
Cloning and sequence analysis of the rpsL and rpsG genes of *M. smegmatis* and characterization of mutations causing resistance to streptomycin. Kenney, T. J. and Churchward, G. .(A) 179
Novel mutation in 16S rRNA associated with streptomycin dependence in *M. tuberculosis*. Honore, N., *et al.* .....(A) 352

Subclinical,
Evaluation of PCR mediated DNA amplification in non-invasive biological specimens for subclinical detection of *M. leprae*. Santos, A. R., *et al.* .....(A) 613
[Study of a suspected case of subclinical leprosy infection.] Rodriguez Barreras, M., *et al.* .....(A) 474

Sulfone(s),
[Prevalence of sulfone resistance in patients with hanseniasis in the city of Bauru, state of Sao Paulo.] Costa, H. C., *et al.* .....(A) 312
[Sulfone syndrome and reversal reaction.] Opromolla, D. V. A. and Fleury, R. N. .....(A) 597
[Thrombocytopenia associated with the use of sulfones?]. dos Santos, S. N. M. B., *et al.* ...(A) 313
[Variation in the concentration of hemoglobin in the dosage of sulfone used to treat hanseniansis.] dos Santos, S. N. M. B., *et al.* .....(A) 136

Superoxide,
The superoxide dismutase gene, a target for detection and identification of mycobacteria by PCR. Zolg, J. W. and Philippi-Schulz, S. ..... (A) 191

Suppression,
Macrophage-T cell interaction in experimental mycobacterial infection; selective regulation of co-stimulatory molecules on *Mycobacterium*-infected macrophages and its implication in the suppression of cell-mediated immune response. Saha, B., *et al.* ... (A) 359
Suppression of cytokine production by supernatants from CD8+ lymphocytes activated by mycobacterial fractions: the role of interleukins 4 and 6. Wadee, A. A., *et al.* .... (A) 156

Surgery,
Intraoperative electroneurodiagnostics to detect a second granuloma in the cubital area of median nerves affected by leprosy: a new approach to prevent incomplete surgery. Turkof, E., *et al.* ..... (O) 409
Vascular surgery of the posterior tibial compartment for plantar ulceration in leprosy. Arolkar, S. K. and Antia, N. H. ..... (A) 488

Sweden,
Infection with *M. malmoense* in Sweden; report of 221 cases. Henriques, B., *et al.* .... (A) 175

Switzerland,
Leprosy upgraded within WHO. ..... (N) 130
TDR faces no-growth budget. ..... (N) 309
WHO Chemotherapy of Leprosy; report of a WHO Study Group. ..... (N) 130
WHO Report of the Monitoring and Evaluation Meeting (1994). ..... (N) 131

Syphilis,
Sir James Simpson: leprosy and syphilis. Turk, J. L. ..... (A) 135

Testing,
Assessment of the methods available for testing sensation in leprosy patients in a rural setting. Owen, B. M. and Stratford, C. J. ..... (A) 474
Evaluation of Etest for rapid susceptibility testing of *M. chelonae* and *M. fortuitum*. Hoffner, S. E., *et al.* ..... (A) 176
Field comparison of 10-g and 1-g filaments for the sensory testing of hands in Ethiopian leprosy patients. de Rijk, A. J. and Byass, P. ..... (A) 319
Rapid susceptibility testing of *M. tuberculosis* (H37Ra) by flow cytometry. Norden, M. A., *et al.* ..... (A) 498
Testing for antibody to human immunodeficiency virus type 1 in a population in which mycobacterial diseases are endemic. Sterne, J. A. C., *et al.* ..... (A) 620
The predictive value of sensation testing in the development of neuropathic ulceration on the hands of leprosy patients. Kuipers, M. and Schreuders, T. ..... (A) 167

Thalidomide,
Characterization and crystal structure of two polymorphic forms of racemic thalidomide. Reepmeyer, J. C., *et al.* ..... (A) 139
Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysical studies to detect thalidomide neuropathy. Gardner-Medwin, J. M. M., *et al.* ..... (A) 350
Effect of thalidomide on the cellular immune response in experimental tuberculosis in mice. Moreira, A. L., *et al.* ..... (A) 651
Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5, 6-dimethylxanthenone-4 acetic acid. Ching, L. M., *et al.* ..... (A) 627
Embryotoxic effects of thalidomide derivatives in the non human primate *Callithrix jacchus*. 4. Teratogenicity of afag/kg doses of the EM12 enantiomers. Heger, W., *et al.* ..... (A) 175
Evidence for teratogenicity of thalidomide using congenic and recombinant inbred rat strains. Bila, V. and Kren, V. ..... (A) 171
Exacerbation of acetaminophen hepatotoxicity by thalidomide and protection by nicotinic acid amide. Kroger, H., *et al.* ..... (A) 632
High-performance liquid chromatographic assay of plasma thalidomide: stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease. Boughton, B. J., *et al.* ..... (A) 490

Immunostimulatory effect of thalidomide in normal C57BL/6 mice is compatible with stimulation of a highly connected central immune system. Arala Chaves, M., *et al.* (A) 345
Rapid and sensitive determination of thalidomide in human plasma by high performance liquid chromatography. Delon, A., *et al.* (A) 473
Stereospecific determination, chiral inversion *in vitro* and pharmacokinetics in humans of the enantiomers of thalidomide. Eriksen, T., *et al.* (A) 469
Thalidomide and the immune system 4. Down-regulation of the CD26 receptor, probably involved in the binding of HIV components to T cells in primate. Neubert, R., *et al.* (A) 355
Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Nogueira, A. C., *et al.* (A) 152
Thalidomide as replacement for steroids in immunosuppression after lung transplantation. Uthoff, K., *et al.* (A) 364
Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. McCormick, P. A., *et al.* (A) 181
Thalidomide as treatment of refractory aphthous ulceration to human immunodeficient virus infection. Paterson, D. L., *et al.* (A) 356
Thalidomide does not perturb CD2, CD4, CD5, CD8, HLA-DR, or HLA-A, B, C molecules *in vitro* on the membranes of cells with immune potential. Shannon, E. J., *et al.* (A) 330
Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Silva, S. R. B., *et al.* (A) 186
Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Cole, C. H., *et al.* (A) 492
Thalidomide is agonistic to the synthesis of IL-2 and it can be agonistic or antagonistic to the synthesis of TNF-alpha. Shannon, E. J. and Sandoval, F. (A) 654
Thalidomide treatment reduces tumor necrosis factor-alpha production and enhances weight gain in patients with pulmonary tuberculosis. Tramontana, J. M., *et al.* (A) 638
Thalidomide-induced polyamine acylation: a new insight into the acylation mechanism. Audit, C. O. (A) 346
Thalidomide-resistant HIV-associated aphthae successfully treated with granulocyte colony-stimulating factor. Manders, S. M., *et al.* (A) 632
The effects of thalidomide treatment on autoimmune-prone NZB and MRL mice are consistent with stimulation of the central immune system. 2. Vilanova, M., *et al.* (A) 364
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. McHugh, S. M., *et al.* (A) 327
Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. Carlesimo, M., *et al.* (A) 626
[Use of thalidomide in dermatology.] Poenca, N. G. (A) 315

Therapy (see also **Chemotherapy** and **Multidrug therapy**),
Diabetic ketoacidosis following steroid therapy in a rural leprosy hospital. Edward, V. K. (C) 289
Effective application of modern immunotherapeutic measures in the treatment of leprosy. Kaplan, G. (A) 280
[Effects of overall therapy on leprous plantar ulcers.] Tan, W. P. (A) 344
Initial clarithromycin monotherapy for *M. avium-intracellulare* complex lung disease. Wallace, R. J., *et al.* (A) 190
[Leprosy incidence during monotherapy and multidrug therapy in Camaguey, Cuba, 1984-1993.] Carrazana Hernandez, G. B. and Ferra Torres, T. M. (A) 486
Low-dose desamethasone as adjunctive therapy for disseminated *M. avium* complex infections in AIDS patients. Wormser, G. P., *et al.* (A) 190
M. avium complex: advances in therapy. Havlir, D. V. (A) 350
Misdiagnosis of Cushing's syndrome in a patient receiving rifampicin therapy for tuberculosis. Terzolo, M., *et al.* (A) 475
Oral zinc therapy and recurrent erythema nodosum leprosum: a clinical study. Mahajan, P. M., *et al.* (A) 142
Rapid development of resistance to clarithromycin following monotherapy for disseminated *M. chelonae* infection in a heart transplant patient. Tebas, P., *et al.* (A) 363

Selection of clarithromycin-resistant *M. avium* complex during combined therapy using the beige mouse model. Lounis, N., *et al.* ..... (A) 354
Stationery phase induction in *Escherichia coli*–new targets for antimicrobial therapy? Smith, A. W. ..... (A) 484
Type 1 reactions in leprosy, neuritis and steroid therapy: the impact of the human immunodeficiency virus. Bwire, R. and Kawuma, H. J. S. ..... (A) 135
WHO Chemotherapy of Leprosy; report of a WHO Study Group. ..... (N) 130

Tissue(s),
Activation of protein kinase C by mycobacterial cord factor, trehalose 6-monomycolate, resulting in tumor necrosis factor alpha release in mouse lung tissues. Sueoka, E., *et al.* ..... (A) 636
An improved method for the species-specific assessment of mycobacteria in routinely formalin-fixed and paraffin embedded tissues. Richter, E., *et al.* ..... (A) 336
Clinical utility of LSR/A16 gene for *M. leprae* detection in leprosy tissues using the polymerase chain reaction. Misra, N., *et al.* ..... (O) 35
DNA of *M. tuberculosis* in formalin-fixed, paraffin-embedded tissue in tuberculosis and sarcoidosis detected by polymerase chain reaction. Popper, H. H., *et al.* ..... (A) 184
Early detection of rifampin in human nerve tissue after an oral dose of 600 milligrams. Guebre Xabier, M., *et al.* ..... (A) 588
Growth-deficient mycobacteria in patients with AIDS: diagnosis by analysis of DNA amplified from blood or tissue. Emler, S., *et al.* ..... (A) 494
Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. Child, J., *et al.* ..... (A) 491

Training,
1995 Leprosy training courses at RLT&RI. ..... (N) 463
ALERT 1996 Training Calendar. ..... (N) 462
Use of a facility-based assessment in the evaluation of a comprehensive leprosy training program in Nepal. Roos, B. R. and van Brakel, W. H. ..... (O) 552
Workshop on health education and training materials held. ..... (N) 464

Transmission,
Experimental leprosy in monkeys. I. Sooty mangabey monkeys: transmission, susceptibility, clinical and pathological findings. Gormus, B. J., *et al.* ..... (A) 616
Restriction fragment length polymorphism of *M. tuberculosis* strains isolated from Greenland during 1992: evidence of tuberculosis transmission between Greenland and Denmark. Yang, Z. H., *et al.* ..... (A) 366
Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: a molecular epidemiologic assessment. Shafer, R. W., *et al.* ..... (A) 360

Transplantation,
Thalidomide as replacement for steroids in immunosuppression after lung transplantation. Uthoff, K., *et al.* ..... (A) 364
Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Cole, C. H., *et al.* ..... (A) 492

Trial(s),
Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi. Ponnighaus, J. M. and Boerrigter, G. ..... (O) 1
Case report of leprosy and a trial of screenings for the family members in Ecuador. Hosokawa, A., *et al.* ..... (A) 595
Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Silva, S. R. B., *et al.* ..... (A) 186

Trinidad,
A survey to determine the prevalence of leprosy in a community of East Trinidad. Suite, M., *et al.* ..... (A) 167

Tuberculin,
Boosting of tuberculin sensitivity among Southeast Asian refugees. Cauthen, C. M., *et al.* ..... (A) 171

Community-based tuberculin screening in Montreal: a cost outcome description. Adhikari, N. and Menzies, R. ....(A) 623
Evaluation of tuberculin reactivity in BCG-immunized siblings. Sepulveda, R. L., *et al.* ...(A) 185
The delayed-type hypersensitivity reaction is dependent on IL8; inhibition of a tuberculin skin reaction by an anti-IL-8 monoclonal antibody. Larsen, C. G., *et al.* .....(A) 603

Tuberculoid leprosy,
Variants of HLA-DR2/DR51 group haplotypes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis in Asian Indians. Mehra, N. K., *et al.* .....(O) 241

Tuberculosis,
A case control study on human immunodeficiency virus-1 (HIV-1) infection as a risk factor for tuberculosis and leprosy in western Kenya. Orege, P. A., *et al.* .....(A) 487
[A case of tuberculosis verrucosa cutis diagnosed by polymerase chain reaction.] Ran, Y. P., *et al.* .....(A) 356
AIDS and tuberculosis/leprosy in Nigeria: the urbanisation factor. Awofeso, N. .....(A) 617
Altered expression of CD11/CD18 on the peripheral blood phagocytes of patients with tuberculosis. Yassin, R. J. and Hamblin, A. S. .....(A) 157
Amplification of DNA of *M. tuberculosis* from peripheral blood of patients with pulmonary tuberculosis. Schluger, N. W., *et al.* .....(A) 185
Analysis of the population structure of *M. tuberculosis* in Ethiopia, Tunisia, and The Netherlands; usefulness of DNA typing for global tuberculosis epidemiology. Hermans, P. W. M., *et al.* .....(A) 631
Biometals in skin and sera of leprosy patients and their correlation to trace element contents of *M. leprae* and histological types of the disease; a comparative study with cutaneous tuberculosis. Jain, A., *et al.* .....(O) 249
Cell-mediated immunity in skin tuberculosis. Ramesh, V., *et al.* .....(C) 293
Chromosomal DNA fingerprinting analysis using the insertion sequence IS6110 and the repetitive element DR as strain specific markers for epidemiological study of tuberculosis in French Polynesia. Torrea, G., *et al.* .....(A) 637
Circulating immune complexes in patients with advanced tuberculosis and their association with autoantibodies and reduced CD4+ lymphocytes. Dlugovitzky, D., *et al.* .....(A) 628
Comparison of the immune response against *M. tuberculosis* antigens between a group of patients with active pulmonary tuberculosis and healthy household contacts. Torres, M., *et al.* .....(A) 155
Cytokine regulation of disease progression in leprosy and tuberculosis. Kaplan, G. ....(A) 326
Delayed hypersensitivity and HLA in smear-positive pulmonary tuberculosis. Bothamley, G. H., *et al.* .....(A) 490
Effect of thalidomide on the cellular immune response in experimental tuberculosis in mice. Moreira, A. L., *et al.* .....(A) 651
Elevated interleukin-2 receptor level in patients with active pulmonary tuberculosis and the changes following antituberculosis chemotherapy. Chan, C. H. S., *et al.* .....(A) 491
Emergence of fluoroquinolone-resistant tuberculosis in New York City. Sullivan, E. A., *et al.* .....(A) 637
Euthyroid sick syndrome in pulmonary tuberculosis before and after treatment. Chow, C. C., *et al.* .....(A) 627
Evidence of a superantigen in human tuberculosis. Ohmen, J. D., *et al.* .....(A) 153
Exacerbation of acute and chronic murine tuberculosis by administration of tumor necrosis factor receptor-expressing adenovirus. Adams, L. B., *et al.* .....(A) 488
Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. Raviglione, M. C., *et al.* .....(A) 357
[Glomerulonephritis due to immune complexes associated with pulmonary tuberculosis.] Villar, I., *et al.* .....(A) 189
Immunotherapy with *M. vaccae* as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Onyebujoh, P. C., *et al.* .....(A) 498
Implications of multidrug resistance for the future of short course chemotherapy of tuberculosis: a molecular study. Heym, B., *et al.* .....(A) 176
Induction of immunity against experimental tuberculosis with mycobacterial mannophosphoinositides encapsulated in liposomes containing lipid A. Singh, A. P. and Khuller, G. K. .....(A) 361

Misdiagnosis of Cushing's syndrome in a patient receiving rifampicin therapy for tuberculosis. Terzolo, M., *et al.* ..... (A) 475
National trends in the concurrence of tuberculosis and acquired immunodeficiency syndromw. Burwen, D. R., *et al.* ..... (A) 625
Outbreak of multi-drug-resistant tuberculosis in a New York state prison. Valway, S. E., *et al.* ..... (A) 187
Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis. Kennedy, N., *et al.* ..... (A) 179
Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Chapuis, L., *et al.* ..... (A) 347
Protection against tuberculosis by passive transfer with T cell clones recognizing mycobacterial heat shock protein 65. Silva, C. L., *et al.* ..... (A) 331
Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of *M. tuberculosis.* Horwitz, M. A., *et al.* ..... (A) 496
RSM Conference on Tuberculosis 2000. ..... (N) 584
Relationship between bacille Calmette-Guerin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Brewer, T. F. and Colditz, G. A. ..... (A) 491
Restriction fragment length polymorphism of *M. tuberculosis* strains isolated from Greenland during 1992: evidence of tuberculosis transmission between Greenland and Denmark. Yang, Z. H., *et al.* ..... (A) 366
Rifabutin for the treatment of a newly diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Gonzalez-Montaner, L. J., *et al.* ..... (A) 631
Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis. Dannenberg, A. M. ..... (A) 348
T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infections. Zhang, M., *et al.* ..... (A) 333
T-cell-epitope mapping of the major secreted mycobacterial antigen AG85A in tuberculosis and leprosy. Launois, P., *et al.* ..... (A) 151
Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: a molecular epidemiologic assessment. Shafer, R. W., *et al.* ..... (A) 360
Thalidomide treatment reduces tumor necrosis factor-alpha production and enhances weight gain in patients with pulmonary tuberculosis. Tramontana, J. M., *et al.* ..... (A) 638
The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993. McKenna, M. T., *et al.* ..... (A) 497
The use of high-efficiency particulate air-filter respirators to protect hospital workers from tuberculosis–a cost effective analysis. Adal, K. A., *et al.* ..... (A) 169
Tuberculosis control strategies: the cost of particulate respirators. Nettleman, M. D., *et al.* ..... (A) 355
Tuberculosis: is the past once again prologue? Comstock, G. W. ..... (A) 348
Tuberculosis; Pathogenesis, Protection and Control, Barry R. Bloom, ed. ..... (B) 122
U.S.-Japan Cooperative Medical Science Program, Thirtieth U.S.-Japan Tuberculosis Research Conference and Tuberculosis/Leprosy Symposium, Fort Collins, Colorado, 1995. ..... (A) 641
Use of various genetic markers in differentiation of *M. bovis* strains from animals and humans and for studying epidemiology of bovine tuberculosis. van Soolingen, D., *et al.* ..... (A) 188
Variants of HLA-DR2/DR51 group haplotypes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis in Asian Indians. Mehra, N. K., *et al.* ..... (O) 241
Vegetarian diet as a risk factor for tuberculosis in immigrant south London Asians. Strachan, D. P., *et al.* ..... (A) 362

Tunisia,
Analysis of the population structure of *M. tuberculosis* in Ethiopia, Tunisia, and The Netherlands; usefulness of DNA typing for global tuberculosis epidemiology. Hermans, P. W. M., *et al.* ..... (A) 631

Uganda,
Is the leprosy blindness avoidable? The effect of disease type, duration, and treatment on eye damage from leprosy in Uganda. Waddell, K. M. and Saunderson, P. R. ..... (A) 475

U.K.,
Inflammatory bone changes in leprous skeletons from the medieval hospital of St. James and St. Mary Magdalene, Chichester, England. Lewis, M. E., *et al.* ....(O) 77
Leprosy workers on the move. ....(N) 131
RSM Conference on Tuberculosis 2000. ....(N) 584
Robert Cochrane Fund for leprosy. ....(N) 584

Ulcer(s),
[Analysis of 1973 cases of plantar ulcers in leprosy.] Yan, L.-B., *et al.* ....(A) 344
Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysical studies to detect thalidomide neuropathy. Gardner-Medwin, J. M. M., *et al.* ....(A) 350
[Effects of overall therapy on leprous plantar ulcers.] Tan, W. P. ....(A) 344
[Frequency of chronic plantar ulcers in leprosy patients according to treatment by dapsone monotherapy or multidrug therapy.] Mane, I., *et al.* ....(A) 589
Infected trophic ulcers and tenderness of posterior tibial nerve in cured leprosy patients. Srinivasan, H. ....(C) 291
Recognition of a unique peptide epitope of the mycobacterial and human heat shock protein 65-60 antigen by T cells of patients with recurrent oral ulcers. Hasan, A., *et al.* ....(A) 496
Thalidomide as treatment of refractory aphthous ulceration to human immunodeficient virus infection. Paterson, D. L., *et al.* ....(A) 356
[The effect of a comprehensive protection measure on the feet with plantar ulcer and numbness.] Xu, S., *et al.* ....(A) 623
The efficacy of podiatric orthoses as an adjunct to the treatment of plantar ulceration in leprosy. Cross, H., *et al.* ....(A) 621
The predictive value of sensation testing in the development of neuropathic ulceration on the hands of leprosy patients. Kuipers, M. and Schreuders, T. ....(A) 167
Vascular surgery of the posterior tibial compartment for plantar ulceration in leprosy. Arolkar, S. K. and Antia, N. H. ....(A) 488

U.S.A.,
100 Years at Carville. ....(N) 132
1994 Damien-Dutton Award to IJL. ....(N) 300
1996 Fred L. Soper Award guidelines. ....(N) 466
ALM International Conference on Leprosy. ....(N) 585
American Society of Tropical Medicine and Hygiene 1995 meeting. ....(N) 466
Carville Centennial: International Colloquium on the Future of Hansen's Disease Control and Research. ....(E) 269
Leprosy statistics for 1993. ....(N) 132
New leprosy cases in U.S. in 1994. ....(N) 132
Prevalence of human T cell lymphotrophic virus (HTLV) types I and II and human immunodeficiency virus type 1 infections among persons with Hansen's disease in New York City. Glaser, J. B., *et al.* ....(A) 141
The Heiser Program. ....(N) 584
The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993. McKenna, M. T., *et al.* ....(A) 497
U.S.-Japan Cooperative Medical Science Program, Thirtieth U.S.-Japan Tuberculosis Research Conference and Tuberculosis/Leprosy Symposium, Fort Collins, Colorado, 1995. ....(A) 641

Vaccine(s), Vaccination,
Analysis of vaccines prepared from armadillo-derived *M. leprae*; results of an interlaboratory study coordinated by the World Health Organization. IMMYC Steering Committee. ....(O) 48
Antileprosy vaccine; an apprehension. Parkash, O. ....(C) 572
Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Fine, P. E. M., *et al.* ....(A) 324
Differential T cell responses to mycobacteria-secreted proteins distinguish vaccination with bacille Calmette Guerin from infection with *M. tuberculosis*. Roche, P. W., *et al.* ....(A) 330

Effective vaccination of mice against *M. leprae* with density gradient subfractions of soluble *M. leprae* proteins: clues to active protein epitopes. Gelber, R. H., *et al.* ....(A) 164
Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes; antibody responses to mycobacterial and leishmanial antigens. Sharples, C. E., *et al.* ....(A) 360
Immunoreactive antigens of a candidate leprosy vaccine: *M. habana.* Chaturvedi, V., *et al.* ....(A) 481
Influence of mouse strain and vaccine viability on T-cell responses induced by *M. bovis* bacillus Calmette-Guerin. Daugelat, S., *et al.* ....(A) 600
Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of *M. tuberculosis*. Horwitz, M. A., *et al.* ....(A) 496
Regarding analysis of vaccines. Convit, J. ....(C) 576
Relationship between bacille Calmette-Guerin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Brewer, T. F. and Colditz, G. A. ....(A) 491
Relationship of secretion pattern of MPB70 homology with osteoblast-specific factor 2 to osteitis following *M. bovis* BCG vaccination. Ulstrup, J. C., *et al.* ....(A) 364
Vaccination with pure *M. leprae* proteins inhibits *M. leprae* multiplication in mouse foot pads. Gelber, R. H., *et al.* ....(A) 148

Viet Nam,
Complex segregation analysis of leprosy in Southern Vietnam. Abel, L., *et al.* ....(A) 485

Vitamin(s),
Reduction of clastogenic effect of clofazimine, an antileprosy drug, by vitamin A and vitamin C in bone marrow cells of mice. Sahu, K. and Das, R. K. ....(A) 317

World Health Organization (WHO),
Analysis of vaccines prepared from armadillo-derived *M. leprae*; results of an interlaboratory study coordinated by the World Health Organization. IMMYC Steering Committee. ....(O) 48
Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi. Ponnighaus, J. M. and Boerrigter, G. ....(O) 1
Field evaluation of WHO-MDT of fixed duration at ALERT, Ethiopia: the AMFES project–I. MDT course completion, case holding and another score for disability grading. de Rijk, A. J., *et al.* ....(A) 312
Field evaluation of WHO-MDT of fixed duration at ALERT, Ethiopia: the AMFES project–II. Reaction and neuritis during and after MDT in PB and MB leprosy patients. de Rijk, A. J., *et al.* ....(A) 312
Leprosy upgraded within WHO. ....(N) 130
Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Jamet, P., *et al.* ....(O) 195
WHO Chemotherapy of Leprosy; report of a WHO Study Group. ....(N) 130
WHO Hanoi Declaration. ....(N) 582
WHO Report of the Monitoring and Evaluation Meeting (1994). ....(N) 131

Yemen,
"Flu" syndrome on monthly rifampin dose; first case reported from Yemen. Al-Samie, A. R. and Al-Qubati, Y. ....(C) 574

Zinc,
Oral zinc therapy and recurrent erythema nodosum leprosum: a clinical study. Mahajan, P. M., *et al.* ....(A) 142